var title_f0_24_384="Diagnosis Cushings syndrome";
var content_f0_24_384=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Testing to establish the diagnosis of Cushing's syndrome*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 474px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Testing can only be interpreted in the context of sustained hypercortisolism and may be unaccurate with cyclic hypercortisolism.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_24_384=[""].join("\n");
var outline_f0_24_384=null;
var title_f0_24_385="Hand-assisted laparoscopic approach";
var content_f0_24_385=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F84019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F84019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Hand-assisted laparoscopic approach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 533px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the nondominant hand inserted through a hand-assisted device when performing a complicated laparoscopic procedure. The hand-assisted port is inserted through a mini-laparotomy-sized incision.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_24_385=[""].join("\n");
var outline_f0_24_385=null;
var title_f0_24_386="Patient information: Sex problems in men (The Basics)";
var content_f0_24_386=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/45/36562\">",
"         Patient information: Androgen replacement in men (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/40/34433\">",
"         Patient information: Priapism (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/20/16706\">",
"         Patient information: Sex as you get older (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/17/11538\">",
"         Patient information: Sex problems in women (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?28/33/29205\">",
"         Patient information: Sexual problems in men (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Sex problems in men (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/sex-problems-in-men-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H544483176\">",
"      <span class=\"h1\">",
"       What types of sex problems can men have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sex problems in men can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Being unable to get or keep an erection most times you have sex. Doctors call this &ldquo;impotence&rdquo; or &ldquo;erectile dysfunction.&rdquo;",
"       </li>",
"       <li>",
"        Having little or no interest in sex. Doctors call this &ldquo;low libido.&rdquo;",
"       </li>",
"       <li>",
"        Ejaculating too soon after sex begins, before they are ready to ejaculate. Doctors call this &ldquo;premature ejaculation.&rdquo;",
"       </li>",
"       <li>",
"        Being unable to ejaculate (even though they can get and keep an erection)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H544483183\">",
"      <span class=\"h1\">",
"       What causes sex problems?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Men can have trouble getting or keeping an erection if they have a condition that keeps the penis from getting enough blood. Things that reduce blood flow to the penis can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Getting older",
"       </li>",
"       <li>",
"        Diabetes",
"       </li>",
"       <li>",
"        High blood pressure",
"       </li>",
"       <li>",
"        Smoking",
"       </li>",
"       <li>",
"        Drinking alcohol or taking drugs",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sex problems can also occur when men feel depressed, worried, or have other things on their mind. Plus, sex problems can be a side effect of certain medicines. For example, medicines to treat depression or heart disease sometimes cause sex problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H544483190\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse can help figure out the cause of your problem. He or she will talk with you, do an exam, and order blood tests. He or she might also order another test, such as a test that measures your night-time erections.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H544483197\">",
"      <span class=\"h1\">",
"       How are sex problems treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on the cause of the problem and can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Medicines to help you get and keep an erection",
"        </strong>",
"        &ndash; Follow your doctor&rsquo;s instructions closely when taking these medicines. Also, let your doctor know if you are taking any other medicines. Men who take medicines called nitrates (such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?9/10/9382?source=see_link\">",
"         nitroglycerin",
"        </a>",
"        ) for heart problems, should not take medicines to get an erection. Examples of these medicines include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?27/8/27781?source=see_link\">",
"         sildenafil",
"        </a>",
"        (sold as Viagra&reg;),",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?13/36/13893?source=see_link\">",
"         vardenafil",
"        </a>",
"        (sold as Levitra&reg;), and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?9/38/9829?source=see_link\">",
"         tadalafil",
"        </a>",
"        (Cialis&reg;).",
"       </li>",
"       <li>",
"        <strong>",
"         Devices to help you get and keep an erection",
"        </strong>",
"        &ndash; Erection devices work in different ways. Some are implanted into the penis to form an erection. Others work a bit like a vacuum and help pull blood into the penis.",
"       </li>",
"       <li>",
"        <strong>",
"         Hormone treatment",
"        </strong>",
"        &ndash; Sex problems can occur when a man&rsquo;s body does not make enough male hormones (testosterone). If your hormone levels are very low, your doctor might treat you with testosterone, which can come in a shot, skin patch, skin gel, or tablet that sticks to your gums.",
"       </li>",
"       <li>",
"        <strong>",
"         Treatment to improve mood",
"        </strong>",
"        &ndash; Doctors might prescribe medicines or talk therapy for men who feel depressed or worried.",
"       </li>",
"       <li>",
"        <strong>",
"         Treatments to delay ejaculation",
"        </strong>",
"        &ndash; Doctors can prescribe medicines to keep men from ejaculating too quickly. Some of the medicines used to treat depression work very well for this. Some men also use a method called &ldquo;pause and squeeze.&rdquo; In this method, a man stops having sex and presses behind the tip of the penis when he feels like he is going to ejaculate. After the feeling goes away, he continues having sex.",
"       </li>",
"       <li>",
"        <strong>",
"         Treatment to help ejaculation problems caused by depression medicines",
"        </strong>",
"        &ndash; Sometimes, medicines used to treat depression can make it hard or impossible for a man to ejaculate. Let your doctor know if this happens. He or she can change your dose or your medicine so the problem gets better.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H544483204\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/17/11538?source=see_link\">",
"       Patient information: Sex problems in women (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/40/34433?source=see_link\">",
"       Patient information: Priapism (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/20/16706?source=see_link\">",
"       Patient information: Sex as you get older (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/45/36562?source=see_link\">",
"       Patient information: Androgen replacement in men (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/33/29205?source=see_link\">",
"       Patient information: Sexual problems in men (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?0/24/386?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15497 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-8641F3AC89-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_24_386=[""].join("\n");
var outline_f0_24_386=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544483176\">",
"      What types of sex problems can men have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544483183\">",
"      What causes sex problems?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544483190\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544483197\">",
"      How are sex problems treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544483204\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/45/36562?source=related_link\">",
"      Patient information: Androgen replacement in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/40/34433?source=related_link\">",
"      Patient information: Priapism (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/20/16706?source=related_link\">",
"      Patient information: Sex as you get older (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/17/11538?source=related_link\">",
"      Patient information: Sex problems in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/33/29205?source=related_link\">",
"      Patient information: Sexual problems in men (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_24_387="Technetium Tc-99m oxidronate: Patient drug information";
var content_f0_24_387=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Technetium Tc-99m oxidronate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/23/5491?source=see_link\">",
"     see \"Technetium Tc-99m oxidronate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13210110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Technescan&trade; HDP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13374382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3560724",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used with an imaging test of the bones.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13374381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3560722",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to technetium Tc 99m oxidronate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13374385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697292",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low calcium levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13374386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13374387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13374384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13374389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17085 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-BE5EBB4FC7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_24_387=[""].join("\n");
var outline_f0_24_387=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210110\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374382\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374381\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374385\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374386\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374387\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374384\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374389\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/23/5491?source=related_link\">",
"      Technetium Tc-99m oxidronate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_24_388="Prenatal ultrasound anal atresia with rectovesical fistula";
var content_f0_24_388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound image of anal atresia with rectovesical fistula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 402px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound of fetus with anal atresia and rectovesical fistula. Oblique view shows dilated fluid filled rectum with intraluminal calcifications from urine mixing with meconium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dorothy I Bulas, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_24_388=[""].join("\n");
var outline_f0_24_388=null;
var title_f0_24_389="Insulin glulisine: Patient drug information";
var content_f0_24_389=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Insulin glulisine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/9/1176?source=see_link\">",
"     see \"Insulin glulisine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/2/22566?source=see_link\">",
"     see \"Insulin glulisine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2114407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Apidra&reg;;",
"     </li>",
"     <li>",
"      Apidra&reg; SoloStar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2934392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apidra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702304",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to insulin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697009",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are 80 or older, use this drug with care. You could be more sensitive to low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696704",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep workouts the same. More workouts may lower your insulin needs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699163",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use out dated insulin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 15 minutes before or within 20 minutes after starting a meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3629482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Give a missed shot as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3629483",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next shot, skip the missed shot and go back to your normal time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699570",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store unopened vials and cartridges in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may store opened vials at room temperature or in a refrigerator. Throw away any part not used after 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store opened cartridges at room temperature. Throw away any part not used after 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect opened vials and cartridges from heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699287",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect opened vials and cartridges from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11547 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-3399DFF423-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_24_389=[""].join("\n");
var outline_f0_24_389=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2114407\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934392\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018806\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018805\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018810\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018811\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018813\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018808\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018809\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018814\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018815\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/9/1176?source=related_link\">",
"      Insulin glulisine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/2/22566?source=related_link\">",
"      Insulin glulisine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_24_390="CT scan of Petersens hernia after gastric bypass";
var content_f0_24_390=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F75430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F75430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Computed tomography (CT) scan of Petersen's hernia after gastric bypass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 316px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE8AiIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3n4ofEDSvhxoFvq+uW99PbTXS2irZojOHZHYEhmUYwh7+leYf8NV+B/8AoFeJP/AeD/49R+2t/wAks0r/ALDUX/oievKfgN8HvC3jr4f6p4h8TajqtmbK8lhY2ssaRrEkUbliGjY5+du/QDigD1b/AIar8D/9ArxJ/wCA8H/x6j/hqvwP/wBArxJ/4Dwf/Hq4r4XfBz4W/EnTLy80HUfGEItJhDLDdy2ySDK5VsLGw2nnHP8ACeK+X6APtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/Hq6DwF+0B4V8b+LLHw9pVhrcN7eeZ5b3MMSxjZGznJWQnop7HmvgqvVf2XP+S7eGf8At6/9JZaAPrD4ofGvw58ONft9I1yy1ee5ntVu1azijZAjO6gEtIpzlD29K4//AIar8D/9ArxJ/wCA8H/x6vKv21v+Sp6V/wBgWL/0fPV+L4QeBLTw/wCA5dQ/4TG+1jxTZxzQ2+mzWgUSeSkjjMoUKPn4yx6UAejf8NV+B/8AoFeJP/AeD/49R/w1X4H/AOgV4k/8B4P/AI9XlPiz4V+Bk+C2q+N/Ct34kM1pKkKwak8OFf7QkThgic4DHBVsZ/KvAKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtuy/ag8HX13FbWukeJHnlYIi+RbjJPbJmxU5/aW8KAkHRPEoIJBzDbjBH/beviGCV4Zo5YjtkRgyn0IORXeeJZUO2+t12x3saXCrnoWHzD/voEUAfVUX7RXhuZmEeg+JGIXcf3dt0/7/ANOu/wBofw7Z6Y+oXGgeJUs0YIZPLtiMnoMCfNfNmhWlxe6jHa2AQo6ASMFyRnA/PPAFbP7ROkXvhTTdA0W5jVY7lPtIKH+6Nu1v9oFsn6igD2P/AIar8D/9ArxJ/wCA8H/x6j/hqvwP/wBArxJ/4Dwf/Hq+KxjPNKuNw3Z298UAfaf/AA1X4H/6BXiT/wAB4P8A49R/w1X4H/6BXiT/AMB4P/j1fFZxk46UlAH2r/w1X4I/6BXiT/wHg/8Aj1dBoHx50XX7JrvSfDniS4t1cxlttonzAAkYa4B7ivhx9Wkbw9HpH2e0EKXJufPEIE5YqF2l+pXjO31r6R+DNjCPhbpEiFWaSeeR3x907sEfkBQB7NH8W7eT7nhTxGf+BWX/AMk1KfikgIz4R8Sc9Pnsf/kmuHs7QwOz5Zdy9D0x2NWlVtoDMBs4yvPNAHWH4qxhwh8I+Jgxz3su3/bzSP8AFeJELN4R8ShR1ObL/wCSa42dJJYgVcBuqAjgnOQDj3qN2DRx/aPklx+8AOQCO4/KgDsW+L9qvXwp4l6462X/AMkUsfxdtpDhPCfiU9v+XMf+3FcEoR/uuNzDnsB7VetlPymOPaByfpQB2f8AwteLI/4pLxLycdbL/wCSacfiog6+EfEnAz96y/8AkmuQwQpG4kMwIyOmKinZwpBwFJyaANjxD8f9D8OwW82s+HPE9tFcMVjbyrZgSMZHyznB571h/wDDVfgf/oFeJP8AwHg/+PVwHxg0ibV/A969qBJJaOt2VI52jhiPfBz+Br5poA+6fDP7RnhnxPrdtpGiaH4juNRuSRFEUtY95AJI3POB0B71r+KfjRp/ha8W117wv4ltZ2AIXFnIOenK3BAr4S8NXkuneItLvIJnglguY5FlQ4ZCGByK938f3lxf6dc3F7O13crOGeZvvE4wPb2xQB6yf2lfCgIzoniXnGMQ2/8A8frpfht8ZfD/AMQPE13oekWOrW17a273MhvI4lTarohAKSNzlx2x15r45tlSJ4pZWzEDvXHHI7GvSv2QbaW0+MuuRTjD/wBkTNn1BngII+oNAH2RRRRQB4B+2t/ySzSv+w1F/wCiJ64/4CaDrPij9m/xPofh24tLW7v9YeCSa5ZlVYTDb+ZjapJJXIx7nmuw/bW/5JZpX/Yai/8ARE9fFVAH3/4E+GWoeB/iFLqWlaot34fu9Mis7qK62JOJYQFiZVijVCoQBeeeSTmvgCiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr1X9lz/ku3hn/t6/8ASWWvKq9V/Zc/5Lt4Z/7ev/SWWgDq/wBtb/kqelf9gWL/ANHz16+3ga/8W+CfhBf2dno2oWuj6ZDLc2OqSMkdwHtogBxFIOCM8r6V5B+2t/yVPSv+wLF/6Pnr5/oA+yPiP4Sv/B37NHjOy1O5t3e4v47uK2tSzQWUb3UO2CIsASq49B16evxvRRQAUUUUAFFFFABXW2119u8P6PbMN0lpPJGwPUo2HX9d1clXs3i240zUvAvgzXdNe0S5WwXSL6CFMNHLAflZh6srZz3oA6r4DXWm6d4tS71l1EEchZTgnY2MK2B6H8q4z9prxzbeNviI39mMX03TIvscTkEeYwYl3wfc4+iiur8A+HbuDQrnxLLBMbFTuecLlIwvJOf615x8P/BFz4+167vJWa20lJy884HJLEnYv+1/KgDmfC3hfV/FF6bbRbR52Xl5D8qRj1ZjwK9m8P8AwS0u2jVvEN/PdznH7u2Plxr+JGT+lepaTp2n6NZRWWjWotbNMhI1GC3ux7sfepo9gCliWBwCvoKAOOi+GXg2FWT+xt4AxueZ2P169ax9U+DvheZGFqbyzlIONs29R+YOa9Kbbu2A8g9ccCjbuJOV4ICr6e1AHzb4i+EeuacWfT3i1GIdAnyv+R6n6Gus+DOvXemaVfeHdTintpoJftVuJEK5zgMvPuAR+NexFwvXIZRkHHI7ZqnqGmJdxJ56lWDbg6gFh6UAVPDGq3LTTQ6gkiRsf3bMPXtXRhhguCATxhf0z6Vz8+rtpiY1G1kkiOFFzAMqP95Rz+NaWmaxpepgC2uItyDBjYYJ/OgCdJCUJIDYU/Ke3sP1qGVmFu77DvK/MF7dttXpgrmQrk89c4BHrVURHZLG+TkkZHbj1oAyrK3zIeMR5xgn7w9BW4Cdu9QVYLuGOef8P8axgpjuMK5LbucY5/8ArVrj7q/LjvjrnigB29WBypBP5/570vlgKQV3KDuGeNpqqt0BI4kZTyV4HH0zUrNI5GQAq8kHp9frmgCC6CFCFIIY4YdiD1H0Ir5P+ItvZ2fjfWrfTYUhtUnKpGowE6ZA/HNfU19dRWKPcMGPkjz3z0wP8fSvkLW5jcazfTFgxknd8g56sTQBSr7Q8b+G9L1f4G+HtY0yKNLgWNsTJGNvnbowDu9Tu7nnrXxg23cduce9fSnw/wDEOoTfDbw/o2oTqdMjSRohj5ixdsKx7hcnH/1hQB5LeFfLROd3zbhjuPSvZv2VcTfEtrknLnQp4T9EntyP0bH4V5P4htJbbVLyMLkK3y+nWvT/ANkxifipfKM7Bo9wy+2Z7figD67ooooA8A/bW/5JZpX/AGGov/RE9fFVfav7a3/JLNK/7DUX/oieviqgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK9V/Zc/wCS7eGf+3r/ANJZa8qr1X9lz/ku3hn/ALev/SWWgDq/21v+Sp6V/wBgWL/0fPXz/X0B+2t/yVPSv+wLF/6Pnr5/oAKKKKACiiigAooooAK9AsUitvC2n2yhmEwN3JjncxJXH4AV5/Xa+FXkvdCkhePcbWdFhfviTOU+mRn8TQB9neG7KysvgpZwz7JNMm0p0kjU4855hjH/AI9iuI0LTbXQtDt9M0uERxRcAdycZJPqep5pnhy4vjaW1hc3krWNtGGjiz8kZ9APYk1sOgJ3IdpB5A/iH1oAilRt3yq2xm9M8DHQU4jco8wc46Dk9cf/AFqRiQNzqQOQCpx+PtTFO4ArgbyTk8E/4UAL99SQFZiSPk6AA9vekSJnyRv8wnggcc8/jR8vzCU7VPyj8KmMj24LAAxNg4I6Nj9DQBV2jeQc7mYA9/xFKWZmDbih3Yx6c9fpQytl94A4yWHYUisCY+QpxjLevY/jQAAFANuM43KSM5H+Pes+60mGdhIqRpIQWEqLtYDqMYrTjiuLl5Cq7nUDKj5doqSOEyP+7GMEoUB+YY6bvbrQByi2PiC0n8yC9ivYxjaJRsOMUk3iHVoiyT6WpbBAeJw3I9vSuuSxuIXP2hNyqp+dTnGKrXVgs8ipNbBlCckjGD7H8KAMGxv01CBiFkibABWZSjD19sVrRXhWIBZFmVecjqf/ANVNawiuI1iM1wqu4b5Gxz071ENLkSXck4cDqWjAz26igCaN1xI7Qhd/LDPbPoKWa5wsm/7vBCngD1zUP2B2QMJEUbeD16fjUR0+HJlllyrYwCcBuOevFAHj/wAUviLDc2k2kaLI7yM225uAMKQP4V7n6145X09qKeCNKiubiSwsbqctykNuJWLHuT0GfevMfER0PUrweTpGn6bCeiK+1m9SSD1/DFAHmFfW37OGh6Rq/wANLFdZhNxLfXdzYQSbiBb7V8wYA/iPzHPpgfX52u/DFtdAnRruMzdraSVSW9lYd/Y/nXp37Nvja78KRa9plzpv2uBJI7mNJDt+zXHMZY/UcHv8oHrQBnfETTJLG8Z2XO3dHJg9CpK5/Sur/ZHJ/wCFp3y9ho0+Pf8Af2/NY/xNvI2SINKJJpmaVyfVjknHYZNbX7JcbL8UrxyBg6NOoI74nt/8RQB9eUUUUAeAftrf8ks0r/sNRf8AoieviqvtX9tb/klmlf8AYai/9ET18VUAFFFFABRRRQAUUUUAFFFFABRRViys7m/nWCyt5riZuiRIXY/gKAK9FdjB4DvIUWTXr6x0dDzsuJN8xGccRrk/ninQ6f4btColXUtQlJOOVgjOPblv1oA42krt1utHSACDw3a5Kgl5biRz17c1ILu0+0Og0XS1jOG2+SSVPoCTkigDhKK9Klv9ONtm10HRomBAy0Bck+vzE8VGdUeJXEen6VCWOCVs4+PcHHFAHnNOCMeik/QV6C3iHUpEZEnijO4EhIIweOOu3pjtSx+JdaQqYtTliVCFQYAzjrnigDz/AMmX/nm//fJpfIl/55P/AN8mvQD4q1yNCTqtx5ZY5QHGOeKjTxJrzSHfqd3uVVyQ/Tv+lAHBGGUf8s3/AO+TTGUqcMCD71358U660c3mancssh5Bbhhn/wDVU0PirVkz506XC4w6zRI4GT7j9aAPOaK76PVoZ/mv9H0u5JY5LQeWT+KYOKifTvDl5Eytb3lhcBiC8MglT/vluf1oA4aiurPgu5u1L6Fd22pf9MlPlzf98N1/Amuau7WezuHgu4ZIJkOGjkUqw+oNAENFFFABRRRQAUUUUAFeq/suf8l28M/9vX/pLLXlVeq/suf8l28M/wDb1/6Sy0AdX+2t/wAlT0r/ALAsX/o+evn+voD9tb/kqelf9gWL/wBHz18/0AFFFFABRRRQAUUUUAPhjeaVIolLSOQqqOpJ6CvXvBWnRx6lBp8Sq9vZAyTuv8cncn+Q9hXn3g9Vhu7jUHx/okRaPP8Az0b5V/Lk/hX1B+yn4ftV0/UNdv1WR3ZYI93OS5wf6D8TQBc0F90Ms4G9eBz/APWrV83jDKAc9Mfp+VLqFjBo+o6lptohW2inbYo/hDfMBn0Gf0pgKxKSgHmrggk52nuBQAoKoSrh/KXkt97P0/xqEvG6bUTJBw3PBOf85pZRvbLSAHOACcY/xpqMYwc/JnKrxyD/ABUALJIc5LYycIfQ4wP8KZLNC9zBbTSFHk+6Oh4680qbIZtzIWfBIBOce+O1EsMdwFSVIyA205X7vcc96ANUjMDoAmw45xgKPpWHaXcU11dGNR5MT/I38LDAzj8aS30yK28xDvZJiQd53Htx9O2KtQ2wChU2r3K7cHPb8sCgCNpiZPtC7tzNzyQx9R9B/wDqpN+6UhSMO3BJOT7H+tXIrB5JdsaMyqcBupJz0HqK1bfwbqdw/wC5tzCp6SO2OCevPP6UAYMd3Ju8pS+4NkLuxnFWPtpc7ipBK7SD0IP+fwrrrf4Z5MZudWmXZ0WGMDA7jJz/ACrl/if4YufD9tbXOlatcAXEnlurxq7KMfeHQfpxmgCKXULa1t5GuXjt1UZzK6quPxx07VxHiL4naHYqI11GKSQEsMRhsflXCeNPD17qmnk6nfXF55GSsseWI99nf6CvF7y3a1uHifkqeCAQCPXmgD3aX45WdiXbT9KhupWUYM8e5Q3cgNwPyrP1T45/8JAulDxLoUN5/Zd2Ly28t/LBYD7rBcAr04rxWKN5XCRqWc9AK6DTPB+q3v3ohCpQspdhzxkcDkUAey/8JRpsHhXVPE19oEcMWo8QW8PyoGY+meB19a+f7+6kvbyW5mxvkbJAGAPYe1dn4xv9en0HQ9AurRvsdlEPKeOI/vTzznvgHFcKRg88GgB8E0lvMksLskiHKsp5Br374UzS+LrKVbK1jOtXUq2906kBpiFJDk9gACfwNeFaVpWoavdC30uyubyc/wDLOCMufyFfR/7OfhnW/Aviy0fxZp1zp8OsM1tbCVMfPsY5J7E5AA60AYvxF8InTbz7PcNJDcwEC4B+b5cZ3D1yOa1f2S9YXU/itfRW8At7K30WYRR53MSZ7fLMe5OB7DArtvj9G8L2zl40v108eeV5+ZWO0n1yM8Vxn7J1lBD8VLu8s4/KhutEnzFnIR1nt9wHtyCPrQB9dUUUUAeAftrf8ks0r/sNRf8AoieviqvtX9tb/klmlf8AYai/9ET18VUAFFFFABRRRQAUUVueHfDl1rJeXfHaWEX+tu5+EX2Hdm/2RzQBiqrOwVQSxOAAMk11ln4FvxElxrlxb6LasAwN0T5rA+kQ+b88VtG7sfDymPwxbutwp41K4x9of12r0RfTHPqaw7mSSad5ZndpZWJJkySx7/jQBp28PhPSypt7G91yePJc3TeTEceiIcn15aprnxNqbWj29lNFp1kxB8jT4xCpX0JHLfjWLCyeRKAzrIGBjYcgeuafudplLqASQpYdDQAGJjI3mbmBxhupz7GkeN3RlfG4Zww7/hV5g/7xYpj5QOVDDgHPT8KcyCIndKNxALDGCP05oArLh7eWLycy7cIehUdyPWmiJ5EDksNhAyOT75q9Jc2MKAmW6YDJCooUD169al+2WMkkYMVzggBypUZP096AIIYiY3kch42G5QeCMdsVXmUssSyEYGchB97vmtBLizjby2hlLOAUP90Z/nSui/2nHBFayzBiCFiH3vYfjQBk7W2koh3Y646EjvSyxbEBfBKjoBgf5713OneCrqctcXrx2ityIlYu2M8qe1bEXgLT1HmSyzmYjPyNgE5/woA8qKbyFwWU4GSMD2/KnMZlBI4LKOR0I6YFerDwPpLxmItcsVJxl/l/AU0eBNOkdkWadCxBGccEDoPSgDyxo2VGjUAHp8xxjPWm+WGDbsMzrhlH+etemXXw/tmErRahI5cE/vF5J71g3vgW4hbdFMCXHy4UkL78fSgDi2XzH2AEBSM49hU5DmXOANwxJt9e5+tat9ot7ZljdICePvAg/QY71n3FrPEPmhZFLHg8Hjn8uaAKiZVQVO0KMghsYOa349XS8txb69apqlivyjcds0ee6P1/A5HtWH5aRR4lZhL6H7vsQe9NVWRSOSu3PHTOO3vQA7W/CBS3a/8AD8z6hYYLNGVxcQD/AG0HUf7Q4+lclXb2l9cWNylzb3EkNwhBUo2G6e3b2qXVdMh8ThrrT7WO01kJvktoxtS7Pcxjor+q9+3PBAODopzAqSCMEcEGm0AFFFFABXqv7Ln/ACXbwz/29f8ApLLXlVeq/suf8l28M/8Ab1/6Sy0AdX+2t/yVPSv+wLF/6Pnr5/r6A/bW/wCSp6V/2BYv/R89fP8AQAUUUUAFFFFABRRRQB1WkqkXh2MFRvnnaQnr8qjaP1Jr6h+BPiSw8LeF1g1EN5dwqzRkLnDjPB+vrXza8LJFY2W0q8dskeB/eb5jn/vqvbdJtvJsrO3IGYxGg4wc9aAO3url7+6nvrnCyXD+ayZyFGP8MCogUEnzHb8ud4PT2+vpUrExALgYUAnjqPSoL68ttPiV7nYOoG7nB9h9KALSR+XELiRUK/wxtyP96owcrGVTDhBvJPXnnJrlNR8Xi4nfybbKphRz0A9qpnxPO4kZYUJx8u9jj6cUAdiiEuxxn5SBjqDj/wDXWfqXiDTrC5htXmD3EgzHCgDM3GS3p614Z4w13xrq2sPYQvOsJwVFuuxSPdv8TVuOebQvD73V8TqGtwYeUeaC0cRwNuOoHqcUAd9qfi68Zra50qJTbxybDET5jSe7FeF9gK0Tr+q3MTfYzp8Esn3fNWTOQf514hb/ABN1G0nlWzs7SGxkbJtlBAx9c8H3rsbbxS2s+FBe6XpzfaEu0hltg/O7aWMgfHTAxz7UAe6/AzWpv7S1FPE93E99OR9jkA2RBBkFFzwGzg+pr3CvkDTtYjuLPfpNwCLgYDyY2AqCSH9OhAI6muq0T4kataCH7FqSTwLEDs2eYgbHKMudwI9qAPpWvJ/i1O/9oQC6ZYlRT5ALdiQGY496wr7x54j1KB/IvDYQToVVobYF0PTgnJB9K4uI3lvd+XqGpS6laGAQxy3DnzITk8NnoDk8+tAEOoCK9gdLeRVRhjzkbj/eA65GO9eX+L9MS9AttQtyNSgJC3cRx5iHlSw78c+tezi2s4LQqDgKTnJ4yema4DVYzc6is0gMck0beWAflLr0TP06UAcB4StNNGtSafHIYyCC91KoY4H90V3Hi3xCbewWDwxY+VkiNjnLNnuT61zehabBpF3q1ndNvv12zyKgI+Un7oz9RS6nq0WlXbpcySqgIdAwBLDrj9aAPY/hN4lvbJobK7tIbqF+P3ybgrHqa7f4l/BjwdrEseuDShFOkiNcx2rGJZkJG4kDvg9RXzt4d+ICtqsKw7SWcbcjBH+elfZ+nyTan4RVbqNraaW0BOCD1X/AD86AJvC3hzQvD2nRw+HNNtLK1K5HkIAWHuep/E1k/FqGOXwLfbx+8Ro5ImBwUcMMMPpV3wndmGyt7C44kROCfTPAp/xAjV/B+p70DhY92D7EUAfGvxGvNULCS5vbi4F2S0jTPuLMvQEn2rsP2Q2LfEG5yc/8Sy7bHpma0rB+J1vu0GGUALsl2qexzW3+yDn/AIWLd5GCNMuhj0/fWtAH19RRRQB4B+2t/wAks0r/ALDUX/oieviqvtX9tb/klmlf9hqL/wBET18VUAFFFFABRTkRpHVEUs7HAUDJJ9K9A0rSbXwxa/ab9I7jXyN0cDYMdp6Fv70nt0X69ACjpPhe30+2jv8AxOHUyJvttPU4kl9C5/gX9T7dataleXmptCJEENvEB5VvEu2KJR02rUV1eG8klmuZpZLlzuYvzuP4/wBKgZpJmKjIA+XA6gnuMdaAJbizJCyh1XcOUf8Ai9hSR2ZlwonQHAIjUly2PQetbukeHLi9u4lvCbXfgpv+8w9QDXoel+H9O0O2F1axjIODcn5Qvtk9KAPPdI8FajeyJKyGFMc+eAGx9O4rqrDwNp9sUN1I8/8AEVTgZ7AV0FzrVpY2Ut/qc3l2cKhjKFJLE9Avqx9vrXDRfEOXVLi7fRrOQvBE0oikA3Oo78dx1oA7iLw3p0ULiOAKwGWA53evWr9p4TSNXljt5Ftxk7yAEHf7x4z7V5D/AMLp8URIyWkWlW+P9Wws1d4/oXz+ua5LXte8S+K5WutZvtS1LLdZGZkU+yj5R9AKAPbNSbwtaTyLqmpaQrFRmPzA+eevyZwfYVy6Dw9qt8U0OGK7UP8ANGjsr7R1ZVIBI+leOOrIxV1KsOoIwRW74D1d9B8Z6NqkTBWtrpHyewzg/oTQB6QdAupLpYk0j7HcyFpYoriTDtGv8YXrtro9E0i6to57zUdQXT7e3tZJWfywW+UZIHqSOBX0jeaRY6xENQms4Tdw27CG8CDeiHqoPUA9xXjV/b2skUsEhjdGLRmNv4l7gjsDQB5EPirLZI0kFpFeZO2Mygx7Mc8gZz+BqnP8ZNdeMrBY6XAxOdyxM382PNepeLfCmiapo+k+FtJ02GyWR3uVeAAOGVeSWbJPBIIJ9MVxcXw38OWF4ILxtRumU4d2lSNAf7uACefXIoA2Phz4g1zxVZzTXUFrAqHZHOkZAYAEtxntxz711NjaXhZpbu5D88+WuAw7fQDpmtDTbO20uxjt7SOOCPACKowvfHHtVjjyPlJwIwB83IA5x/M0AZcNrcPOyZmJTPThSevH6VS1m40zRNHlvtUuLiC0VlTEfJdz2AHYVug/vmKjzJGO5MHrjtn8aL7w1beLbc6Des0EF9tRJEG7ymHzBwO+Pw70AeeHXPA2uCIT+IrqKRDuH2lXX5vrgj2GTXV2ulQSWQlsJrbU9Pk4Qh1l+bHcj+tef33wIurG+ME3iTT2jGfnjhkY8dtuOvtmnab8K9W0e6s7nT/EiLGZA8wgZ4W2juueGPsaAN3UfCmmySO7xzQ7lx+7XcuAecVzV14JmkBOnzRXOFztU7fwx617Y1lbyaFHdi48nUZ5j5cDJjdGowSf7pJ6Vzd9ooMjKEMbsPlaM8Ek9M9u9AHieo6PqGmyN59u6AZJkAyPrWckjxsjKxjZWDJjO4Ec5Hp0r2LZqNlO9jMkd5ABjew7Hrj1IrC1nwva6qJZNMJt7xMkxHgt70AcB4gshr1lNrFsipqUK77+BRt3j/nso9f7w/H1rjK7Mm70u/DjzEuoCScjIOOox3HaqPijS4GgXWNKQJZyttnt15+yy/3f904JU/h25AOaooooAK9V/Zc/5Lt4Z/7ev/SWWvKq9V/Zc/5Lt4Z/7ev/AElloA6v9tb/AJKnpX/YFi/9Hz18/wBfQH7a3/JU9K/7AsX/AKPnr5/oAKKKKACiiigAq1pkAudRtYG6SSqhxzwSBVWtjwkB/b9u56Rh5P8AvlCf6UAd34atV1bxgCVAQTM5UH+FTwP5V7LBp13ZanZrckNHNKZAwOdvy/d/CvF/ABYa7G8LFW8hmLYz2r6DudU0/VP7JFjbT214V33IkfMaYXGUPU5PPNAF24dIo5JpCFjiG7k9gteW6rqL6hcGSThAPkTsoz0Fdp4wmaHRpgWw87Ad+ncfoK4GNmz1GCeh7tjtQAE5UNn5j8ufbvSRrnA3Z4289eKbtVlXDBVBxnv17mq+vSfYfCuo3CXEcd+8Ja3DOFdv7xUdzigC9pFzcXyamNKNqtxa4YzPiUqw/wBj04I+pry7X5INH8WDUD5shmk82WMuuSGJEiMPRlJ/Oua0TWL7RNUi1DTbh4bqNs7geG9Qw7g9wa7Dxfbz+NJrTWfD1i8iNAEuoowMwzLy2fY9QfT6GgDmfGejDQfEt7YISYFYSQMepicBkJ99rCur+HMM154N8VW6bggMEikqSpYFuOO5FaKeBJtYstPn1rUHgngtljkymSEU4UZ9gQPwr0fRvDlnoulpaaef9FyfMVsFXcqMs3fdj8hQB5tqU8ul/DW7unYxXl5erDGhAzGgBJXjr/8AXqnoUcv/AArXW9XubqRZ/MWC1ZAE8sggvgj1yBXqWo+GNE1awjg1CAyxo5ZMSlApxzjHY/rWZrngqK50G50XTLkQ2jFWgiC8I45JY9ST0PegDyfwr4j1J74xahfXk+mrGZLhRJlgiLkFSeh6D8a9A8J6k3iTSZRYs0McMxWSORi77TyDnvxniuD1Hw9eeH9F1Q3ktubqNktfKjYEpGzbi5+pUL+JrovhVND4e0zWtT1C5AtEMUciqhPJ5Ug+pBIH40AZnibxzqVpqFxp1kqR2kLbNrneWx3yD716B8PtIHjrwjqcxu3jmsbCa8VVkHEqcbX7hcHII56VxvxA07w5JJFq8V6QjxKFt1UDzO4Ixz0POaf8JdabSdG8Rx6ZE32yeE2zy84a3l+VtwzjIxwfU0AT6JLciO3i154711lWPzg/z+V/dL9T6jNdDPommavbXlxqlnPcWkOCkjNsl2noVPfJrN0/TI5dGtZ7aKSWdZm84ZG0RbtoB+tezaj4Qn0HW9G1rWlF3FLhY7UDakWBkRkfT+VAHmvhnwT4X0todT/sjxBdTRSLKjvtESr1yR1JzXofxI/aA0iw0qbTtLimS8dfLdeDIgx7HaDj1Ofaue1jXL2TXrtSLgQymVQIjtijYcqu0dPx9a+a4dN1bWNcktLezubvVJZW3QxxlnL554FAHrlr+0JrFrdxzRaeNykZdrgliPTpivWfD3xk1P4iaDdWdpoLW0ReO2uLtmyo3tt46DOf51xPws/Zl1HUvI1Dx3K2nWhIb+z4iDO4/wBpuifTk/SvorxFpekeFvCenWmn2kFhpFte23mJEuAqCQHJ9TnGSaAPCP2h9Ai8LadDZW8rzW8iLMpfG4NuwxPt6VS/ZGYt8RrrO3/kF3WNv/Xa15rY/aSvYdcuLqW1uFmtLeKOFGj+ZWPLHB7jnH4VifshH/i5N0hIyNIuOPQeda/4UAfX1FFFAHgH7a3/ACSzSv8AsNRf+iJ6+Kq+1f21v+SWaV/2Gov/AERPXxVQAUtJXXeErOLT7X+3b6NJSGKWUDjIdx1kI/urx9T9DQBp6RZL4Rt4bmdY28Q3Me6FXGRZIR94/wDTQg8f3fr0zpZWkdnuG3bznLHlvx71FJLJPK8sxld5Dli/8Z69a6Pwj4bk1eQ3UwMVkgyxJxjFAFHRdFvNbudttE5jXlt38I9c9xXpGg6JYaTa78xvcjrdSKNigHoo9RVtZLGxs1jT9zZ5KpGow0x9fp715T448dXWoXn2fT2EVvD8u4AfMQewPT69TQB1fizxzpnh6WWDQYRf6yygPe3Q3LD3wqnv+n1ryzXPEGra7cefq1/PdP23twPoOgqK6E+otLehWkfgzYHIP97A7GqO1tu7B2+uKAPa/gQbDx9JceBPFgmuY3he40yXzSrQyoMlM/3SMnHbB9a97+GvwS8G6NHfXlhJfz6jLE9q5uZVZrQkYYKFUDPuc8fjXy78AprvT/iZpmrW0TSQaeXluCP+eZRlI+p3YFfQlz4/1qXU9S/sx7WxhvHLNtTdLjkdexx3oA1dIm+HumNLb+IPDulXGqWE7wm7XTo2M+0kBzxnPqfWuwh+J2gJbumnQMsEMZYZURqAB0wOleIXenSJEsltNHICNzM33ge5J7gnv2qttWeQqJPs00i42+TuGO+McelAG7q/j2DWbuQeLvD+matpfmYVJLZHbaeySjow4r1X4eeCfh3PYw6n4f8AC1lC6twbm2LyI3B4MmT9CK8Zj0rQdP2i/vbqYg5WCCPAB7/KD1Nd54l+Kl5YaBb6fpOn3VpM0YiFzcAbkGOCqjuB+VAHn3jrUNQ0rxjq0dhrt1BF9pcvaxuxfr2B+UDpzXP25hln3Tedd3DjAZpiHHuMda0ZZLcrDe66zNIdxiAJZ5P9on69apXNy4uoJrG2jtrXBaIx/eI9PxNAEshn0O8t7gO0qKVdHkJ3R+x9iODV2GRNRu7zUbUR2l2i4WzJLrcAnuT19aoXlpqkcjS3LMVWNZGjc/w4z9D1qqqM0lmtorEH/VueOp/pQB3Gl3dxe2QmtLe4faxilQrllkA5wT1/D2qlca1cTyyQadA5mCnYZMDaFznH0pmh+K7vSry4thCgijYsxi52ZH8J75PWuPfWTc65YDzPLtoT5ckigkDe2Sx9eTQB2nh/VpL6zDSwJD5DbS0sojA9Tg89e1alhrdvHiS3k+1sQwBTOwE9QGHes3xcmhT6O0VrbK0yLg7eCAOhz355yak8KLd6ppFpYadLFHHZREzGM8Bix2g8cHvxQBraPfG6t1vrpwMkj72CoHUfXpzW1YaFf61NHEBFYWkn3ZrjAG3rhFzk+v41yFlFZTz2EtkhZBcmKWFR8uc8lh6kU/xrrF/Z395e3Vhd3ywECGK2+crltu3HbAx+dAHQeL5LqPUY7e505bBLFPJDgsVljB4Zc9c1wHjbxcukeH0vNPZpcvsjEYxjjkvnoO2a7C31JmhQ+ZcNG8SRmCY7ioPJQhs4H+FUH0uzur438saiVwYyZSMFfdaAMPQp5L7Q9P1J3+S4G75jn8/xzUk9ubhTNE2LqNvkYdSff0GKl8YQQeH/AAXfahp8klxLCoKiTgfM3zYA6KMcfWq3g2+h8Q6BDqluGjj8xoGiYjO8AEjjtzwfegDmfF2kRatp8moWqeXexfJJH7jrXCWM4sLl1uENxBKpiuIRwJFPX6EcEH15r2rUYktbuO4CP9ncGOUcDB7Mf0ryrxno/wDZusyM4C20nMZB+XHt/KgDivEWk/2VegRSedZTL5lvOOjp/iDwR6ismu7hjgv7aTSLt0SORs20pPEEuB/463Q/ge1cVd281ndS21zG0c8TFHRuqkcEUAQ16r+y5/yXbwz/ANvX/pLLXlVeq/suf8l28M/9vX/pLLQB1f7a3/JU9K/7AsX/AKPnr5/r6A/bW/5KnpX/AGBYv/R89fP9ABRRRQAUUUUAFbnhFd2pzY6i2lI/75rDrZ8JE/23HGP+WsckePXKHj86AO6+HAV9XkXcFxbnB9PUiva7KGCLXbMWtx5yi2IdsDG4jg8e3avAvB179h8QWTsAAzeW3PGDXtOmv9nVCoG+Fz04Bz6/hQBd8cnGnQEKSokAA9cjgV51qutafosyQarKftDrkWsQ3yDPQHH3c+nWu6+Jw1C18IXd/YMivaRGRgq5w2QNwz0wDnFfLSXDm8W5mZ5ZN4dizHLHOeTQB6nH4502LUWt9QspoIoegb5uR2OPWsvXZdL8bR3F7pUk1lq9sAILCVs+cmedrf3hnpxXJ388Gq3hWxhFpbKrSbGfczsBliT6nsKyY3KSoyMY2U5DLwQfWgC0sBuSsMVu4vEyGQZJk57DsR6e1eyfDPTJPDui3kN6i/br50YR5yIwAcA+/wAxz6Vx/hS4n13xRaXQtI0uLRPOurlwclxxuJHqMYB75r1q3tURfNicNtBDBjywI/nQBYigW4szuA3ZKHng+34VY065jtLZorlD5G3ErOM4J74HX04qvpyy2UMsT4ZOTgdj1xmnmVCwMk7CMAuxK4YA8j5aALly9hHsS1gSWWLOZW/1aY7D17UsMonLSnKTOwZgp+X6j6npVLUkmXSftdmF8kKflYZBXvz+PHeq+l6i8Elwt1vljRUkMixYEQPRTQBp61BbC0M15pljeW0mftLTLjamMnLdvWud8MaJ4ehtJtR8ORG40XVMxPBcHchKnhGDdgen1p0V1ea1rsmlQxNHaOCskkvMRJH65Fa1r4EfRoL+00iFJI7wpIzrNsjjdOgVT0zn1NAHmk3hO913S/E2oRWUhmkmEOnwyx7diK+SEz04GP8A9daXw48D3mn27/2lG6C4ZXlQD5mVeiD8zn8K9evtRjvYYYrK23vEqx+WOJFZRhwR2571hx3lxc39zaXEE9s8LbW8zpnGQAe/FAGx4X0vSo/Elq18ILfT0lWUnoA46A/jXq3j9IPEOlWmm6dLBc3NxcK6Ksg4ReWY+wH8xXkMUskFm7Q24luIv3oRVDEtgkA57muf0mCWyNxqUMVxKxkZbZPNbJDHLs7ZyeTgfTigD3bSvh/Yq85162s70lNkc+CsgHoSPw5rnvhxFovg7xJ4gsr6WGGeScG2uJAPmiGQBu7HpkE89a4h5dVePeL+58yNMw77h2APbAJ6f410XgK1tdYiv1uZpf7SAMvlM+XfHUj1+lAHtL6jZRxea95brH/eMox+ea4D4xa7p8nge4t7O8tri5uJYo40jkDZ+YE9OnANZXg2HTdVlvY7aFkvUBeOC4Hyufy4rP8AHWlSanrGg6LZ2lva3F3P58yqQViSMfM5Ppk/yoA8m8WReX4buxIVCquFx2I9fapv2RF2/FS/x/0BZufX9/b1r/G7SrXw1avBYzvcQz28c5klbJYkkZ9hxwKy/wBkcEfFS/JOc6NP2wR+/t6APr6iiigDwD9tb/klmlf9hqL/ANET18VV9q/trf8AJLNK/wCw1F/6Inr4qoAvaLp7apqcFqrBFc5eQ9EQcsx+gzXUazcx3s6eQhWzgQRW8THGxBwPxPU+uag0CH7D4dmusf6RqDeRHjGViUgsfxbA/wCAmi3DSzJDHFtZzypYk/UUAbPhTQ/7WvY1BKR5y/PyqK9UjgheEW8ESm3t1yQgw0mB+tUNE0wabpiQRo5uZlDO4PzHPau68PWcUFqjeUfn+ULIMAAcZFAHitxdyTaiZLndtdjF8uf3Qz0H0rzq80PUbK4vFuLGd1gyHfacDPRs9/Wu8+LJm0W8uLeKIo085ImH8K4+6D2zxSeBPGUEWhTW3iC5ieOE4j80b2YdcY69eh/OgDC8Oz6To0ME+oW+244LZdvMYEj+EcBcZ+tdRqXivw6Bc6bOg1Szll2RC2TyyiHHVsDOD0xXUf2l4R1izj+2Ppt0k2GRZnUPGTxjHBH0rd8GfD3wrqOt2jizg82Jnmj8osVYD1GSDjGc0AZmjaZZeHkNtYQfZomxvbGS/wDvk9OvWmfZ5EuXSOORGRt6tjjj3/rXQXkOyaUJKpiVmT96AQRux/nrVR4p4mBcBY2UhduRg/SgC55cb6aHOHbBTbn5gOnXuKxXkboy5RAXUKfmRc9D6+ladi3lRx7uTgEkN0OfvEelS3ECtKAjpGd+dycZx2+tAGLBMiX0c0QeA7wQV+Ye2fX8e1dFfvLLYpPPqmY1G7DIp2Me4Hp14rBew2XDvFOYnLcvK3y8jnLevsK2DaSnTlFqq+Y7czsu5W49Prn0oA5qzsbq4uBqF/DPcMoZbazRefLByGYdia6K8vbzXilnpelfYltQGkeZeEPG1Mkfj+NdF4TKWtp5LshnZvn3koznPJBpZb/ytTuhaxvKGcNvJwAx7e+MfjQBha3FBbaRP/alwDI4VjEDn6fhXHGfzTLPO4jhjCxxRKCC7d+f89K7DxHp7XmlX1xNGHnJ8wumcHBBPHoOled68klnHAb5JEkhyYyhPlt3Dfhn6mgCRZxH8k8pG4ZbauOewOKZcWTSSR3EIUtx+7PGR7f1rc8M6LcXUK3bxqliJUEvILspHb/CtXx1baTHOn9mupmXiQKSRg4A465PPH1oA5+1voZrvyJYTM03GQx4HvXc3vgKK4tUnjvhYIv32ifaOR0OD1/xri4dI/dxxyYinlOFeNuXTnt3PHXNaUUeq3UTKs73MELqrR+YCpx6/T9cUAFmh8Ps+mqfOillLQ3IyFLY4z7ZxXT24u7jRhqyhpIN3lz3JHCS8ZBHr0xnisTW9OTUPKF/K0EKuC7bgDjPbkYwewq9pksunWmoWUV47QyuGMBYjzFBBG9e79OfT6UAWGkDA+Yp2heG6HPX8+9WoSkTiQMsgchm3jK8HgfpUDqHG1yIy770LtuGegFAkCIzSEtNlh83Y/480AWvE9jp+syahpdhHMLW/gwwnIZo27qp/ujjFQeDvAaeGPDlzZpKzwSSeeWzk7wv8ugrW8I2b6nrVl5Sv9mjYvLvxgY6g/X09q9OubSC8s54mKkMcHjHHbA+negDw51S5S6hcZBARg3OOeCa5bxTpX9p6HKJo911ak7GxjcO+O/I713HjK0n0bWRelQlvMBCzKMgDoGPvWbeKVuo5VIdiBhSOCfXP50AfP0ysuAoAj5wx4x/9epPEtqNU0aLWYebi32wXfy43Doknv8A3SfpXQ+OtMFhqzyRRlbabLxMVwAe4FYui3aQX7x3K77S4XyLhQeCjcE5PcdfwoA4ivVf2XP+S7eGf+3r/wBJZa811axk03Urmzm/1kLlCfX0P4jmvSv2XP8Aku3hn/t6/wDSWWgDq/21v+Sp6V/2BYv/AEfPXz/X0B+2t/yVPSv+wLF/6Pnr5/oAKKKKACiiigAq7o0/2bVrOYkAJKpJPpnn9KpUUAdndRNa3kirk7ZDtP0PavZfD96NQ0m3lLqCY9jn/aHfNePXzF2tbjODc26SZ98YJ/MGuy+G10biC+s3YE43Bfp0oA9Z1jyZ/CWpG6YLDJaukhJ6Blxj88V4JZaBZWPgjxCZhDLqJVfKuGPAUMCUUHvgEk/hXe+Lb7UJNHsoLMiXT3fMyqfm3joCfSuH0HXra0167tdRniW12nCzx7sOQRgdsHjNAHnaQ3EcS3SxSLEGAEm07c/Wuv8Ah34Qh8UC+nvZpY4rfaqLCAC7tk8kg4HHpWR4g1e81Kyt1upbVokZhGsKbCQOBlRxx2r0P9n7wvrF+/iDV4IpU02ysS7llIWV85UKehIAY/8A66AOw0vwvBpGmpY2eyOM/PK68tIR6nvjJrZs7aPYYQA6qQN4GeSOBWZKs3mFRsx8uWLHHI/yau2skaLlbgSyNkk9F46/rQBTvJJnmBeIgISPlOFGOAT+NWAsQW6eRizBCNgGWZscc++Kz55XfzLcZVifn4xn61Z04pFObZgJbvhkG7G8cfp/WgDf8MSw61ouwjY0f/LM/wB4dj+dRWbRSfbSFxbSytI0iDOSpxg+3tWdp9/PbLc3mnWvmLGSZpUYbUHdSPUGut0eW3uITc2O37PdnzBt/wCWbEYKk+poA8vm1aXStUv0tf8ASLMnIjl+Vl9GyOn9K7Dwp4nWeO3Ny8kkuzaW3DgjsR3+tUdc8NXb6sWs4Ip/lKB5H2kj6Dr1/lWZb+CL6C0SS42RkA4bdkqOvIHfFAF8udL106h9uxHeO4aVkGW6Y47AdPequo6oZbuGCGU3DRXBlkEbfeUg7mPr2xipLnSNNe2aS5uXTyo9qysN24+yjt71a0DS7DQYlvNQKXc8v+qCrlgpI4A+negCxLqNrqOnKkEwRZSAzngoD1Pr0rYCQ6lbiXSDs0zTEWNnZsB2Y4AHqc5/DNY2qRw3cd2qQwxeYGYYHQ+ufyqz4TuprLRdT0pVUpeRJKc8ZMZBDL6nGQR3oAvSrISzKqhD99+4J6YHpVizvpNNvodSgUCaBwzDHJH+TWdaeZcxJLJkHLKrRn5cZ6CnF2MJI3SSscbT+VAHqFjqMH7m+061ga4LjflwB5f8W7354x6VgL4ksdO8W65Pq0U1yzWqWcAjbaFTlmXPYkkV1UOiWA0qOCe0QEwAl147cnjpzmvFtSnisbu+klkJ3zEBnO4tjhc+poA5r4s65ca1pA1C5iiiaZ0iihVvlhjXhU9Tgd+5NX/2SmDfFjUdo4GjTjPr+/t65f4lSKtpaRIo3q5LKeMHGOldN+yNuHxVv1fII0Wbg/8AXe3oA+wKKKKAPAP21v8Aklmlf9hqL/0RPXxdbwvcXEUMQzJIwRR6knAr7R/bW/5JZpX/AGGov/RE9fJngaIf20146b0sYXuCD03AYX/x4igDY14Il6LW2x5FnGLZGQg529W+hbJ/Gt74e6V9p1RrmQKY4MOd3f2rkZD5kjvgAsPQnk16p4Etfsfh8bQGeViwyOM+9AHV2kM0zI21FLNgso6fh6YrsAiRqsSnYq8AZBBx/TrWBoUYa8UjaWjG44GMYHp+NdJHGxPzKEP3gwwQKAPD/wBoG3t472yEsjRpcEOkgG4cDac/mK8v0vwve6qHOnS20wGdv7zaW9sHv9a9k/aM0xp9A0vUY4zm2laKXAICq3Tj6ivBbK7nsblJ7WQxzJ0YUAbl94L12y80z2R2RgEurAqc+hr03wJ4sv8AwppiLq+mtHp0MbfZJIl5ww5U9zuJyDXm194h8S63pUwubyV9Pi2h1UBV46Dgc1NZeP8AXrPSG0yK6ElssJhiZ0G+Jf8AZPX6elAHtum30mtaMLq3jNtMAd8coG5CeenY4/Cqtpq00DiI+TjHzZJ5/wAK+erPUryyvUu7a5ljuFbdvDnJPv619EWkMet2VnqsixwSXVvHK0Y6IxGfxFAGmn2f7R+8D280IBZmHD57HB5HPWq9xdqrG3hUSDJJWLomf7ueufapreDysyShS6qFCbeR2BzyOPSnLFGIUKRsZA27BwAoJ5wPU0ALp9nFkT3ayNLGcosjFggxyAegJrXSRNoZIwcIcMSd2QOSR0Bxx71TUKq7tztLjILc5H9QKtxI8xRouQq8ZbHtyfx70AQyXSjAzmZUwEyRjHPX9akNyoWNGG1tnKjkkk52gfXBNWYrVZ0XcG2xnjOFyfQf3ue9YmrTNY61FGwg2RTIWuCfmyfb2zQB0baV9shEd4/MnDRg+n97GPf2rkPGOkz2mltE8kV5ZfwnPzQkdOemAMcV6I29vmTymikVTyMq4Hr3OfUVmeJVii0O6Sfy1XGxQRwpzxj+9QB5zp2qwpocISdCWQoQxK+vA47nHSodCMEGuWeoX6yFYlYEKvy+Z0BPv15rqp9At7Pwdez3M8bXdvmRULcK39wDvkc+1Z3hkRX9kudx+fBUnk+3/wBegDrLe3sNS3ajGm2eM7Itg4XHYj0J5rjtJ1OWy12eSa28nS5ZNs6qPuMeMj19K2rjRlmgZLKSSxmVtyGByVb29z9a1fCHhK/8TWt/FLqdvBGreV5bKF3E849TxQBX+Nfw913X/h3YJ4QsbbUYVvTcMIGXzmi2kJjkAgEnIyTnHvWV8PvA/jLQfAz3viTSJZZ7aZlht3cNMsBXnoegbkD69BVmWw8Z/DPUEGjatFdWL5+QEvGf9nB6Ee1b/hX4k+K9YuX+2XlhZxxJiUzQ4CsTgDb15oA5pXu7qEXGnsLyKQ8QsNsqMuCyt2Jro/DWnNqd/l1YeVIolzwQccjA6H61wzTXi+J5rnUENnpUkm+SS1YrE7jOHUnucdPyro/DfjO00/VLie6mcedJlVCYB4wM/QUAeu6dpVpprLLbWwhdlxyccjnJA+taTF1V5ZCu5QQD2PH865O18baLdhvs94qhctknBz/WsvVfENyb2S30y5KQXAG53IZox7HsD/WgDG+MHjXQtI057XU3bzLnMShEyRxyQOuB6/1ri4pSNCiaV0ka2UJ5qtkOh5VvxUj9a77xl8E9E+IX9m3Da1c2GpQRiNyqiVZYs54UkYPP3s/UVteGvB+maP8AEGfQZrRJtObS1WAS9wmF7d8ZoA8S8f20dzoaySFjtIGQc5+leTTwOkp38Y5Unow9RXuHxA0e50dPEWjgtKlrIfJLdTEcMvPsCPyrxkSAK0VxEZIh90A8r7igDP8AGMfn2+majtIeWIwS8fxx8A/ipX8q679lz/ku3hn/ALev/SWWue1AC88K6gFAxazRTKScsc5Rv5r+VdD+y5/yXbwz/wBvX/pLLQB1f7a3/JU9K/7AsX/o+evn+voD9tb/AJKnpX/YFi/9Hz18/wBABRRRQAUUUUAFFFFAHWW8hl8O6fJzvjaSDd24O4D/AMere8A3r2/iCEZyZAc/Tvmua0cNJ4buQpP7m5Vz9GUj+gq1pVwbLUY7hQxYYB78UAe1G32RvACCruRgjnnoa9E+Ffwp8Eav4dtNV1bTU1DU4WeKdp3OwOD02g44BBGfWvPrORLiKOTG9Z4gRgd+K9E+Gt9/Z66iph8+KTbItuWwA3QkjvQB2TeCvhzHC3naJowEeQY5EBI+gNas1oX0CWFYF0nQliKm2t4h5rx4wRgcLkdhzXM6tPLqifaLrQJYbmIiSG5t0IIwfl3DvyMc9quQ/FbTINPjn1i2ns3yVkUDccjjgdf8KAPCfE0VjHqrw6N9qttPRSoWV+W9Qx60kEv2VGuJ9qpgFgq4wg46f49ap67rD3niXUNSw0Vk8zSQ27AFyCfvt/hXUeG7CO/tZ728R2iQhkiVS7SNggAgfn7YoA5O61K61Fm+yQCOEAxgDmRzngZ9favVfg14RsbA6lYeJLRJrqSJLtZ5QV2x56AnpyecV538G7db34hQ2pjOILwB43HKABmJ9skD86+k/G3h661cRT6fJGs8UMsJR+A6uOmfqBQBk3Pw28IXumytBbNFBJlw8EzYDd2HOCfrXhOtyXPhfX7zTfD9yNQs1AZ5FHyH1Ddt30rUk8QarqdnHpNpeG1085M8anLkA4YZ9DirUdtYQ6NJdahGBEDtCj7qkcLgepoAxbXXdUj0+C+aJTbSybFY/NsA6/5NT2fiWS7eSKSyvZolQlxGoVQo65I61Ul1V9MhC2nnRhuTCE3BieN2PxFSaPrU9xJLBHFO95v8sJwFGR0P+HpQBqWOqeHbp4pnn+zxhQ0e4bWA6EHHX6VV8WzXttLA+lPshf7qzp8xUnAIHUjrUVnpK2JVrfy7i9XJ4wRAx/u9s1kWn2oeIo/tbFyrNG0s5YsSxyCD9e1AG3b2V1PZot44L8lht2qw7YA5z9atO0NncwGKXbcRYeMoOFHfjtU9yXFrKEYFgepOecdPxrC06WbTL29kBR7hisuH+Y7ccj8D1FAHQSXIuIhtjCS7txEQxGVI6bexzzVuwl8ie2tZEEb43MynJlwfvHPQAenFYdjqN9fXCqq78nIAiwMY5ya9B+GmjLdR3Op6pAkkz/u4xjKRqO3vQB03iTUE0zQJ5gf9ZGFiOc7gR1r581aCW91DTY+WhSVppCR8x9K9V+LF1HFcWsESYnCcqDwqdAK85ZStwJJCdsUWc9j7596APNPiNd+dfuse79ydmQeK7r9j8MPilflm3A6NPg/9t7evJ9auWur2e4Ylt7kB8e54r1z9kNWHxPvd3H/EnnGMY/5b29AH2BRRRQB4B+2t/wAks0r/ALDUX/oievlXw2nleGtSmKgm4njtx9ACx/8AZa+qv21v+SWaV/2Gov8A0RPXy/YxiPwXp4IdTNdzSnHGQAqj9QRQBWXcWRW5Unbtxn8fpXs+j7LPR9NBA2rGMHHr6149CieYZUQDAyBnvXrViQ/hyyIXDmFMcHrn/wCtQB3WgKbkPMpEqnAO1gOp54NamPkbZlDnacjPTtWJ4XkhutPlKENh/ukcjjpmt8SkRb1kwOwIyBkdhj2oAo67YW+seHdR0u9G+C5h2FsZKnqrD0IPNfMd98PNTtNXntGmt2toYvOkvN2IkX3J6H2r6oeRCC0hZVzgBemR6gV4h8ebS9tLOEWjN/ZzzFrhEzgOeV3dsdfxoA8wmez0/WPKtonureI5QM+5ZmxwSMDj6Va0Oz0zXtTls7q5XSrqZ2McuP3BPXYR/D7Vz6yTRLG5B29ELDjj0PtUZZi3mYJIOSTzk+9AGrJoFwdQe0tZre4m8zZGqPgye4B7V9FeD4YtP8J6TYzKplSHy5iRyCMkkeuOxrwaS5uvFnimwOmWxhvGVIyUPGV6v7DH8q9r1Oby5Y7dFJMSgHAGC2f5cfrQBuB4yyhMguSoCnGB6++fWqtgspu2eV9kaErzxkdMAAev61Q0y+kkvVWcEh92Bgcc8j2+tbCSgs4LEocBUAyWA9P89RQBYTIeRJAME42liSg69uv1rVMaKibscjHl4OTn1P4e9YkMqqVZMRiIbvm+bd/tcfMMcjiq/iPXIo7GSK1nZbqTKqFGdueygclmoA2bi/c6hFbWFtPe6lOdkcUK7hnoCfQAdfzrprT4RT3Fm66zewoJMFlWPzXB/PH6mvU/Dun22g+G7O3VFhSCBfMJ6lsfMSTyTmornWVLMIYgygr8xHbGT+Pt9aAOTt/hvc2FuiafrRkCDCLcwAgcYHIOce1cZ4s8A+JLh5v7U+zzaOoZpGtG+fAXO4qQCPwr0tvFSW9zsllVUXLENyQD93dxwOvP4VsaZ4isL2NsTxrKilygOSVHVh6igD5Y+16bdeDL8WiQzQFTFG4PzM+cdfbFavhLSn0+xjhnVTcbSTtzuJPPB7/SjxLpljo3xDZ9IWNNGvHeWFVGEEhOTtHscmtu1gRkDEK8qONrK5JBPb249aALQQgKrbuoYKvXGOuO/rk4ry74v+ItQ8OaPawaZcPbTanJIS8RxiONuoI7lifoB716Tsub24Wys8vM7AFx0IPH5jp+dbN78PfD97q2n+FvGWmpNBPG09hNHMyPDL/GgYEZBx0OeaAPjm08Ua7aTmaDV75ZC24kzM2T6kHivf8Awxq6+M/BVrq726Lq1tOLW4UDCygAEuPwOcdAc16af2ZPh+Z/M26uE/55i7G3/wBBz+tVfFvgIaHpFvb+FLJLfTrWQxpCkmScHJd88sSe5oArfA3T49R8S61BqTNNY2rpJa2suNhkXIL7T6DH+RXsOv8Ag7Q9agK3em2xlVSI5FQKyZ7givnPwxfyaT42s7jzHijldw75x5ZIxz39a9L1n4lTWs8ItZJPKDktvA+YDA69QCaAOd134ejRtXtlRJksp38vduDFR+FUrLTv7O1L7I8e6Pz8b2fnr6fTFQ6r4sTU9S+029w/nSOoa2kckoT1Pt+FdVrt5pVw0U9pcQtcygSNCoy0bjhjj0PH40Adn4B0T7OXnnl/eRylkRRtwhHAPtUDSJefGa0ZSM22mydG55YA1Q8GeLYomlS+MqOE+WPZjcAex9a5nTdd2/G+O+KstnNA8LZ/5ZqeR/48BQBQ+OUKR+K9QcZJlsFLgZ4wCK+X8Fw6hikiN1PAP4V738WtcfUb/VtSyI8/6PCjc5VeOD6/414FsxPKBywGcZ4P40AXNNQPa6xbvljJYSHJHdMOP5Vufsuf8l28M/8Ab1/6Sy1k+GVZ9VfJQRtBMh9eY24Fa37Ln/JdvDP/AG9f+kstAHV/trf8lT0r/sCxf+j56+f6+gP21v8Akqelf9gWL/0fPXz/AEAFFFFABRRRQAUUUUAdH4ZUtpOr4/hMJ/VqerNjDdN3an+EEZtI15gcKkUTE/8AA6Qszxqw6+ijGBQB654LnM/h6HzCTJCeD04FddaSeXd2kyK7OsqnaJNoI9zXnnw+lkmtZbcHOF3g5711c0spg2qQE27PofWgD3vUtY1iZESWW1+ztHvuPsWSUQ9cueh+leZ+IfAl7qRN7ocb/wBlzMDFI5+ZskKOvTJPWvaPBsOnP4QtHt2jmtp4A80jkHedvzbj+Yrl9d+LHw/0V7fTT4h0/MUyIY7dvMWMA55K5GBj1oAksfhD4cTR0t76B57/AMsKbzeQyN6qOmM+oNdD8PdLGieHk0p4o0uLR2jldB/reSRJ68gg8/StTQtd0rxBZi70PUbS/t+MvbyhwM9jjofY1znifxtpfhvxLbW11I0nnwt5yxYYxEEbS31ywx14oAXxT4SS48S6Tr2jWUEWr20p825BCb4yMFXA+/8AzFWfHniqDw14Vury4kjivShihiJ+9KRxj1A65qrd/Evw5BAHjuJp3YZWNIWyfzrxjxHq5+IHjFb7UAkWhWAMQjDZIYHOG/HnPpQBl+G9kllF/Z0fmzuWDPnAjbHzf44p2s6iioukLKJFiH+kP1G4HPQd/emXvilLyQ2vhmxRo8lS65CfUkdKz9GF3aT3S3U1nNIFBEaRgrFnuSOpoAi1G4ln8i3spnjg5eSaU8ogHQenaq+kCVrdX075YY5Cqyq2C7f3yTzgjOKLy5tpbqOG8LyxOojWFFIVmz3x1FXvD1nqEcN1JfRrFDKxIxxgqflIHbAoA6q1NskTKMxMkZAIG0s/U1lavbzTWyyRyLbyoBLJKpICr0wQe3fNX9Pkiv7VpZl2SISmc8cf5zU1v5M0R+XzAWKEnoR7igCDSL03liJDCfMLbXBxnIPHT2rLs7OLWfEf2feBMOdgJUf7w9uxFXrKztLWzUqG3biUBbGB6H19qo6TBJqOvRnTJVjukcgt1VR3J759cUAe0eHNAsbaNJYoUjWQLuhIH3h3z2PrS+ByyWN8Ix/o63Uixqc9M1kajaa3psljaHUI2lu32ZjXAGOetWpI77wdO0loHvtOmyzqx+aNs8mgDiPHdwlz4tnUj92nAyef88Vx2v3PkaRqD7sfIcHOc9sVuapdLd393ePtzMxZTjt6Vx3jJvJ8NyLIwVnYD/61AHlchdow6qpBJOG55r279kqPb8RZ3LBi+k3WT/22tf8AGvDHG1yDgE9j3Fe9fsnq48dl3H39KvD/AORrSgD6xooooA8A/bV/5JZpX/YZi/8ARE9fMciLD4e0CJ1LAwPLgnj5pG/LgV9Oftrf8ks0r/sNRf8AoievmfWovL0/RI2B8wWER6YGGy349aAKqFFQttGcg7i2T+VeneGJzceE4gygvFJtO58dDXloQ7kR8qSMsQOT9K7HwJdNNHd2Hyr54Dggc/KefagD0v4bTq51aD7ymVZACMHByOM9uK7SGaSKOQK7jdwQRuHPT8vavPfBMq2Hi2e2iYKk8TIFPr1A56DIIrvthEisUAIHzFeo57c0ARsAvzR4B6ngsD7f1rjviVMIPD927OkIl2qXYlQzjleD612+1ADneFGAxLcn0PtXL/E7RJdY8E6nBZo097HHvhHDZAPzKPcjOO9AHhWmS+G5pbS1voZJbjDBg27bvPUnB/zxW5o2m6PZXxsJLSS4tLpAJYiSFkXPyuCehB7g+1eUyLLb3JWVXinjbDBhhlYeo9a9q+Cthq/jLWp76/VX02wgaHz/AC9pLNjhe2cckUAdVYeCptFvt+lWlqUu0JkSHCiFOoJbp/n1ratPBt2YhNPLEm4gCMAsfpnjivStD0u3gQKqxiKNTkLnc2Mdu9Q61rOm6Ukzap5NuGfESbgWf3IHPfpQBww8FwJGSkiZT+Mk4UZBxn3/ACrL8RW15o1gs8kpa0TIZgBlPUj1611q67Z79iywsspAOHGAMZ69Bmuc8XeI7DUtLe3hkglT5o9gGCp9fagDgdY8bRW1q0ul7Li7kQYJOFXsSfeujsotP1a7029sfJVIPJ80jqp3Bun97OfwrkZtKsZYzCsTkYwG+7kj09vetHwNBJFFrcLqGlhkQ7l54IGD146c0AfSut+NIZ9CmRBGJ3KqFZSQR34/LH1riG1u6Yt+8ZZt65AGAw/ut3aodJifW7SO5sl3tIfJZupBzj5vcenpW3B4H1Rgj3KGNRlRtXdt5/ujGB+vFAHN3EsoaVZMTvuyd54zngY7EA/44pbSZ1uEkgnkDxkCPAJKk5HXHavQofABVJGDqJ2GGJ/i+uK2NA8GWum3K3cuHuVAxgnGRnHU80AeSeO9OkNlaTXcaorXKLu9Sc4K+nbPatD4YeHV16W9hu7yYG02h2jIBkDfdyPXg81s/HRrRbHStJjeNZmla6cNk7UHG7Hux/Q151ofiO/8Hayl/Y7ZllUxXMTZwVH3T6+3rQB9DaJoOl+FrKd4CyxqC7yzNuKgDnnHSuL8Z6jP4lFrJoSJEbG4WaG7kOScdTt6gfqfSufm+KaeKr7TfDbWEltPeFppJBJ8jJHztGffGc8V0UV1b2kDmd03tzuddrLjPHHegDOu7zxLqDiS8v4mic48m2Voxj6g8fzrBuLjU9CnkubSymusHc6BxIQ46ZBOTXRXevWyS3Fu8I5HyQ5OHJ759uTjNattbW0mmxu07BimWC/y7HNAHgviKDVbfU18USoWtLiXzHUZSSJs4O5f4c5PFcz4gvr1NShuL3UbWLTWDYScBJHxnG0jt0wf0r3rVdDs9ShkSaFgiuDvdicHPBI7/wCc15x418Ktd2k1reIs4XLJcxqFMy8cc/doA880hbrVJ7rUGmlFgEQ20asNzEryrH396qz6Tf3lidSgj1DTdWt4miAt3LB9nQZBzg9veuotrKCxji0+wQgxsu4SHJEeMY981vaMkCTxIUWJym1CMdFPI+g/OgDjPhbf+JVna81We7uLEuD5c7tvyOrKT0Hb3rvJdRmv9VudZQeRHduIoI167VxzWVrt6J9Sew0xy9xdIElcg4jXuAPU96l1G5Gh6fmHY8VmNkaucbnxz16f/WoA534m3RF/HbpIXjjUuypwN5rgZnlyvljYmOO3/wCutDVbye9u2adQS+WDHtnr9azndyPKHzrnCr3X2FAGh4YGNWeYSqI4baaVi3OAI26Vq/suf8l28M/9vX/pLLWNqTponh26MzH+0b9PIjQ9Y485cke/T8a2f2XP+S7eGf8At6/9JZaAOr/bW/5KnpX/AGBYv/R89fP9fQH7a3/JU9K/7AsX/o+evn+gAooooAKKKKACiiigDsfAm1tJ8RK3/PvGfyeogqmNip5PAzUngLmz8QrnA+xgn1x5i0wAn5QCCenHb3oA734Y8vLjGSmOucivQICrQsdqllbBFcB8OMJcMqkKdpxjvXdWmC0ynIBOX98+n+eKAPLfiVq15pVtd6da3VwkGpTsZEWUhFRcfKFHHJOT9K8tru/iJdo3iu+0y9BS0jlBimCZePKgk/7QPp7ce/P6h4Y1O1sRqEMJvNLfOy8tgXjOP73dT7MBQAzwv4h1Hw7qH2jTL+7tFlAjnFvKYzJHnlTjrXuoX7RALi3lE6kKAwbOQcYbJ654rwjRPDuqa3MY9OtJJMDJYjav5nivYtGs4dG0uO0h1LOrBVj+yGRWEm0ffAP8Of5UAdNqF8NO0hrmcNJOF8qNV67jXO2mia1Lp4huClnYSOXmCDk56k+p9+1anhyCa7M9zqkqvJCQiKE2qgxycevvU2s+KrTTzNEivK4UlEX7qv05NAGYNSLW66VoUXk2qjBcDDTN6nuB/hW9a6Y2keGhtBeeRcsxXkk9R+tZ3gKKbUJ2SWPALeZcSYwEU9Frp/HN3JBpElvYhTPEFBB5wPQ/XigDmdE0eWFvtU29psnYcfcXpwf0rpXV52VUDgsOSeMEf41D4fvRe6cjtsS7kHzxE8pjg4Hbv+NX5lZoyFJCkZZj1GPT2oAhs0gjMoiQFnyyhuF3dDTpFmeDbGFSNiV5GTx1IqMqqIhlcBlOeT1H09K1vDOjXeuA/Y1KoJSzSyAgJ+HrQByviaZLZbYIhLOr4x1x9P1rR8LaPe6TqYv7uB1jZQFeMZEgHQn+Rrd8eeEoNG0vz0uW+3yMqQswyZOct9BXX+Cr+3vbeGwvFEU8ChYznhhjp70ASWmt2WrLA8rIs0BAw3DI3TI9iO/atDx7clPCssqlSwkXJ7803VfCWn3f7y2X7Pc9FK/Lk965TxbaavpmjLb3twlxZ5G04w3HYj6dMUAedtIwaUYyTyAenPWuS+IMp/sy2jcjDbmX2OP88V2AANrv3Mig78H61x/xAh86xt2IVHBLDHY/40AebqUlmVJAysOpxyR9K+gP2ZlSH4i20Mf3P+EeuZfxa6g/wFfPs+Rt4zIDgr+PSvfv2biYvjLLZtw9t4ZKsvoWnhbH5MKAPqmiiigDwD9tb/klmlf9hqL/ANET181eJXCvpi7gw/s+24DdP3Yr6V/bW/5JZpX/AGGov/RE9fNuvZksdDueAJNOhGFI/h+U5/KgDKiY4b5mL4wGyTit3wXenTdZt53bdGMqQf4sisRmJ5O3GPcZ/GpLeRomChTwd24dD+dAHsbWc6yLeRFFuWRXGwc7wcj/AArvNNvLe/tIL2BG2SqDsHG09CD+Nea+CvEiapAlvc5+3QKE28DcOxFdDY3smg3bOQy2UrnzolG4o3976UAdnK6zOxwU4wduCv1z3NNV9mWMo+U4JA+8QOP8mmxzRTjzIXDoVyPLw2V6jj1p6NnqsUaZBCgZYk549uKAPC/iV4Ftn8axvZb1bVGDpAj7i8jHnBxkDPJr6H8H6LaeGNEttPt7cG3towVWI4JdvvN68nufSuag0y3uPG9hfyqPMsrV/LLIdpLNjJz2Azj3r0W5SKK1jh89njXkRLjex759qAOY8TagXMz2kUkTRqR56Eg4PceleOasA2tzvMXkmX5TI5JZfxPT/wCvXtHiPUbeCyjiuVBt2cDZtIBx02gdecfWvM9O0yPXNUultWZyrlpC3UZPGM96AMGGCSSZo4I5JJdox5XBX2xVy60LUY7VZJLY7PvDAGc56H1+let6FptnY/Z4LOJI2cZkYJ8yjHX3NbN5p0bWpk8xtqDBzyM5xyR944yfagDwCzsru8vktraLfOOOGBwevftVvR7aSzXU5LjPmuAjZ+Xn8fw5rqfHFnNpkx1Dw8gtr2RkjYLEcMnuB19a4+/0xv7Hvnu75kkZvOdw2SJPX0zn+dAHU+APFmo+FfENxaw2kRtLlxMYppQEfPGVbHynIHJ616P4h+MUdmGtrLTSb9F/frJJkQsenQfN69q+eNC1K7ubeaLVPNN9CoYZQAvGOTz/AIeleheC/BEvi22vta0BSLaeVVdJ5MK7hQdwzzgZA/pQAyX4jeLHv5LyPVZUDSHMQQFFXtgHiuosfjTqFrGsGrw20k86kRSwrjaw6gr0ziuPvPDWq2mtro93p9wt/cOI4UClopMn7wYDGMd+2K9Csvg+lqWu9dv42ghjZ5DCpLEYzjnoBj60AeSa9q8Q8YXOr3d3eSefGFee4xvOegA6DHHAGMVdSWDVNHdoGmAzhJiQMEHrg9q5W7lOu6RCIVYu8plLN95gSAuPwxXX6MJbOze0ddwgUFMIOeOeOhoA5LQNQfTfifYPfIyRwy+XvXshGGOSOnrX0hD9mmszbOlpt2ku7ncApPUH/PtXjt5a2OtWQjuN80bscSIpRkY8YUjnH1rpPhy0llpEumalPJNNbPut5HYbmi9Oev0oAp+LNNv9E1u2Cia5t5YCyzDkYH6r2966jwjqM0At7e8EMrtG+xY5CzbdvGAPTPeukm0+2vYo4ZxBIACCHOG/Hv09OtVtM0uLT5ZJdPVVaRdjFTkkDsOM/hQBJaXEkZbIfdnO0j5hx79/61i+JbMX9hcCKNnDZIB+8B6gnvXQaID510wE6eY217eUL8wx97B9+9R61Eqx4Fu0ZwRuByPw54oA+eRKLO8utPlheKS1ZfLLS72kRvTHPHcmtbS9StLHSr65nkElpEWfcCNwdugB7/QelYXiLxDZWniO9F/aC4u4AYkuIeJGVuCnHf0rsvBnw4vLjSE8QeOC+g+E9Kja4gsJD++fHO6TPcn15PAxQBmWFuUsWupgxvrrGMjBRT23euK4vx2ZGuIbQh1SMcEvy59a7WG+XU7K4vwZLaLcGjc8HaPUe4x+VeXeIdRGpaxNKrFohkJwB07/AI+tAFB8urxtHJ+7YnJbtjmuh8BabHqXiW0imIaFOWDn73pk1zIRuXCMuFyWDZFaOlXMlhdxlARuIBw39aAOV8YXElx4n1N5QVIuHQKf4QCQB+Vd7+y5/wAl28M/9vX/AKSy1yHj+FRrf2qMALdIJCP9roa6/wDZc/5Lt4Z/7ev/AElloA6v9tb/AJKnpX/YFi/9Hz18/wBfQH7a3/JU9K/7AsX/AKPnr5/oAKKKKACiiigAooooA7D4ZMsut3dgx+a+s5IIx6vwyj8duKa8aebiTiTd0PbFcxZXM1ldw3VrI0c8LiSN16qwOQa9Qv7SHXL/AEfVbGIRx6nHvkiHSOVThwPbIOPY0AdN4FtSLOWXjzQcL6E98108A5lVcblPH41HbWyabaMqLuAAA44z71Ja2zRFixBaQndgYIoA8p+LHh68u/EUd3YxtctNst2jjXLB8YBx6H19Qau6H4V/4QcQ6x4j1qWzUOP9HsyWDt12Mf4h6gA/Wuj8ZLHbxaqHujbyTQG3h2AlnbGQMDnHHXtmvEdW1XUNTlQ6ndTTtENiiRuEA4wB2oA9ZvfGGr+L2ubLwlFHbQxLmSZsK7A/3Rjj/PSuV8FeEbnVfEt6b24k+zaeczTLk+Y+eI9xx15z7Cs74X6fdX/i2A2vmiO3Rp7gxMFYxjgqPqSB+NfQBgjgs8JEka/eEanAA7lj3NAHLapdyS+IDaQRkWyqEIjbABH/AKEO2aiGi53uQhZQSFI4B98dannvSuqrILFZIAwLM5xkYJBU/pg+taOt2CTaetrBeT2DsFKSoRlWz0weo55oAu6RqKaLpJhtEjczAFyW+Yt659AayLm4kiLyX84aa8bMYYgBsd8+hFYN1pWrwXcd00kUkLRHzCuSm7oWB9MCqeqW8kttbRyyPHcb1AVjlI1z1FAGo8tyt7brZzNcR+buKJGEd+Ocnuua3dL13U0Iju7MyNg/NuCZx1JzXO2FmlhehWufOlZPLRN2BjPUntU2tX9tBqGm2V2z3c9wR5drbMDtH/PRuwXj8gaANLU/EFvNdxJLkB2WIueFUkjA+nvX0x4bQQ6Ba+QqxR7Fztxhjjr7186vDp80E1nbzQSTqpOxV+8cdh1Paug8J+OL7wlp2nw+JdQgeIOIfPVT5Y3E7c56DHegD0f4lR27S2bPneUYljyMAcLjtyc/hWPDp0qeHLW8hJjvgA9uQOAR1B7cir7sPFWowmBhNaqjNujOfmP/ANavRLO0toII7dEXyI1CqpG7nHWgDI8NamNY0qG6j/12SksZ4MbDqKxPivgeGmdychshhx9KwvGHi6z8K+L7caDAdRF1kX0MBwkbL91wem49DivP/iL8QtU8TX1pp8Vkllpts4nmYzDzD2GU67c+lAFIGRbTfwXVcDP8qyPFUQk0dZ3GMH5iBxyK19OkRpp4mKuyndgd1PQ1Lqdh9u0u5tpGwXXK7ev+elAHkdjBY6PbJrOuNvj+Y2trnL3bjp9EBxlvwHNehfsfX0+p/GTXb27bdPPpMzuR0yZ4OB7dq8x+J2lX51hrmIGfT4okii8sZ8hVGNpHbnJz3zXon7FP/JU9V/7Asv8A6PgoA+1KKKKAPAP21v8Aklmlf9hqL/0RPXzVat9t8CaXPjeLKeS1kJH3QTvX+Z/KvpX9tb/klmlf9hqL/wBET18u/DidLue98PXDKI9TjAgL/dSdeUP48r+IoAh3sw4YL6DqeKkjEbEsz7MdeT0FJMGhdoJAA6HY2BySPSo9hI46Dp8/T8fWgC5F51vL5lpI6NkPG68k89677w740e5T7HqcaecTgTMBg/UDqa88MgMKgMC6tnFO3ELEsjLCD3BGVPvQB7hYXz6f89gd1qfmcIQ2fp6V2WmNcalpjXunwefEMpJ5I3OjdcMB3rxTwnqUd1HFZ3FyY8nBB43+mMfSus0DWdf8G61LqnhqdJrNjibT5jiOZfXPXcOzf0oA7Dwrq1lqfi3U4IZGIt7aNSHfkHcc8enIr02DT7f7PDMQbo8ncANqnoT/ACFcJpR8LfEjVP7X8Lyp4e8cQg+fZzgYuF/iV1HDqf7689yO1W4fEM9hdtY6xC2nX8bgyQy8hyOhRhwy+lADvEWl6hqF157+WIFcLHEMFQewz/QVoQ6eLLQLcQoFvEPlvsXO7PU+pxz06Vbub8X8tsZzG/lfvEUEKC2OuPX1NM1bUI7hAZpIYIlBLhV28dQQfrmgCW0gMUEIuoWW3IL7/LxuI7HJz/npVHUNXVImR3YRBtuzdgOOvOOvFcv4g8b2Ol2MZXeyDglQSoz1IPck1yV5430u682ae8lRVQbQ6MSv5UAbeqag17L5jqwWMfKoXaUP0HsRx/KsbVLWYwoJYFuFzvWNTlU7bj6kflS6tKZtLS4sSrwyhCu3I8wEj34H+TVsL5gCzks2NryRD5c+g+nSgDBs9AfWdWitrK4hkeNTMZEITyiM46d67v4SfEvw74Q8L6rB4on/ALPvhetIsCxs7TAouCoGRngjsK5OS2t9Kml1e3syxKiOfyMjandiO/HXHajytN1GE5EEkcvDEICCMcEDr360AfSHg3xlo/i+B5NJkk3xgMYpk2OFPRsdx1GRXnXjz4w6c41rw9pWl6jeXDW9xbC4QBULAFGK9SQDnnAzjivPfCNz/wAIJ4w0vUYpZxpDSmGdCCcROpGMdcKwVgKyrZFu/FN1d6ZJujuYWmQZICqZWJ/EUATaHY2Nv4NMdxDIuqIY2gdXxhhwVZf7uMVU0aK7mklup5T9naY4j3f6odOG69cmpvEmoSxtFYWPmPNPKsZcAN5WTn88cmtpYxB8kBKgDHz45Pcfp1oAydW+3ebDcaYsEioN0kRBAb+6M8ZPU5pP+EpsoLZJL1jaylvmWPBMbZ5z39/etnzHaJvMJZHBADZXB9c9KzYtLtTezzvaxv8AaANyyrkbRxQB0uh+NIrtUWES3luwGWRAGx689v1rt9P1m1YhrRYgCo+UHIUk4+uRXla2ED2Rtmj27W2qIW8vB3cH2p7R52ILuWJlIUbHwy9cHI60Aen3esB7hp5plUhCDl++eoOOAa5Txh40s7azmWCQXd2QVWNT9044Jx/niuM1yO7bSZ/sM9y1zENsb+bkMKwUs49I0xp9Qm8ydxvcrgZ9uOc+1AHq3wb8J6BoGgTePPF9zbPdysZUe4YMtsBnov8AfOCememOa4/x/wCONR+JmobIIpLLwfavuSGYbXuyOkj+gB6L+dcPMJtRhik1e5ktNJhYNHHJzu9wvT+tZviDxO1zb/ZdPjRLOMH7vVyP1FAE/jDxIssKWVhGxiA2SSDnJHQY9vauPjbdHudWDEY+Tt2/KliDE+cCTtwQM/N+FIQZVDpnc33cjA+n1oAiCxkxEhRxt3nPI/lUrvsJIIdVbAG7PHtRGxATcoDdGTdngd6ihZnmVEXb820Bk7UAHjYhrTSXCkKY3A5zwCK6r9lz/ku3hn/t6/8ASWWuP8eSY1WG0GB9mhVGUdAx5P8ASuw/Zc/5Lt4Z/wC3r/0lloA6v9tb/kqelf8AYFi/9Hz18/19Aftrf8lT0r/sCxf+j56+f6ACiiigAooooAKKK1PD1pFc32+5ANvAPMdT0b0X8TQBreHdKsoYFvdZiM+//U2oYruH95iOce3eu102YgWBEK2cEIMdtCDuxlsk88k5rm7dBqN/HJKmJJXVQF6Kvcgew6V9z+EvBvhG38PWo0nTbO7s5o1YTzIJWkGOpY5wfYYwaAPCGhmuHRmI2gcZ5yaV2MbLwo9N3H513/xV8LDQI4dV0WFI9M/1VxbqD+6Yn5XU9gehHTpXm+6WZ1BETQONwGNxHFAHC+P/ABRN4clzpo/064kfbOwz5aLgce5P8q8cHmXV0MtullflmPUk9Sa7T4wStJ4mjAGIUgATnIJ3Hd+tclo1hLqmrWdhbgma5lWJcepOKAPabbwNa6Ff6bptnNPNFqaFb9n48wIVbClfuDdg9ckCug1nW7NfOspJ1k8hcTB2OcA4O5v7xz0rZmkQajNBFIGS2i2L1HI4BryH4j+dcPLBbSHG5ncABQ+DjLe5zj8KAOo1TUrHV9KlsSFNpdRhjIGx8u75cH2xWPq4lFvNHNcTvCYkg86V9zsMEnnvnAHauL0mYXGmsskjrNaHfsZSVmUEfKAP7vWtfStQmeJYtQZGs7dGZ7WZsO25uAp67QOfp60AdB4OuDK19bxXTfYpgFlR+AowMlF6jsDWvZeFbrUXg3yExFMGQEkuAfvH/Cl8I6ffT7b24a2e2kUGIxqV3KeAhJ9Bzn6V6FaOIrWONyNuCQw/T9c0Ac5H4QjsNNuohNKrXMe0zDkr2yPoOa4e88HJo2pve2UrTNJA0SKRwWIwWz2yMnHqa9pQvKycB0YZyeFDd6xNUt0jUptTnGHA6E0AeS6Hp2pR6vaSwxNDE8uTuO+QNxkFz27cV32t2EurCXTFit5VLLMTN/q48dvf60txBDpK3V7PIjxRKTF82MMeCfxz0rOni8/wwsZd4bnUiTvQnIiBxjPYn1oA6j4Y3+p+GNWu49EvLXUI5j5k1o5OFYddh+ldDrvxRv8AV9NMdjBDZQvCZt8M/mOQCQVJH3TXm+m29r5tm0EZjWPAEQciQof6etM0uC0sNTvRLO0VzqEzMiKPlCkYA/HrQBzNh4jxfOZbifzric7GaImNCONoYHJU9vxrsvFFl9o0ueSLi58raWwCcDnr6V5bqtpd+GvEN2jNPb2u4sqxKT5m4YyM8AA810Pw21zUdSuI4GuVPkvhotvDJ/Fuz2xzQB0Hhe6+2Wy6qkiiWK3MDo2BvZT1/Ku88OaBrvizTzdaFbIqpnEtw+2Jj3UcZJ+nTvXMfCr4czeJ/EM+ZJYNGWZplC8Hy93GfQkdB+NfXOn2dvp9lDaWUKQ20KhERRgACgD4g+IthqHh7XZLbUI5rG9zuIJ+TB7q3Rl9/wAK679lIq3xb1BvJjjlOjT7zGMBv39vivWv2otHttU+GUk0mxbu0uI5LeQjkc/Mv0Kg/kK8l/ZPbf8AFO7bcrE6LOcr0/19vQB9c0UUUAeAftrf8ks0r/sNRf8Aoievi6GR4ZkliYrIjBlYdQRyDX2j+2t/ySzSv+w1F/6Inr4qoA9W1oJ4g0mDxNpyxiWRdl/HGvMcoHzHA6A9R9fauSU4PyBTz1zkn8aq+DPEc3hvVfPCmWznXyruDtLGeo57jqD2Ndb4r0VLJob/AEoGbSrsebbyDnOen0x39DQBhElY2Izk/wAROT+FJblTIomXcxyMsODnvUIjU7flUkj5nZs7TTlUYdgMDrvIxx7CgCyXMMyiIsNwyPm6H0rptB8V3dtthn/0mLbyCMEfQ1yGSrbkbYhyflPP0J9TUsU+5QrAktnacHKj+tAHpajTtfl82zk+zXq7ZIZd4jkVwexH8629a8ba5cWENl4oktr2SE+XBclNrsvGCzjqfwrx1SE2ylz5YwFKjncO1bFt4iu4RHDK4ngGAY5sHr6e9AHfrd3MlupsprmxkVMkBiUfJ6huw/WsiFdWvPEtpY6vdTi3kYl/nO0hR0B/rUWk67ZyRGJZWijLfLFNkx9PzrpdPuBM4cMM/wB1iCvHdWHTrjFAGs2n25iiR03RO3zCVuCAMjA/pUkltFKv2doYhhcY8rHHbPvTlZsKZYh5zYCnhlwCP19KRkC52sIwCSXyTk+3rQBDFEkElqluVWEIVAA4OeTxV4jdcfKjDcCdueQO5z/SoniBIKsyyKFbcxGQp9uwP505WBkWPzAB987Rkt23Z+n5UANldSEEh3NJ8oC8IRjG0++KYdMRWL2aJFJlSAvCAY6Ed6nPDYBaPc2TlAABzj3ApkKJvVFZfLLjPOR09fc0AZujXo1PzUurWW2iMxjnadfuso7GkutOOiRzjR7Nbl3Vi53Yfc54IH93J5xWD4i1Z59eFuIEie2mf5kcsDngsfbHrWDdavcbpRbTzgDhZImO+HngL/eXpxQB6JoqMNNg+05e4lyZio+YvzkD6Vad/wBzuD7gqjG7BPHBHvWZoesR6ppsDC4iFxGuJwzhDv8A7xFaa7juDqpwM7lABJ/woAmG8g9/LXdnB+Y9gf8A61QnM2+QBGVcMSMdD1Hqazrq5N7cf2fYs+VYG4nibGxe+Pc/0q6zKoUxvFt3HcMbWxjrk+1ADnDEOwLsq9Mtnaf84pY2Jdx8jgNjOwKeORmoHkRT5oHmHGWLY2+3PrXN67rVrAjJeXxViu0W1uoYkdclhxQBt3+qJBvht08+RM/P0X15OOlcNe65Bb6i898Y9Tuv7iHCxf4/WsXV9fmuYXto90NmvAjiJ5H+13NYzxYO+Rwqg9CPmxjtQBf1HWLrU7stMwK4O1Dyo/8Ar1nkIJW82QE7sgA9OOhqORwu9YIkQZ+YAfMec96aGRMlhyRjpg4z3oAecGaMSOARlQVGMZpHZ0yuWDA/MGAwcfyNMwWYkMQcD8aY5SZZElCBwOCcgH/PrQBK7BgFeP5kyCQccdau6KkcIm1G8DC0txvJZ+rdlHueKXTtMWK3kv8AU2NtYRfKWYZZv9lfU1zfiLW31aVEijFvYxcQwKeB/tN6sfWgDPv7qS+vZ7qc5kmcu3416b+y5/yXbwz/ANvX/pLLXlVeq/suf8l28M/9vX/pLLQB1f7a3/JU9K/7AsX/AKPnr5/r6A/bW/5KnpX/AGBYv/R89fP9ABRRRQAUUUUAFdh4e0/fZQwtG3+kHzZZM4CJ0H9TXJ28ZmnjjHV2C12mWmuwq/6pBtUDptAxQBteELPzvEscbANFBnLf3gK958AeMbjwteiKQl9Ilf8Aew9fLPd0/qO+PWvIfhrYNsvL1+jfu1PcCu1IEJDgZB6gj360AfUt/bW+r6TNbuVktrmLAI5BBHBH6GvlbxBY6jprTpYD/SYJGilQcLuBINe6/BnWft/h6WwlfdLYvtXP/PNuVx9OR+Vct8TtNWw8WtPGCsV9H5p9N44P9DQB8seJ7S41jTgJIyNQtXZkQfxqx+ZfqDz+dafwq0P+ydROp6kRDqGDDaQuOY2YYMh9wDwPfNdj430Era/2ppqP58TnzIwPvA9x71zFr4ikkhWIGJZwcFynI+h9aAPTLSCO3QL8sjBipJbJYAfzzzXm3jLR4NQlmtbm4W2u4nLQSHO2aPsWPQEHI5rsdP8AEFnHZJJcLIsikgjy88etVZ/EOnapC5t7LzQHCEsmCc+vtQBx/hvwhfWeoR30l9arAo4Ek2SxPb6HvW5J4XguZZEeRDnCRsjbjtHqfTPNDxwxO3lxozNwCwzj0A9Kv6VffYJXZFwjL8wHX8P8KAOtgtI7aHYq7UjUIM/dHHYetSiRgyBFwR1HXjP8qS3c3FqhQo4dVAx0J9x2qdYnSdWYhiFbco7enNAEqyGOMLklx0AHBHesrxFerbaXNczOIkjGWZmAHsCe3JFaWc2u98Eg/K2f6Vh+K7T+1dB1OyQ4kngZRlejcEfqKAMhtNaSYNIDPC8aERyjIRsfMQffP4VNFZ+XdNEAXs5IyBvYjYc+3Q965rwVNH4W8KvdeJNSYiZgYoWcsYwuRsUdST3A4GK7qEq/lyFWR5SGG8cbT6/WgCDTLI2kJQSb2LDL4AJQdjXL+P7W6stUSWxBwiBVRTkY9cHr+B713UaCPCqysnUn/AVwvjvW7+y8SRWsKxzK8YaMMuSe3HvnvQBpXAttX0OCa5kSCVseUZgceYB0IGM8HGKm8LaVaLHJHZAzQSSHMpTaZHJ5jT2zxn8KyLTw7q+ui3Oqv9ms/MDmFBtKY6Eemf617j8JvDy3msC8dALDTcCJccGTHH5Dn6kUAekeBPD6eHfD8NsVX7TJ+8nYDq57fQDiuU+IPxRh0K6k07RIo7y/jbbNJIT5UJ7rxyzew6dz2rV+Lvis+FvDH+iyBNTv5Ba2vqpP3nA/2Rz9cV89aZBI1sjSIxAZ2TJ684/xPvQBf8Q67q3iNJLjVrua4B48g8RxggglV6fj1qP9lyE2vxdv7RsZg0a4TI7jz7fmpDAAoRcldhVsHIOeaufs92hs/jnqqk7g2izOD65mt6APqKiiigDwD9tb/klmlf8AYai/9ET18VV9q/trf8ks0r/sNRf+iJ6+KqACur8H+LG0iGXTdSiN3olwf3kOfmiP9+M9j6jof1rlKKAPRNZ0dLeBb/S5Vu9Ll5jnTt/skdiO4NYiLtPmMDgDHznqapeGPE1/4emc2pjltpcedbTLujkH07H3HNdtbJ4e8WEyaZdLpeqMQfsl04CsT2jc8EfXBoA5gSKoXIBxnaNvFPTDYdeo4Gf8BWnq/h3UtJeRZ7SQ7CVMi8g598c/hWQoIVQ5y4O1UORzQA9ZpInU+YR8vG1c4GefpTzIC7NLER0HHDZqON+gzsX7xPXIpsP7xlYoMHLLu7dsn+dAFp497F4280MectgjHt3q7puq3WnSk2sxhdjkqD39COmKyVZM/KmRk7DgDGO/41MbpthJO5BxtIBP1z3oA7LTfE9rlvtKXKSE5823ctkj1XpxXR2viS28mRm1KKZcBSJoypz7GvJzKN2WAVlBVT1wPTHpUweUIEE8YXPIJxj2xQB7MmuQSAhdh3OpO1xlvYD/ADiorvxFptuJTISoUgb0I+Y9h8p5+leQRSyZJkWFgRkc+n+elSpOVVCdoOM7VIGPY/WgD0Gx8aPbSSpcr9tgJJR9hR29if8AOaz9T8WXs+5LciyhYAEqvzY64X/61cXLfuEyvyqcL8ufXn60iebdXHlxxySyBdiIBls9cfWgC7c3LSmZYmdUJGX3/MSfU+9VrWQxyKobfEWycnqen513Ok+E4LTSUv8AxJcxWenK4LtcNsBbH3eOWI9ACarXPjHwEJksxFfSwL8v2pbZQgGMZ2k7iKAOaluVilMroxBzhkyG47H1+tWG124aKOI6hcRqP4WY4H+fWt8eEdM162M/hXUYLwEYMMcnzr6ZjbDD64rktU0XUNNRw8WQgKsAC3A7fWgDQtNfu7LKW1+qICchh97PYnrmpLjxFeOu03XK5YEjJH0IrlzIuWyAyMucZHB/KkjAIkdkOd204JHFAGzfa5dXgDPcz7ww3h24HoMVmySNI5EjnZy2NucgH1qEOSXizt3DIznkduaYTseRsEjGAU75HX3NAFqS6VYwsatu/hc/e6f5NVzKMMGXflu5yMe3pSBVDoB8yhchl7jtwfxqe2tbq8VRbQO7HAyFyBjrQBE2/cJEI2cg88g0FwUk+cYJGcjp7H6+tdTB4KuvsT3utXEGmWnG6SdxGG74A9celULrxJ4c0BxHodl/a1wow9xcgpET7L1YfXFAFLT9Cv8AUGkFnaTyNjccJlSBx1q7qH9ieGkja8mTVdTxn7HE4McR773Hf2H6VzuveM9a1pDDNci3tD/y62q+VEPwHX8c1zdAGv4h8QX2uzq146rDHxFbxjbHEPRR/XrWRRRQAV6r+y5/yXbwz/29f+ksteVV6r+y5/yXbwz/ANvX/pLLQB1f7a3/ACVPSv8AsCxf+j56+f6+gP21v+Sp6V/2BYv/AEfPXz/QAUUUUAFFFFAGv4XgE2rLn/lnG8gz6hTW3FHJHYNcgnD/ACKfQ/SsrwzGNt7cMduyMIuDyST/APWrba1nkW0bYwhl+VGB+UnPSgD1TwZavB4btgpALjcTjv6VrzMGVtjLu6YYdv8AGksIhb2EES5yiAY7DillcSZ3YAHYdTQBpeD/ABTe+FdWTUIrdZ7VwI7mMfeaLOSVP94dcfUd69g8dQweLPB9nrGhzC6t1HnxyRDmSIj5sZ54wDj2rwySaK20+eWVGAijLHOOgHTFfQ3wpaGX4beHXhjVIpLJH2AcDIyR+ZoA8TKKnRycLuHGQa4TxJ4QjOvafe2eFgluVE8XYc53D2r0bxFaDStd1DT49yRwzsI8/wB08j9CKx5plHkmNCPnxye2KAKOpaRbMBuVtjtjahwT6Ul74Xt9C0+S58w7rhgPKxgL/jj1q1qU5t7XzI8NIHAjYHoScZx3xS/EIbTbZnJVU8sIW4B9ce9AHHycgL0TPGOtRx4PGcknsOp7UpbIJOWJHSlwWdSVA56gdaAOn8MajHEDDOwUdAT6V0SNE0LwxAu8g4bsOK8142ZBOM9hVmK8ngUhJ2XI4+bqKAO0uJ1iG98IgGNvfp6etUo7uGZyIi2GIO7pj2rk5bqWWXe5JkODu3Zz9KdHIYZCUOD/AJ5oAbfA+fMl9YW8qxSGaMyRbtjggk49x0Ira1W5mmH2mOKWS3jwzGM5GOufbg9KonUpAgwEMmPvbfmH410Pw8v/AC7m6sjArR3SmVQDjYw4Ye4PWgC0gCbChzvAwcZwO1Z7WVtda/FeTRLJLbIyxswyOT6VbE5t4QV3lSxwSw7E0tmqtO5GNuzgKSeuaANCzhaS8SBMytI2AuM7mPAH0r3vw5pEOjaPDpsakttLSuvGXPU/4fSvNfhNpQutde7kDeVZJlVI4DNnH5DJrvviHrD6F4N1O+jn+zy4EUc7LkRM7BA2PYtnn0oA8Z+L2o/298QYoFIez0k+QozwZCMufrnC/hXPqRsSDDqUyTjvzxVexj2RK+4XCE8SBgfM5+/nvnrmrUDKHZjnnG30NAE5YI4AZQQMHNbXwXhCfGWSYEES6HcjIHXE9t/jWLKEXDMSwJ4FdN8H23fFG3woVRo17jAx/wAt7SgD32iiigDwD9tb/klmlf8AYai/9ET18V19u/thizb4caONTa4S0OsoGa3UM4P2e42kAkA84yMjjNfGraNPJE01gyX0KjLGDl0GerJ94flj3oAy6KWkoAKKKKAOp8PeOtb0WNbdLn7VYj/l2ufnQD/Zzyp9xXVQeL/CusMv9sadPps5PMkI86MDvxw3868sooA9dPhXTdWEh8La1bXCZBWJpFWTnsQ2DxWdqXg3XNOJ86xZmTBbae1eaAkHIJBHet7S/GHiHSwVstWu0Q/wM+9fybIoA03sbqNz51tIgyRll4FVhISkjBjv4X5RwPp71rWnxT1mMqLyz0u8UdfMtgpP4rirn/Cy9PmbN14Uss5yDDMy49eCDQBgo6hS0m3e2ByentTCymNWAAYtkjrnFdInjzwwJVkbwowKEhV+0KRt9D8vant488Kqg8vwpIzr90vcKOM85+Xk0AcwQPlJRstgqvpWjpuh6nfACCxlcEZUsu3cSeOtak/xO0+Mg6d4TsomU5R5p2cgemABWZqXxV8UXaeXbXNvp0fYWUCxkf8AAuW/WgDr7DwGtjp6X/inUbfTLdhkCZwhb6DqfwBqpcfEPw94bdl8J6X9vuAvFzdqUiVscsE+834kfSvJ769ur+4ae+uZrmduskzl2P4moKANXxH4i1XxJffatYvJLiQcIp4SMeiqOFH0rJoooAkgnlt5klt5HilQ5V0Yqyn2I6V3ek/FXX7a3W11TyNXtBj5btP3mPQSDDfnmuAooA9Wg8T+BdX3/wBq6Ze6XIyjJgAmXd+anHtile18Dzj/AELxEI9xyVnhkXqPpjtXlFLQB6xHovhFNhl8VWZQL90b8g46D5ahRPAFtuF1rNzcDO4eRC5OfxAryyigD01/FHgvTHZdP0i+1EAEBrhliBJ7/wARrPv/AImam0Ag0ezstLiAxuij3yfXc3+FcFRQBc1PU77VLgz6ldz3Ux/jmkLH9ap0UUAFFFFABRUtvBNcyiK3iklkPREUsT+ArT/sy3s+dWu1jcf8u9viST6E52r+JJ9qAMgAkgAEk8ACvZv2atD1TT/jR4VvL+xntreRrlEaZNhY/ZZjwDyRwecYrgD4tlsY/J8NWVvo8ewI00Y8y5f1JmblSfRNo9q7L9mW4muvj54bmuZpJpm+1FnkYsx/0WXqTQB037a3/JU9K/7AsX/o+evn+voD9tb/AJKnpX/YFi/9Hz18/wBABRRRQAVLbwyXEyxQqXdjgAVFW9aRLaWcbREPPMuXb+6p/hH9aALdskFvClqrE8/M237znj8h0rodBT7VrFjbR5ENu4JBORnua5yx3+eOoOQAetd74NsmeGS8HUtt3ew6/jQB6G0iqqBTw3r2PvRIN2XGMdsGsOe5k8uPn55WCrgH5VzWvCwSFd5XaBk54x70AZviSOW8WDSrMZmvpQre0a8sx/QV6r8GPHdppulx+H9akkjKTFLWbYTHtP8ACSOmDnBPHNeQabq7Sa9fao6s0CL9kt8deOSfzroLdEhRDMCoxvKn1oA774p2Yh8bTyhsieBHI7Agbf6A1x0653FDlUOOnJzT7jWJbm3t1nLARIdpZsnr3/wq94d02fW5J4bYPJM0g5XnOBjOOwyf0oAyrtWks3DdACDkcA1S8cEuunuSHUxDPHeuq1zw1qegRML63YwjI81RlCfXPauD167NxDbwIjqI/mDdn9ceuKAMkqBMSGGD0HtSAbV4IKjqajAYFyRwf9nANSnJUlHA7DPSgBjHIwDx6mjg5JDevp1ocqOuFJ5yOaC2QdzH2IHFADVI3D5ScD1p8QOQCAAe/wDSkA+bjBHakVizANn5qAHnAUgOSoPI7GtXw45GtW7Jgjfk/SsrgHLDJ9h2rU8O3MsWpwxQxrLJKwjVMfMxbgAe+TQBu3Ku0BSFVJCbvp3qp4ae5mu0h8tpLhvlCqmS/px1r2sfC3TrVFdL+WOIAGXzcNjjnB4xXY+HPDek6BCRpVrGjPy0x+Z3+rf5FAFDwHob6HoBFyrC7uD5sqg5KcYC/gP1zUXxW0ttb+GviCwTAaW0YjcP7uG/Piutrg/ip4it7Xwzd2NjcJJqFyBGEjYEohPzEntwCPxoA8A8Osk2i22wORHmIAcHKnBBrQSRlm2l9q4BBwTg9+ahiURX1xFHGsSTjzyOcb8fMB+hp5bY6EIQmcNj1PT6UAWS/IbGSo5GeldN8HX3fFGAZBxo170/672lcwTvBGWIPOOOPaup+ESgfFaE8h/7FvAwP/Xe0oA99ooooA8A/bW/5JZpX/Yai/8ARE9fFkbtG4eNmRxyGU4Ir7T/AG1v+SWaV/2Gov8A0RPXxVQBqDVfPAXU7eO8UYG8/JKB/vjr/wACBpWsrC6JNhe+U3aK8G0/g4+U/jtrKooAtXdhdWn/AB8Qui8fN1U/Qjg1Vq1Z311ZMTazvHnqAeD9R0P41a/tG2uARfafEzH/AJa258pvrgZU/lQBl0VrGz024f8A0PUDFk4CXcZXH/AlyP5VNH4V1i4jaSxszfxj+KzYT/opJ/SgDDoqW4gmtpmiuYpIpVOGSRSrD6g1FQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRWhpGjanrVx5Gj6deX839y2haQ/koNdQPhvqVkc+J9R0fw6o5KahdgzY9oY98n5qKAOHpyqzsFQFmY4AAySa7kp8PtFGWm1nxRdIwO2NRp9o3/AAI75WH4IfpUU/xF1G2RofC9hpvhqAgjOmw4nI97hy0ufowHtQBnN4L1i2gS41iFNHt3xtfUW8lmz3EZ+dh7hTVaddCsWxFLc6pKP4tvkQ/h1c/+O1k3VzPd3Dz3c0k88hy8krFmY+pJ5NQ0AaE+rXMkJhiKW1ueDFbrsB+p6t+JNZ9FFABXqv7Ln/JdvDP/AG9f+ksteVV6r+y5/wAl28M/9vX/AKSy0AdX+2t/yVPSv+wLF/6Pnr5/r6A/bW/5KnpX/YFi/wDR89fP9ABRRRQAVu2jD7NCNx6enSsKt6zjkktoguMFRx60Aa2myLGzNIPlxgce3JJr1TwzaJb+GtOBUBpYy5/E/wCFeTohZWQZOSEHbOa9uFsYba2hO9TFGAOQeAMUARTQDBeAMdqgLjt2rA8WXMkVn5cLMEfbHuz1Y9q62BJXjQgAkDnjFcvr0Ql1i0i4K+YZ2I9AMKPzoA0tEtI4YbaEDCWy4K4+8x6mtO8XzCpJcjO0Y9vWq+gDz7DzmfOXJz0rRvGCyRDLEb8DB7mgAjt8AMx+UkZyORn1rtfhdeQWHi+C3lKhZ4nRHbjDdcfjg1ylpI0l9DAVyu7PHHAFSXkrSGWSFMsn3SO2PSgD6VnhiuYHhnRZIZFKsjDIYHsRXlfjz4S217YPN4ZJt7uIFo7R3/dN6qufukkden0rjPAXxim0W8Om+Jo5JtMDbUuo1LSREn+Id1/Ue9e9WV7Ya5ZxXWm30VzbsNyS28gYcj27+xoA+NJxLFPLDdxtFcwtskhkXDRsOoI7GhpMjOMAc8dq+hviV4Ds/Fd55kMsVl4hiAVZWBEd2uOFf/aHYjPpyOnz7qumX2jahJZalbTWlzH96OQYPsQejDvkcUAVVZWPDDOONx/nUjBSewJPGDUI2g5c+Zx19aI5EfGAN2MgDjJoAcWfgLhTxgN3FShm2HcwyPQd6jO0H5iNwPA3Zp7I3mIIoy8hICquSWJ6DH9KAGPIxychEUfexn9a9c8B6GfCnh3/AISXVIUfVbvB0yCZQDECP9aw9cHj0z6njR+F3wsME9rq/i+NVlyHttObn5uoaQeo/u9u/pXf+K/C1zrUi3RmSaVD8sOBhB6An3oAj+H8F3f2817q1615IWwAWyAMdCBxXZq0huSoULCi8nuzH09gP51xvhSa60DS7ifXUjsNPhBLPIcY54P49AB1rptF1aHXNIjv7ESCOXdsEg2twSOR26UAaLHAzXJeNvCVl4kspFhCQaigJR1AGT/db1B9a6ETJFGEuJEaXq2D8qkn/wDVUmn3Ed1b+dGFDE7X29mHBBoA+XdQjmt3khkjMVxasQyk8hgcEe9Vri7W7smnilBUjcCD3HUfWus+IMaR+MtaMG0jfu+7kAlRn9a8fTU5NM1O9SKJJIJXLiLqoPfHoe9AHa2d39st90SkAHBB9RXa/B9NnxUgUsSRot5nP/Xe0rznR7kO/lxjCzR7hu4IP/1q7/4KZ/4WhCW3b/7GvAwJ/wCm9pyKAPoWiiigDwD9tb/klmlf9hqL/wBET18VV9y/ta3tpp3gPQrrUtMh1SzTWkEtnNI8ayg21wPvIQwIzkEdwOvSvkrVoPBmpRedoVzqejXJGWs9RAuIs56JPGA2P95PxoA4+ird3YzWxyTHJH2kicOp/Ef1qpQAUUUUAFPilkhkWSJ2jkXkMpwR+NMooA6y0+IPiWC1FrcagNRtB/yw1KFLtMfSQNj8MVc/4S/w/fEnW/A2lMx6yaXcTWTfll0/8crh6KAO7MPw3vo18u88U6NMeSJYIb6NfbKtE344pf8AhCNCvOdI+IHh+U/3L6K4s2/8ejK5/wCBY964OigDvE+FXiW5YjSv7I1UD/nw1a2mOPXaH3fpVO8+GXji0J83wnrbADO+GzeVcf7yAj9a4+rdrqN7aAC1vLmAA5HlysuPyNAE1zomq2rMt1pl9Cy9RJbupH1yKzyCCQQQfQ109r8QvGVqFW38Wa8iL0QahLtH4bsVYn+JXjG4j2XPiC8mXGMSkP8AzFAHH0VsTeJNUnmMs08byHu0EZ/9lqWy8V6vZTGW2mt0cjGTaQtx+KUAYVKBngda6j/hPvEgZGXUQhQ5XZbxLg/QLTpviH4slbc2uXQbrlNqH9AKAObhtbifPkQSyY/uIT/Kr0Hh3WZyvl6XeYboWhZQfxPFEniLWpEKPq1+UYliv2h8EnqSM1QnuZ7g5uJpZSO7sW/nQBuQeEtQMwjvJ9N08d2u72NMfgCW/SrsXhzw7BE7ar4xtBKvSGwsprlm+jMEX/x6uQooA7Rp/h/Y+WYLLxHq7gfP588VnGx9QFWRse2adL43sraNo9C8HeHbDOCJp4nvZQfXMzMv/jtcTRQB0ur+OvE+rQ+Re63em2xj7PC/kw4/65phf0rm6SigAooooAKKKUDPAoASitXTtGe6YNc3dpYQEZ826kxx7KoLH8BXVwT/AA+8PKG+z6l4uvx/z2JsbIHH90EyyYPqUz6UAct4a8Oaz4n1AWXh/TbrULk4JSBCwUerHoo9yQK9s+BXhG28L/GTwqt74g02715pbhZNNsGM4t4/sk+4yTD5N4YKNilupORjny7xJ8RvEGuWB0xJoNK0TJxpelRC1tucfeVeX6Dlyxro/wBlz/ku3hn/ALev/SWWgDq/21v+Sp6V/wBgWL/0fPXz/X0B+2r/AMlT0r/sCxf+j56+f6ACiiigArpdNxFYqyj5ynfvXNV0lsoOnwYGWwD6YoA2dEg828s1YBgsqu+W5wTwBXtE8sYeTJUqUCjnkHtivG9Ah3axp6KpBaUEknoBXsAVd8hLk4YY560ATJujtkSM/PgADGTnpXOwzC/8X30LtjEQgVm424Hb0roHmihdmb5hbruz6Hk4/SuL8L3xXUZ5JgDvLMWA5Gee9AHQ+D7hi+o6XOqpcQSZCk9Aa6KRUmiXdkfNuGKwDCt1cpeWpjS7H3WPCuvdW9vQ1uxyLLABKjQSD7yk8g9vqKAGXDujjy1w0mY9/wDdzipZmSCMxxgtL5e1ACcucdB+NZPifV49Hs0luZcNLKI0U8+5I+gpmlaxDrTTTRK8kUJ2oSMAnuR/SgCC20pW0opcn98+XYLwc56ZrA0XwtHDq/2m6aZbEHOyOUo07k5wSDnA6120YcRqGI653MccelZup+f5oFtAXdX8zfG3GehH5UAekfDXxTNrJuPDHiC5DnJfTLqRz5oYc+UzHqR2PUjI54rfnt7TxFcz+GfFsZlljybW+6SQsf4d3c+/Q9814ykSSjfOGjbr/tKR/X3r13wjdxeMrJrPVeNftYxsnztNzED1PuOh+ue9AHm/jP4a614fvAojN7YO22O5hTP4MvY1zN74ev7FfMkgKsOXRh8wH06ivozwl4gms9STRtReeXe5SF3GSpA6E919D2qzoVnbar4r8Yfbkt7nZcQQAbc7FEStj65bn6UAfNnh7QNR8QXsdrptk80z8k4wq+5J4Ar3Pw14U0b4d29vd30Z1LxHOAsSRjcQf7sY7Dnljz/KutvtSXTpotM0C2t0cNh1VMBPwHf3rmPFmqp4Tha5d0u/FN1HtjeTkW69NxH+c/TNAGf8TPF91Yrb6FExj1u/jP2y5tRzp9uQeFP/AD0boD25b0r55VfE3gC+udS8Paxex2xf5W8wuWUngSoeD9cV2VvE8V9cXV1LNNPO++aWWUuzse9JfXcTSRwCHzo5v3cilRjaevNAHN6n438SeKxA+t6jJNbRncYSNsZbswUAYP1r1n4S+LLnQhJZ3CSTWkp3iMnaUJxyCev0rjbLSrW3XylijliB+Ubu3vWlICsgRcqwGcrxsPagD2rW9a8NTus9xqRhZgAVVSCx9OnWsweOtK0u0eHRbSVyxJ8yc4DNgDce56e1eSRPcXjwzX5Rpohg45DEE4b8auNbK+GQquDgqueR1AoAoeJ9cCXV1cvIJLudt8hxjOT0FectYG7kkkTcyGTkL61p/EIyxX0ZHzSTYQIBgj0wPxrSg0+XT9AV7iU/aANzAY+UjpQBb0e3xZrHJgvF+8Q8ZIxXd/BgbfilAvmrJjRbsgqO3n2mOe/evPdN8Q2psZ42dFuEHEfA39+K3v2a7ua6+LV0JTlE0a52ewNxb8UAfU1FFFAHgH7a3/JLNK/7DUX/AKInr4qr7V/bW/5JZpX/AGGov/RE9fFVADlYqcqSD6ineZn76hvfvUdFADyEI4JB9DSmJsZA3D/Z5qOlBweKACkqUTNjDYYf7QzTt8LEbomT1KN/Q0AQUVN5cbD5ZgDxwwx+tOW0lfPlgSAf3WBoAr0VJJDJH/rI3XPPzKRUdABRRRQAUUUUAFFFFABRRRQAUUUUAFFFLQAlFTR200n+ridhnGQpxTzaSKSJGjjx13OM/l1oArUVY8u3XG6Yv6hF/qaaZIlz5cX4u2f8KAIgCTwMmniM/wARC/U0PM7d8eyjA/SmUAPPlqR1b17UeawzswgP93io6KAFJycnrSUUUAFeq/suf8l28M/9vX/pLLXlVeq/suf8l28M/wDb1/6Sy0AdX+2t/wAlT0r/ALAsX/o+evn+voD9tb/kqelf9gWL/wBHz18/0AFFFFABW/bbjBbjPG0YArAressmCJic4UYFAHR+GS7eIrAFgP3nQV68wAJKKpRSSR3646V4/wCFlUazbOcA7gcnjFevW2TEJV2KSSw9cY4FAFfWGK6Td7ARJKwUAAHj1FcpoFnJIA204ebB+neuymhErxW7g/IgP4n1qC001baSQbSUZsqA3ANADmgjsAsikzHO0oPun601b6W7tppLIfvLUqWRSfmUnGR9K0pJo7mOWEFwoXkY/XNUdPvpbbVNLs9KCQ2kjYu0kTO8E/eJoAyfFfg/Ub9/7Qu7vzYlTEadkHfn+tXfBlr9n0nymXacjDZIzXSaxbajq9lMsYW0tze+THEDkmMH7341Tt7YadfvYBiVSNTyeg9TQA+ZCgYLgHBI3etOs7d4YjvbMhYF9uDTIyJ5GlbaUzhPp3NTlMp8own90c5FAFO7gSX5vLQsOQVbH5mm6Vqt/wCGtQ03UYWhLW0oLBWyXQ8FD9RU2zaMhmA6/OO3tWLr0LNZmeWYEh1ESICoBz1PrxmgD6DvPHPhCO4gv3aUyhQdywEFfY5x+lcboPxBTS/Fut6nc2hfTtWkQqICCybBtDEdyV6+9eIL4qubvVoXuFSG0dmTy3GQRnGSex6Guj1nUDo1jHcpFDIrAbQTgE44oA+iLzxl4c03RL7V9PmjuZynmCLlZHbsuCMivDtZ1O+1e5mv7za11OeSTn6AD07Yrg9N8SXuow3Fgyb7iVc5Q4UjOcAe3rXY6Q26wjZ0McsXyyKc5BA6/WgCeCyMSl7p0dhgjHQcdKhuQZZYhEmCzAN78+1aMbMdxTGSPlBHWlLu3VQMc7SMHPtQAotkL5J29gPQjvWZ4luZ7DSZLvTJN8ynDRkZyP8APNaUe2QNlcyZxnd09qyPF97BBYXEGzl1IJV/880AaGh38WqaJb3kRSMuCHQD7rjqD6VoI7Kxcs2cbnBxj615b4M8QTaJDPBJGGt5D5u1jkjjH610rJeartubyV7a3bBiCMQGHoT2+lAGnbpbX+qtqc0O1oRhEmXJU5+8v1q9qNstxp9wgUj5cg46fWqVuxa4NuXKxxYbCr978f6VrK42TQ7iSwIAY8cigDyC2iMtzK5Gedn3Og6ZFet/s42Etl8UpGlbdv0a6A49J7X/ABFcf4atCkVz54AZJmjPfBr1X4RMG+J9p6/2LeE46f66zoA96ooooA8Q/a70TVde+G2m2uh6Zfalcpq0UjRWdu8zqghmBYqoJxkgZ9xXyL/wrjxx/wBCb4k/8Fc//wATX6U0UAfmt/wrjxx/0JviT/wVz/8AxNH/AArjxx/0JviT/wAFc/8A8TX6U0UAfmt/wrjxx/0JviT/AMFc/wD8TR/wrjxx/wBCb4k/8Fc//wATX6U0UAfmt/wrjxx/0JviT/wVz/8AxNH/AArjxx/0JviT/wAFc/8A8TX6U0UAfmt/wrjxx/0JviX/AMFc/wD8TR/wrjxx/wBCb4l/8Fc//wATX6U0UAfm4ngHx8gwvhPxQB6f2bcY/wDQaefAvjxv9Z4M8QP/AL2jyk/nsr9IKKAPzf8A+EA8Zs2X8CeICOwXTLhf/ZaQ/DzxeVP/ABQ3igMemNPnwP8AyHX6Q0UAfm+Phx4s28+DfFm7/sFy/wDxNMHw28YnOfCPihfQf2ROf/Za/SOigD83v+Fa+L/+hU8Uf+Caf/Ck/wCFa+L/APoVPFH/AIJ5/wDCv0iooA/N1vhr4wA+Xwn4oJ9P7Hn/AMKP+Fb+L1fnwh4pZfUaTMP/AGWv0iooA/N5/hz4uGCngzxW3qG0yYf+yUf8K98Xg8eBfExH+1p85/kgr9IaKAPzePgDxrghPAuvqOxOlXBI/NaX/hBvHwDBPB3iJA3UJpEq/wAkr9IKKAPzaf4f+PZP9Z4S8UMOnzabcH/2Wo/+FceN/wDoTfEn/grn/wDia/SmigD81v8AhXPjj/oTfEv/AIK5/wD4mj/hXHjj/oTfEn/grn/+Jr9KaKAPzW/4Vx44/wChN8Sf+Cuf/wCJo/4Vx44/6E3xJ/4K5/8A4mv0pooA/Nb/AIVx44/6E3xJ/wCCuf8A+Jo/4Vx44/6E3xJ/4K5//ia/SmigD81v+FceOP8AoTfEn/grn/8AiaP+FceOP+hN8Sf+Cuf/AOJr9KaKAPzW/wCFceOP+hN8Sf8Agrn/APia9K/Zw8FeKtI+M/h6+1Xw1rdjZRfaPMuLmwlijTNtKBlmUAZJA+pr7fooA+Rf2u/CfiPXviTpt1oegavqVsmkxRtLZ2ckyBxNMSpKqRnBBx7ivEP+FceOP+hN8Sf+Cuf/AOJr9KaKAPzW/wCFceOP+hN8Sf8Agrn/APiaP+FceOP+hN8Sf+Cuf/4mv0pooA/Nb/hXHjj/AKE3xJ/4K5//AImtmHwJ4vW1gU+EfEgdVwR/ZVxwfX7lfohRQB8CaL4S8V2l9btL4T8S7A4Z2Ok3Jx+GyvS4bXUMKZPD3iQZwCBol5wM8/8ALKvrCigD5NsbbUd80lx4d8TKXc4B0S7zt7dI6nNvfsrbvD3iMM3X/iSXnPt/qq+q6KAPlmC3u4bIRjQPERc5eT/iR3vzN6f6rtWLJZ66NYguovD/AIj8tHUEf2Hd42+uPL5r7AooA+XNRbU5NdsGg0TxMdPiBaQjQ7zlugzmLPSuagsvElx4rvrq78PeI4rKd+v9jXZOwcKABHX2RRQB8uBb2N/3fh7xHgDAP9h3gGPp5VKFvsnHh/xEme66Hef/ABqvqKigD5b8q9Ib/iReJlOeg0O8Of8AyFXLa7beI7ySHb4R8TSwtIYmVdIuVaKMjmQZTBPtX2bRQB8I6n4E1u38v+ztD8TXSkMHD6LdKR6dY8c10fivTdd1XTtNtYfDPiU+Wu6XOjXQCnbjb/q+vvX2XRQB8S6Z4Y1nS9ZtLy38OeImiPLxjRbseV/s5MfNdesGoCdpf7B8SZOeDod5g+n/ACyr6rooA+VVTUwcp4e8RoCeQdEvD/7SqdhqJBJ0XxKT2A0O9/8AjVfUdFAHymkepRyOq6B4oIaQfOdEu/u+v+rzVXxNoE95pc7WmkeI3vEcPEh0K9G/1BPlYr62ooA+HvDnh3xFBqCzX3hfxBGqAsCNGuiS3YDEZ4rv1F7KjCXw/wCIgjrh4n0G7Kn8ov17V9RUUAfJ0Fnqthej7Jo/iWS0YfdfQrwtH+cX8qvFLtmO7QPE2P8AsCXnI/79V9R0UAfJVvYahBq96yeHvEn2aYLIj/2Hd/I/cY8uu6+DNpqP/Cx0ubnStWtbePSLmNprvTp7ZN7TWxCgyIoJIRjgehr3uigAooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan read as normal in a gastric bypass patient. Note the non-contrast filled loops of bowel on the right side of the abdomen, which is herniated bowel through Petersen's defect.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_24_390=[""].join("\n");
var outline_f0_24_390=null;
var title_f0_24_391="Hydroxyzine: Drug information";
var content_f0_24_391=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydroxyzine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/45/3797?source=see_link\">",
"    see \"Hydroxyzine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/23/19830?source=see_link\">",
"    see \"Hydroxyzine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vistaril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F181116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Hydroxyzine&reg;;",
"     </li>",
"     <li>",
"      Atarax&reg;;",
"     </li>",
"     <li>",
"      Hydroxyzine Hydrochloride Injection, USP;",
"     </li>",
"     <li>",
"      Novo-Hydroxyzin;",
"     </li>",
"     <li>",
"      Nu-Hydroxyzine;",
"     </li>",
"     <li>",
"      PMS-Hydroxyzine;",
"     </li>",
"     <li>",
"      Riva-Hydroxyzine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F181161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiemetic;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"     <li>",
"      Piperazine Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F181118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Adjust dose based on patient response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antiemetic:",
"     </b>",
"     I.M.: 25-100 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anxiety:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 50-100 mg 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Initial: 50-100 mg, then every 4-6 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Preoperative sedation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 50-100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 25-100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pruritus:",
"     </b>",
"     Oral: 25 mg 3-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F181139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/23/19830?source=see_link\">",
"      see \"Hydroxyzine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Adjust dose based on patient response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antiemetic:",
"     </b>",
"     I.M.: 1.1 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Preoperative sedation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 0.6 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 1.1 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pruritus, anxiety:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;6 years: 50 mg daily in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;6 years: 50-100 mg daily in divided dose",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F181119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initiate dosing using the lower end of the recommended dosage range due to an increased potential for anticholinergic side effects. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14288818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling; however, the following guidelines have been used by some clinicians (Aronoff, 2007): Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     GFR &gt;50 mL/minute: No adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     GFR &le;50 mL/minute: Administer 50% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT), hemodialysis, peritoneal dialysis: Administer 50% of the normal dose.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F181120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Change dosing interval to every 24 hours in patients with primary biliary cirrhosis (Simons F, 1989)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F181090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as pamoate: 25 mg, 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vistaril&reg;: 25 mg, 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 25 mg/mL (1 mL); 50 mg/mL (1 mL, 2 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride: 10 mg/5 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as hydrochloride: 10 mg/5 mL (118 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 10 mg, 25 mg, 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F181075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F181094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: For I. M. use only. Do not administer I.V., SubQ, or intra-arterially. Administer I.M. deep in large muscle. In adults, the preferred site is the upper outer quadrant of the buttock or midlateral thigh. In children, the preferred site is the midlateral thigh. The upper outer quadrant of the gluteal region should be used only when necessary to minimize potential damage to the sciatic nerve. With I.V. administration, extravasation can result in sterile abscess and marked tissue induration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Shake suspension vigorously prior to use.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F181167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, aztreonam, ciprofloxacin, cisatracurium, cladribine, dexmedetomidine, docetaxel, etoposide phosphate, fenoldopam, filgrastim, foscarnet, gemcitabine, granisetron,  hetastarch in lactate electrolyte injection (Hextend&reg;), linezolid, melphalan, ondansetron, oxaliplatin, pemetrexed, propofol, remifentanil, teniposide, thiotepa.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amifostine, amphotericin B cholesteryl sulfate complex, doxorubicin liposome, fluconazole, fludarabine, paclitaxel, sargramostim.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atropine, atropine with meperidine, butorphanol, chlorpromazine, cimetidine, codeine, diphenhydramine, doxapram, droperidol, fentanyl, fluphenazine, glycopyrrolate, hydromorphone, lidocaine, meperidine, methotrimeprazine, metoclopramide, midazolam, morphine, nalbuphine, oxymorphone, pentazocine, prochlorperazine edisylate, promethazine, scopolamine, sufentanil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Dimenhydrinate, haloperidol, ketorolac, pentobarbital, ranitidine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F181093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of anxiety/agitation (including adjunctive therapy in alcoholism); adjunct to pre- and postoperative analgesia and anesthesia; antipruritic; antiemetic",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F181169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       HydrOXYzine may be confused with hydrALAZINE, hydroxyurea",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Atarax&reg; may be confused with Ativan&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Vistaril&reg; may be confused with Restoril&trade;, Versed, Zestril&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vistaril [U.S. and Turkey] may be confused with Vastarel brand name for trimetazidine [multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F181159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, fatigue, hallucination, headache, nervousness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Involuntary movements, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory depression (at higher than recommended doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F181097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydroxyzine or any component of the formulation; early pregnancy; SubQ, intra-arterial, or I.V. injection",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F181079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade. Screening is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with asthma or COPD.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use of this potent anticholinergic agent due to increased risk of confusion, dry mouth, constipation, and other anticholinergic effects; clearance decreases in patients of advanced age (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate administration: I.V., SubQ, and intra-arterial administration are contraindicated since tissue damage, intravascular hemolysis, thrombosis, and digital gangrene can occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F181155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F181084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: HydrOXYzine may enhance the CNS depressant effect of Barbiturates.  Management: Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine.  With concurrent use, monitor patients closely for excessive response to the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: HydrOXYzine may enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: HydrOXYzine may enhance the CNS depressant effect of Meperidine.  Management: Consider a decrease in meperidine dose, as appropriate, when used together with hydroxyzine.  With concurrent use, monitor patients closely for excessive response to the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F181112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F181101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Hydroxyzine crosses the placenta. Maternal hydroxyzine use has generally not resulted in an increased risk of birth defects. Use of hydroxyzine early in pregnancy is contraindicated but hydroxyzine is approved for pre- and postpartum adjunctive therapy to reduce narcotic dosage, treat anxiety, and control emesis. Antihistamines are recommended for the treatment pruritus with rash in pregnant women (although second generation antihistamines may be preferred). Antihistamines are not recommended for treatment of pruritus associated with intrahepatic cholestasis in pregnancy. Possible withdrawal symptoms have been observed in neonates following chronic maternal use of hydroxyzine during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F181125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14444710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if hydroxyzine is excreted in breast milk. Breast-feeding is not recommended by the manufacturer. Antihistamines may decrease maternal serum prolactin concentrations when administered prior to the establishment of nursing.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F181100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (HydrOXYzine Pamoate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $29.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $32.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $62.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Vistaril Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $210.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $256.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (HydrOXYzine HCl Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/mL (1 mL): $3.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (2 mL): $5.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (HydrOXYzine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/5 mL (118 mL): $19.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (HydrOXYzine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $62.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $91.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $111.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F181088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of symptoms, mental status, blood pressure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F181102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Arax (TW);",
"     </li>",
"     <li>",
"      Atarax (AT, AU, BB, BE, BG, BM, BS, BZ, CH, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, GY, HK, HN, HU, IN, IT, JM, LU, MT, MX, MY, NI, NL, NO, PE, PL, PT, RU, SE, SK, SR, SV, TH, TR, TT, TW);",
"     </li>",
"     <li>",
"      Atarax Uce (PK);",
"     </li>",
"     <li>",
"      Ataraxone (AR, UY);",
"     </li>",
"     <li>",
"      Aterax (ZA);",
"     </li>",
"     <li>",
"      Bestalin (ID);",
"     </li>",
"     <li>",
"      Calmofilase (CO);",
"     </li>",
"     <li>",
"      Cedar (CO);",
"     </li>",
"     <li>",
"      Centilax (KP);",
"     </li>",
"     <li>",
"      Disron-P (JP);",
"     </li>",
"     <li>",
"      Dormirex (GT);",
"     </li>",
"     <li>",
"      Hadarax (TH);",
"     </li>",
"     <li>",
"      Hiderax (CO);",
"     </li>",
"     <li>",
"      Hidroxina (EC);",
"     </li>",
"     <li>",
"      Histan (TH);",
"     </li>",
"     <li>",
"      Hizin (SG, TH);",
"     </li>",
"     <li>",
"      Iremofar (GR);",
"     </li>",
"     <li>",
"      Iterax (ID, PH);",
"     </li>",
"     <li>",
"      Nirax (TW);",
"     </li>",
"     <li>",
"      Otarex (IL);",
"     </li>",
"     <li>",
"      Paxistil (BE);",
"     </li>",
"     <li>",
"      Prurid (PY);",
"     </li>",
"     <li>",
"      Qualidrozine (HK);",
"     </li>",
"     <li>",
"      R-Rax (TH);",
"     </li>",
"     <li>",
"      Serecid (NZ);",
"     </li>",
"     <li>",
"      Ucerax (IE, KP);",
"     </li>",
"     <li>",
"      Unamine (TH);",
"     </li>",
"     <li>",
"      Vistaril (KE, SE, TR, TW);",
"     </li>",
"     <li>",
"      Warazix (JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F181078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract. Possesses skeletal muscle relaxing, bronchodilator, antihistamine, antiemetic, and analgesic properties.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F181096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: 15-30 minutes; Injection: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Decreased histamine-induced wheal and flare areas: 2 to &ge;36 hours; Suppression of pruritus: 1-12 hours (Simons, 1984)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Adults: V",
"     <sub>",
"      d",
"     </sub>",
"     ~16 L/kg (Simons, 1984); Elderly: ~23 L/kg (Simons K, 1989); Hepatic dysfunction: ~23 L/kg (Simons F,  1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to multiple metabolites, including cetirizine (active) (Simons F, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Adults: ~20 hours (Simons, 1984); Elderly: ~29 hours (Simons K, 1989); Hepatic dysfunction: ~37 hours (Simons F, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral administration: Serum: ~2 hours; Peak suppression of antihistamine-induced wheal and flare: 4-12 hours (Simons, 1984)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/24/391/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baumgartner T, &ldquo;Administration of Hydroxyzine Injection,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1979, 36(12):1660.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/24/391/abstract-text/525641/pubmed\" id=\"525641\" target=\"_blank\">",
"        525641",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dasgupta A, Wells A, and Datta P, &ldquo;False-Positive Serum Tricyclic Antidepressant Concentrations Using Fluorescence Polarization Immunoassay due to the Presence of Hydroxyzine and Cetirizine,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 2007, 29(1):134-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/24/391/abstract-text/17333576/pubmed\" id=\"17333576\" target=\"_blank\">",
"        17333576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Serreau R, Komiha M, Blanc F, et al, &ldquo;Neonatal Seizures Associated With Maternal Hydroxyzine Hydrochloride in Late Pregnancy,&rdquo;",
"      <i>",
"       Reprod Toxicol",
"      </i>",
"      , 2005, 20(4):573-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/24/391/abstract-text/16199350/pubmed\" id=\"16199350\" target=\"_blank\">",
"        16199350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simons FE, Simons KJ, and Frith EM, &ldquo;The Pharmacokinetics and Antihistaminic of the H",
"      <sub>",
"       1",
"      </sub>",
"      Receptor Antagonist Hydroxyzine,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 1984, 73(1 Pt 1):69-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/24/391/abstract-text/6141198/pubmed\" id=\"6141198\" target=\"_blank\">",
"        6141198",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simons FE, Watson WT, Chen XY, et al, &ldquo;The Pharmacokinetics and Pharmacodynamics of Hydroxyzine in Patients With Primary Biliary Cirrhosis,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1989,  29(9):809-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/24/391/abstract-text/2572611/pubmed\" id=\"2572611\" target=\"_blank\">",
"        2572611",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simons KJ, Watson WT, Chen XY, et al, &ldquo;Pharmacokinetic and Pharmacodynamic Studies of the H",
"      <sub>",
"       1",
"      </sub>",
"      -Receptor Antagonist Hydroxyzine in the Elderly,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1989, 45(1):9-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/24/391/abstract-text/2562944/pubmed\" id=\"2562944\" target=\"_blank\">",
"        2562944",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8544 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-ADE86C94E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_24_391=[""].join("\n");
var outline_f0_24_391=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181115\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181116\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181161\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181118\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181139\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181119\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14288818\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181120\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181090\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181075\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181094\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181167\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181093\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181169\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181159\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181097\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181079\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181155\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181084\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181112\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181101\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181125\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14444710\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181100\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181088\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181102\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181078\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181096\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8544\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8544|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/45/3797?source=related_link\">",
"      Hydroxyzine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/23/19830?source=related_link\">",
"      Hydroxyzine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_24_392="Hypochondriasis: Epidemiology, clinical presentation, assessment, and diagnosis";
var content_f0_24_392=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypochondriasis: Epidemiology, clinical presentation, assessment, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/24/392/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/24/392/contributors\">",
"     James L Levenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/24/392/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/24/392/contributors\">",
"     Joel Dimsdale, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/24/392/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/24/392/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/24/392/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7947221\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Misinterpretation of one or more bodily sensations or minor symptoms leads patients with hypochondriasis to persistently believe that they have or will contract a serious disease, despite appropriate medical reassurance [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The disorder is heterogeneous and usually chronic. &nbsp;",
"   </p>",
"   <p>",
"    This topic reviews the epidemiology, pathogenesis, clinical presentation, assessment, and diagnosis of hypochondriasis. Treatment and prognosis of hypochondriasis, and the clinical features, medical evaluation, and treatment of somatization are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21926?source=see_link\">",
"     \"Hypochondriasis: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18984?source=see_link\">",
"     \"Somatization: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7947228\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of hypochondriasis in the general population is not clear because the disorder has not been included in any nation-wide psychiatric epidemiologic studies. A systematic review of four community surveys found the prevalence of hypochondriasis ranged from 0.02 to 7.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/3\">",
"     3",
"    </a>",
"    ]. Subsequent studies of community-dwelling adults reported prevalence rates of 0.05 and 0.4 percent; more broadly defined severe health anxiety (unrealistic fears about illness) ranged from 2 to 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypochondriasis is most often encountered in general medical outpatients, with the prevalence ranging from 2 to 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. The prevalence of more broadly defined health anxiety is higher; as an example, an Australian study of 10,507 consecutive primary care patients identified health anxiety in 31 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Onset of hypochondriasis is most common in early adulthood, and rarely begins after the age of 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/1,2,8\">",
"     1,2,8",
"    </a>",
"    ]. The syndrome occurs in both sexes in approximately a one-to-one ratio and is not associated with marital status [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. A systematic review found hypochondriasis is more frequent in less educated patients, and often accompanied by depression, anxiety, and disability [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H86829664\">",
"     'Comorbid psychopathology'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21926?source=see_link&amp;anchor=H4695052#H4695052\">",
"     \"Hypochondriasis: Treatment and prognosis\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7947235\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of hypochondriasis is not known. Psychosocial etiologies have been studied more than biological causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3712854\">",
"    <span class=\"h2\">",
"     Psychosocial etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the different psychosocial theories that explain the development of hypochondriasis, the cognitive-behavioral model has empirical support and leads to effective treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/9\">",
"     9",
"    </a>",
"    ]. In this model, the disorder is characterized by excessive and persistent anxiety about threats to one&rsquo;s health; the anxiety is due to somatic sensations that are perceived as abnormally intense and misattributed to serious medical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The patient then seeks assurance of good health.",
"   </p>",
"   <p>",
"    In the cognitive-behavioral model, risk factors for hypochondriasis include dysfunctional assumptions about the prevalence and communicability of severe illnesses, the meaning of bodily symptoms, and the course and treatment of illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/11\">",
"     11",
"    </a>",
"    ]. As an example, patients may believe that good health is a symptom-free state, or overestimate their vulnerability to developing disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/9,12,13\">",
"     9,12,13",
"    </a>",
"    ]. The dysfunctional assumptions may stem from early family experiences and childhood illness. Abnormal illness behavior in parents (eg, their own hypochondriacal tendencies or excessive worry about illness in their children), as well as a child's exposure to serious parental illness, appears to increase the risk of somatoform disorders in adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An event such as reading about an illness or hearing about the illness of an acquaintance can activate dysfunctional assumptions and lead to hypochondriacal thoughts. Patients may increasingly monitor their bodily sensations for any sign of the illness, and amplify or exaggerate any evidence of illness. Normal somatic feelings are then prone to be misinterpreted as ominous. The misinterpretation triggers anxiety, which patients attempt to reduce by seeking assurance of good health.",
"   </p>",
"   <p>",
"    Despite medical reassurance, patients with hypochondriasis remain anxious about their health. One reason is that patients vigilantly monitor their bodies for symptoms and become sensitive to slight homeostatic fluctuations that occur normally [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, it is thought that anxiety leads patients to confirm their fears through selective attention toward information that is consistent with having a disease and away from information that is consistent with good health. Avoidance behavior may also maintain hypochondriacal symptoms. As an example, patients who erroneously believe that they have cardiac disease may avoid physical exertion because they think this will exacerbate their condition; patients thus lose the opportunity to verify their good health and correct the mistaken belief.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3712862\">",
"    <span class=\"h2\">",
"     Genetics and biological correlates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetics of hypochondriasis is unknown, and there is little information about its neurobiology. A family study found no significant difference in the prevalence of hypochondriasis in 72 first-degree relatives of patients with hypochondriasis compared with the prevalence in 97 relatives of controls, but interpreting the results is difficult due to the small number of individuals involved and the relatively low incidence of the illness [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/16\">",
"     16",
"    </a>",
"    ]. Studies of biologic correlates have found that compared to healthy controls, patients with hypochondriasis have decreased levels of plasma neurotrophin-3 and platelet serotonin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/17\">",
"     17",
"    </a>",
"    ], and smaller pituitary volumes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/18\">",
"     18",
"    </a>",
"    ]. It is not clear whether these unreplicated findings represent etiologic causes or sequelae of the disorder because the studies investigated patients who already met criteria for hypochondriasis. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7947242\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypochondriacal symptoms occur on a spectrum from normal to pathologic [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/6,19\">",
"     6,19",
"    </a>",
"    ], and are considered a disorder when the preoccupation with health causes clinically significant distress or impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/1\">",
"     1",
"    </a>",
"    ]. Transient hypochondriacal preoccupations (eg, disease fears commonly experienced by second-year medical students) do not constitute hypochondriasis. Subsyndromal hypochondriasis that is associated with significant morbidity but does not meet diagnostic criteria for hypochondriasis is often labelled as &ldquo;health anxiety&rdquo; or &ldquo;illness anxiety&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/4,11,20\">",
"     4,11,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The core features of hypochondriasis are [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The conviction that one has a disease or preoccupation with fear of an undiagnosed disease",
"     </li>",
"     <li>",
"      The preoccupation persists despite a normal physical examination and negative medical tests, as well as reassurance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypochondriacal preoccupations are heterogeneous. Patients may be preoccupied with a particular bodily function (eg, bowel movements), normal variation in function (eg, in heart rate or blood pressure), vague somatic sensation (eg, &ldquo;tired heart&rdquo;), minor symptom (eg, cough, small sore, or headache), or diagnosis (eg, cancer or AIDS). The patient&rsquo;s concern may involve one or more organ systems.",
"   </p>",
"   <p>",
"    The degree of insight varies; some patients recognize that their disease fears are excessive, while others firmly maintain their convictions. However, the belief is not of delusional intensity, and patients can acknowledge the possibility that their disease fears are exaggerated or that there may be no disease at all.",
"   </p>",
"   <p>",
"    The concern about the feared illness often becomes a central feature of the patient&rsquo;s life, and psychosocial functioning may suffer [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. Many patients check their bodies to reassure themselves; examples of hypochondriacal behavior include excessive breast self-examination or blood pressure and pulse monitoring. This behavior may increase during times of stress.",
"   </p>",
"   <p>",
"    The preoccupation with illness often leads to high health care utilization, with multiple normal examinations and tests that do not allay the patient&rsquo;s concern [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. Patients may press their physicians to order progressively more invasive diagnostic tests and higher-risk treatments, which can reinforce the disorder and increase the probability of iatrogenic complications. Seeking care from multiple clinicians (\"doctor-shopping\") is also common [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/9\">",
"     9",
"    </a>",
"    ]. Despite extensive medical attention, patients with hypochondriasis often are disappointed and frustrated with their clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/6,21\">",
"     6,21",
"    </a>",
"    ]. Clinicians in turn may become frustrated because their efforts at managing and reassuring the patient seem futile.",
"   </p>",
"   <p>",
"    Some patients fear iatrogenic illness (eg, adverse medication effects or radiation exposure), avoid mainstream medical clinicians, and pursue a diagnosis and remedy through complementary and alternative practitioners. In addition, many patients use the internet to obtain information about diagnosis and treatment of feared diseases, and consume vitamins, over-the-counter remedies, and fad diets.",
"   </p>",
"   <p>",
"    Hypochondriasis may occur alongside a general medical illness, in which case it is often difficult to interpret the symptoms of the medical illness [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/22\">",
"     22",
"    </a>",
"    ]. Having feared serious illness, the hypochondriacal patient may feel vindicated when diagnosed with a medical disease.",
"   </p>",
"   <p>",
"    Although cultural factors can influence how patients perceive, report, and seek care for physical symptoms, a study found that the clinical features of hypochondriasis were similar across 14 countries [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypochondriasis is one of several syndromes that presents with physical symptoms that cannot be fully explained by a known medical condition after appropriate investigation; these syndromes are designated as Somatoform Disorders. In addition, the process of expressing psychologic distress through somatic symptoms is often referred to as &ldquo;somatization.&rdquo; (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H86830141\">",
"     'Psychiatric disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86829664\">",
"    <span class=\"h2\">",
"     Comorbid psychopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hypochondriasis typically have comorbid axis I psychopathology and personality disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/3,24\">",
"     3,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of 42 patients with hypochondriasis who completed structured diagnostic interviews found that 88 percent had at least one comorbid axis I disorder, including [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Generalized anxiety disorder in 71 percent of patients",
"     </li>",
"     <li>",
"      Dysthymic disorder 45 percent",
"     </li>",
"     <li>",
"      Major depressive disorder 43 percent",
"     </li>",
"     <li>",
"      Phobias 43 percent",
"     </li>",
"     <li>",
"      Somatization disorder 21 percent",
"     </li>",
"     <li>",
"      Panic disorder 17 percent",
"     </li>",
"     <li>",
"      Substance use disorder 17 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevalence of anxiety and depressive disorders is significantly higher in general medical clinic patients with hypochondriasis compared to patients without hypochondriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Personality disorders also seem to occur more frequently in patients with hypochondriasis compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/25\">",
"     25",
"    </a>",
"    ]. A study of 115 patients with hypochondriasis who completed self-administered assessments found that 77 percent had at least one personality disorder and 44 percent had at least four personality disorders, including [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obsessive-compulsive personality disorder (56 percent of patients)",
"     </li>",
"     <li>",
"      Avoidant (41 percent)",
"     </li>",
"     <li>",
"      Paranoid (37 percent)",
"     </li>",
"     <li>",
"      Schizotypal (25 percent)",
"     </li>",
"     <li>",
"      Borderline (24 percent)",
"     </li>",
"     <li>",
"      Schizoid (22 percent)",
"     </li>",
"     <li>",
"      Narcissistic (22 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174496362\">",
"    <span class=\"h1\">",
"     ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of patients presenting with possible hypochondriasis includes a medical history, physical examination, and indicated laboratory tests, as well as the psychiatric history and mental status examination. The purpose is to evaluate the patient for general medical conditions, particularly the early stages of endocrine, immunologic, neurologic, oncologic, and rheumatologic diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. A general medical illness may not be recognized because findings in the history, physical examination, or laboratory tests are overlooked; contemporary diagnostic techniques are not used; the medical illness is due to iatrogenic adverse effects; or a new disease has yet to be identified [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/27\">",
"     27",
"    </a>",
"    ]. The medical evaluation and differential diagnosis for hypochondriasis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link&amp;anchor=H9#H9\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\", section on 'Medical evaluation'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H86829446\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As part of the psychiatric evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/28,29\">",
"     28,29",
"    </a>",
"    ], the clinician should address:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fears and beliefs about having a serious general medical illness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      What bodily sensations trigger the patient&rsquo;s health anxiety?",
"     </li>",
"     <li>",
"      How does the patient respond to the anxiety?",
"     </li>",
"     <li>",
"      Degree of insight, ie, does the patient recognize the concern about health may be excessive?",
"     </li>",
"     <li>",
"      A chronology should be established to determine whether current symptoms are acute or chronic",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of serious illnesses, particularly in childhood",
"     </li>",
"     <li>",
"      Current and past medical evaluations and treatments",
"     </li>",
"     <li>",
"      Complementary and alternative medical treatments",
"     </li>",
"     <li>",
"      Quality of relationship with current and past primary care clinicians",
"     </li>",
"     <li>",
"      Psychiatric comorbidity, such as anxiety, depressive, and other somatoform disorders",
"     </li>",
"     <li>",
"      Psychosocial functioning",
"     </li>",
"     <li>",
"      Family history of serious diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86830619\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Self-report screening instruments can facilitate diagnosis of hypochondriasis. Patients who screen positive should be asked about the diagnostic criteria to verify the diagnosis. Self-report measures can save interviewer time, but are more prone to false-positives than clinician-administered instruments.",
"   </p>",
"   <p>",
"    Among the available self-report measures, the seven-item Whiteley Index has been studied most often, and includes validated subscales with acceptable psychometric properties that assess illness worrying (sensitivity 0.37, specificity 0.70, and positive predictive value 0.41) and illness conviction (sensitivity 0.63, specificity 0.87, and positive predictive value 0.73) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/30\">",
"     30",
"    </a>",
"    ]. The 29-item Illness Attitude Scales can also be used [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], particularly the 3-item Bodily Preoccupation subscale, which showed high sensitivity (0.92) and specificity (0.90) but low positive predictive value (0.02) in screening for DSM-IV hypochondriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7947249\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypochondriasis is usually diagnosed in general medical settings based upon a history, physical examination, and laboratory tests. (See",
"    <a class=\"local\" href=\"#H174496362\">",
"     'Assessment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Diagnosis of hypochondriasis according to the American Psychiatric Association's Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) requires each of the following (",
"    <a class=\"graphic graphic_table graphicRef68413 \" href=\"UTD.htm?20/24/20875\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preoccupation with having a serious illness based upon misinterpretation of bodily symptoms",
"     </li>",
"     <li>",
"      Persistence of the preoccupation despite appropriate medical evaluation and reassurance",
"     </li>",
"     <li>",
"      The belief is not:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Of delusional intensity",
"     </li>",
"     <li>",
"      Limited to physical appearance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other psychiatric disorders have been excluded as the cause of the persistent preoccupation:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Generalized anxiety disorder",
"     </li>",
"     <li>",
"      Obsessive-compulsive disorder",
"     </li>",
"     <li>",
"      Unipolar major depression",
"     </li>",
"     <li>",
"      Other somatoform disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The preoccupation persists for at least six months and causes significant distress or functional impairment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnostic criteria for hypochondriasis in the World Health Organization's International Classification of Diseases-10th Revision (ICD-10) consist of the first two criteria used in DSM-IV-TR [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Both diagnostic systems classify hypochondriasis as a Somatoform Disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86829446\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86830127\">",
"    <span class=\"h2\">",
"     Medical disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may notice symptoms of an occult disease during its early stage, when signs on physical examination or laboratory test abnormalities are not readily apparent. Examples include [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Endocrine diseases such as hypothyroidism, hyperthyroidism, or hyperparathyroidism",
"     </li>",
"     <li>",
"      Malignancy such as ovarian cancer",
"     </li>",
"     <li>",
"      Neurologic diseases such as multiple sclerosis or myasthenia gravis",
"     </li>",
"     <li>",
"      Rheumatologic diseases such as systemic lupus erythematosus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, clinicians should avoid excessive tests and over-diagnosing patients. Specific diseases are discussed separately.",
"   </p>",
"   <p>",
"    The medical evaluation for hypochondriasis is discussed separately within the context of somatization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link&amp;anchor=H9#H9\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\", section on 'Medical evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86830141\">",
"    <span class=\"h2\">",
"     Psychiatric disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of hypochondriasis may overlap with symptoms of other psychiatric disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. As an example, patients with an anxiety disorder sometimes experience somatic symptoms (eg, tachycardia or dyspnea) and misinterpret them as signs of serious physical illness; however, the patients are usually amenable to reassurance that they do not have a general medical illness.",
"   </p>",
"   <p>",
"    The differential diagnosis for hypochondriasis includes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/392/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Generalized anxiety disorder",
"      </strong>",
"      &ndash; Patients with generalized anxiety disorder may worry excessively about illness, but are also preoccupied with other issues such as relationships, work, or finances, whereas the concern in hypochondriasis is restricted to having an illness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"       \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Obsessive-compulsive disorder",
"      </strong>",
"      &ndash; Intrusive thoughts about having a disease (obsession) in conjunction with repeatedly checking one&rsquo;s health and seeking reassurance (compulsive behavior) is better conceptualized as hypochondriasis. However, if obsessions and compulsions extend beyond health concerns (eg, checking locks), obsessive-compulsive disorder should be diagnosed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36564?source=see_link&amp;anchor=H4#H4\">",
"       \"Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis\", section on 'Clinical manifestations and diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Specific phobia",
"      </strong>",
"      &ndash; A disease phobia and hypochondriasis both involve fear of disease. However, phobic patients avoid situations that may lead to contracting an illness; patients with hypochondriasis are preoccupied with fears of having a disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/24/22921?source=see_link&amp;anchor=H19509096#H19509096\">",
"       \"Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Panic disorder",
"      </strong>",
"      &ndash; Panic disorder and hypochondriasis both involve fear related to the implications of somatic symptoms. Patients with panic disorder may fear an imminent catastrophe that cannot be treated (eg, myocardial infarction or death), but this occurs only during panic attacks, and patients usually are amenable to reassurance that their symptoms are panic attacks and not a myocardial infarction. In hypochondriasis, fear of disease can occur at any time and the patient is not amenable to reassurance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=see_link&amp;anchor=H111733801#H111733801\">",
"       \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\", section on 'Diagnostic criteria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Body dysmorphic disorder",
"      </strong>",
"      &ndash; Patients with hypochondriasis are preoccupied with having a disease, whereas patients with body dysmorphic disorder are preoccupied with an imagined defect in physical appearance that typically involves the face or head.",
"     </li>",
"     <li>",
"      <strong>",
"       Somatization disorder",
"      </strong>",
"      &ndash; Unexplained somatic symptoms occur in both somatization disorder and hypochondriasis. In hypochondriasis, patients are generally more preoccupied with having a disease rather than the misinterpreted symptoms, and concerned with only one or two disorders that they consistently identify. By contrast, somatization disorder involves a combination of numerous pain, gastrointestinal, sexual, and neurologic symptoms that are generally emphasized more than the potential medical disorders, which are numerous and often changing. In the United States, somatization disorder occurs mostly in women, whereas hypochondriasis equally affects men and women. Diagnostic criteria for somatization disorder are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef73363 \" href=\"UTD.htm?19/33/19996\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Psychotic disorders",
"      </strong>",
"      &ndash; Psychotic patients may have somatic delusions and believe they are ill. However, delusional beliefs are fixed, whereas patients with hypochondriasis can consider the possibility that they are not ill. Bizarre somatic beliefs that occur in conjunction with other signs of psychosis (eg, hallucinations or disorganized speech and behavior) indicate a schizophrenia-spectrum disorder or psychotic mood disorder. It is difficult to differentiate delusional disorder, somatic type, which is characterized by behavior and functioning that are not markedly strange or impaired, from hypochondriasis with poor insight. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=see_link&amp;anchor=H17284630#H17284630\">",
"       \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical manifestations and diagnosis of depression\", section on 'Major depression with psychotic features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=see_link&amp;anchor=H17#H17\">",
"       \"Overview of psychosis\", section on 'Delusional disorder'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/4/3145?source=see_link&amp;anchor=H2370428#H2370428\">",
"       \"Delusional parasitosis: Epidemiology, clinical presentation, assessment and diagnosis\", section on 'Assessment and diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Unipolar major depression or dysthymic disorder",
"      </strong>",
"      &ndash; Depressed patients may ruminate over physical health and have difficulty accepting reassurance, but they also suffer other symptoms (eg, insomnia, anorexia, anergia, and suicidality) that are generally not seen in hypochondriasis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations and diagnosis of depression\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of the disorders that resemble hypochondriasis can also occur in conjunction with it. (See",
"    <a class=\"local\" href=\"#H86829664\">",
"     'Comorbid psychopathology'",
"    </a>",
"    above.) In addition, selective serotonin reuptake inhibitors (SSRIs) are often used to treat anxiety and depressive disorders, and can also be used to treat hypochondriasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21926?source=see_link&amp;anchor=H4695045#H4695045\">",
"     \"Hypochondriasis: Treatment and prognosis\", section on 'Pharmacotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7947298\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The estimated prevalence of hypochondriasis in the general population is 0.02 to 7.7 percent, and in general medical outpatients is 2 to 7 percent. Hypochondriasis usually begins in early adulthood, and occurs in both sexes in approximately a one-to-one ratio. (See",
"      <a class=\"local\" href=\"#H7947228\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of hypochondriasis is not known. (See",
"      <a class=\"local\" href=\"#H7947235\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The core feature of hypochondriasis is persistent preoccupation with having a serious medical illness despite appropriate medical evaluation and reassurance. Hypochondriacal preoccupations are heterogeneous and the degree of insight is variable. The concern about the feared illness often becomes a central feature of the patient&rsquo;s life and can lead to high health care utilization. (See",
"      <a class=\"local\" href=\"#H7947242\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with hypochondriasis typically have comorbid axis I psychopathology, especially anxiety and depressive disorders. Comorbid personality disorders appear common as well. (See",
"      <a class=\"local\" href=\"#H86829664\">",
"       'Comorbid psychopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with possible hypochondriasis are evaluated for general medical conditions with a medical history, physical examination, and indicated laboratory tests. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link&amp;anchor=H9#H9\">",
"       \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\", section on 'Medical evaluation'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The psychiatric history and mental status examination should address the patient&rsquo;s fears and beliefs about having a serious general medical illness, history of serious illnesses, current and past medical treatments, the quality of the patient&rsquo;s relationship with current and past primary care clinicians, psychiatric comorbidity, psychosocial functioning, and family history of serious diseases. (See",
"      <a class=\"local\" href=\"#H174496362\">",
"       'Assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic criteria for hypochondriasis are summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef68413 \" href=\"UTD.htm?20/24/20875\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The differential diagnosis for hypochondriasis includes psychiatric disorders such as generalized anxiety disorder, obsessive-compulsive disorder, specific (disease) phobia, panic disorder, body dysmorphic disorder, somatization disorder, psychotic disorders, and depressive disorders. (See",
"      <a class=\"local\" href=\"#H86830141\">",
"       'Psychiatric disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. file://www.who.int/classifications/icd/en/bluebook.pdf (Accessed on April 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/3\">",
"      Creed F, Barsky A. A systematic review of the epidemiology of somatisation disorder and hypochondriasis. J Psychosom Res 2004; 56:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/4\">",
"      Bleichhardt G, Hiller W. Hypochondriasis and health anxiety in the German population. Br J Health Psychol 2007; 12:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/5\">",
"      Martin A, Jacobi F. Features of hypochondriasis and illness worry in the general population in Germany. Psychosom Med 2006; 68:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/6\">",
"      Barsky AJ. Clinical practice. The patient with hypochondriasis. N Engl J Med 2001; 345:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/7\">",
"      Clarke DM, Piterman L, Byrne CJ, Austin DW. Somatic symptoms, hypochondriasis and psychological distress: a study of somatisation in Australian general practice. Med J Aust 2008; 189:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/8\">",
"      Noyes R, Stuart S, Watson DB, Langbehn DR. Distinguishing between hypochondriasis and somatization disorder: a review of the existing literature. Psychother Psychosom 2006; 75:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/9\">",
"      Abramowitz JS, Braddock AE. Hypochondriasis: conceptualization, treatment, and relationship to obsessive-compulsive disorder. Psychiatr Clin North Am 2006; 29:503.",
"     </a>",
"    </li>",
"    <li>",
"     Abbey SE, Wulsin L, Levenson JL. Somatization and somatoform disorders. In: The American Psychiatric Publishing Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, American Psychiatric Publishing, Inc., Washington, DC 2011. p.261.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/11\">",
"      Marcus DK, Gurley JR, Marchi MM, Bauer C. Cognitive and perceptual variables in hypochondriasis and health anxiety: a systematic review. Clin Psychol Rev 2007; 27:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/12\">",
"      Barsky AJ, Ahern DK, Bailey ED, et al. Hypochondriacal patients' appraisal of health and physical risks. Am J Psychiatry 2001; 158:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/13\">",
"      Barsky AJ, Coeytaux RR, Sarnie MK, Cleary PD. Hypochondriacal patients' beliefs about good health. Am J Psychiatry 1993; 150:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/14\">",
"      Bass C, Murphy M. Somatoform and personality disorders: syndromal comorbidity and overlapping developmental pathways. J Psychosom Res 1995; 39:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/15\">",
"      Gilleland J, Suveg C, Jacob ML, Thomassin K. Understanding the medically unexplained: emotional and familial influences on children's somatic functioning. Child Care Health Dev 2009; 35:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/16\">",
"      Noyes R Jr, Holt CS, Happel RL, et al. A family study of hypochondriasis. J Nerv Ment Dis 1997; 185:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/17\">",
"      Brondino N, Lanati N, Barale F, et al. Decreased NT-3 plasma levels and platelet serotonin content in patients with hypochondriasis. J Psychosom Res 2008; 65:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/18\">",
"      Atmaca M, Yildirim H, Sec S, Kayali A. Pituitary volumes in hypochondriac patients. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/19\">",
"      Longley SL, Broman-Fulks JJ, Calamari JE, et al. A taxometric study of hypochondriasis symptoms. Behav Ther 2010; 41:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/20\">",
"      Harding KJ, Skritskaya N, Doherty E, Fallon BA. Advances in understanding illness anxiety. Curr Psychiatry Rep 2008; 10:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/21\">",
"      Noyes R Jr, Longley SL, Langbehn DR, et al. Hypochondriacal symptoms associated with a less therapeutic physician-patient relationship. Psychiatry 2010; 73:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/22\">",
"      Barsky AJ, Wyshak G, Klerman GL. Hypochondriasis. An evaluation of the DSM-III criteria in medical outpatients. Arch Gen Psychiatry 1986; 43:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/23\">",
"      Gureje O, Ust&uuml;n TB, Simon GE. The syndrome of hypochondriasis: a cross-national study in primary care. Psychol Med 1997; 27:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/24\">",
"      Sakai R, Nestoriuc Y, Nolido NV, Barsky AJ. The prevalence of personality disorders in hypochondriasis. J Clin Psychiatry 2010; 71:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/25\">",
"      Barsky AJ, Wyshak G, Klerman GL. Psychiatric comorbidity in DSM-III-R hypochondriasis. Arch Gen Psychiatry 1992; 49:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/26\">",
"      Noyes R Jr, Kathol RG, Fisher MM, et al. Psychiatric comorbidity among patients with hypochondriasis. Gen Hosp Psychiatry 1994; 16:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/27\">",
"      Dimsdale JE, Dantzer R. A biological substrate for somatoform disorders: importance of pathophysiology. Psychosom Med 2007; 69:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/28\">",
"      Work Group on Psychiatric Evaluation, American Psychiatric Association Steering Committee on Practice Guidlines. Psychiatric evaluation of adults. Second edition. American Psychiatric Association. Am J Psychiatry 2006; 163:3.",
"     </a>",
"    </li>",
"    <li>",
"     Practice Guideline for the Psychiatric Evaluation of Adults, Second Edition, published June 2006 file://www.psychiatryonline.com/pracGuide/pracGuideTopic_1.aspx (Accessed on April 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/30\">",
"      Fink P, Ewald H, Jensen J, et al. Screening for somatization and hypochondriasis in primary care and neurological in-patients: a seven-item scale for hypochondriasis and somatization. J Psychosom Res 1999; 46:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/31\">",
"      Kellner R, Abbott P, Winslow WW, Pathak D. Fears, beliefs, and attitudes in DSM-III hypochondriasis. J Nerv Ment Dis 1987; 175:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/32\">",
"      Kellner R, Fava GA, Lisansky J, et al. Hypochondriacal fears and beliefs in DSM-III melancholia. Changes with amitriptyline. J Affect Disord 1986; 10:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/392/abstract/33\">",
"      Weck F, Bleichhardt G, Hiller W. Screening for hypochondriasis with the Illness Attitude Scales. J Pers Assess 2010; 92:260.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14827 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-E2D9733EE5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_24_392=[""].join("\n");
var outline_f0_24_392=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7947298\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7947221\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7947228\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7947235\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3712854\">",
"      Psychosocial etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3712862\">",
"      Genetics and biological correlates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7947242\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86829664\">",
"      Comorbid psychopathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H174496362\">",
"      ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86830619\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7947249\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86829446\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86830127\">",
"      Medical disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86830141\">",
"      Psychiatric disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7947298\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14827\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14827|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/24/20875\" title=\"table 1\">",
"      Dx criteria hypochondria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/33/19996\" title=\"table 2\">",
"      Dx criteria somatization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/4/3145?source=related_link\">",
"      Delusional parasitosis: Epidemiology, clinical presentation, assessment and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21926?source=related_link\">",
"      Hypochondriasis: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36564?source=related_link\">",
"      Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=related_link\">",
"      Overview of psychosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=related_link\">",
"      Panic disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=related_link\">",
"      Schizophrenia: Clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18984?source=related_link\">",
"      Somatization: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/24/22921?source=related_link\">",
"      Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_24_393="Endometrial ablation: Non-resectoscopic techniques";
var content_f0_24_393=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endometrial ablation: Non-resectoscopic techniques",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/24/393/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/24/393/contributors\">",
"     Howard T Sharp, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/24/393/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/24/393/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/24/393/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/24/393/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/24/393/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The introduction of non-resectoscopic ablation techniques has greatly increased the use of endometrial ablation as a therapeutic option for women with abnormal uterine bleeding. Non-resectoscopic endometrial ablation is performed with a device that is inserted into the uterine cavity and delivers energy to uniformly destroy the uterine lining. Non-resectoscopic techniques are also referred to as second generation ablation.",
"   </p>",
"   <p>",
"    Resectoscopic endometrial ablation techniques, on the other hand, are performed under hysteroscopic visualization, using resectoscopic instruments to ablate or resect the endometrium. Non-resectoscopic endometrial ablation techniques are more widely practiced than resectoscopic ablation, since they require less specialized training and have a shorter operative time [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Non-resectoscopic techniques for endometrial ablation will be reviewed here. General principles (eg, indications, contraindications, preoperative and postoperative care) of endometrial ablation, techniques for resectoscopic endometrial ablation or resection, as well as other management options for abnormal uterine bleeding, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link\">",
"     \"An overview of endometrial ablation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44708?source=see_link\">",
"     \"Endometrial ablation or resection: Resectoscopic techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=see_link\">",
"     \"Chronic menorrhagia or anovulatory uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CURRENT NON-RESECTOSCOPIC ABLATION DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current non-resectoscopic endometrial ablation technologies approved for use in the United States by the Food and Drug Association (FDA) are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      bipolar radiofrequency (Novasure&reg;)",
"     </li>",
"     <li>",
"      hot liquid filled balloon (ThermaChoice&reg;)",
"     </li>",
"     <li>",
"      cryotherapy (Her Option&reg;)",
"     </li>",
"     <li>",
"      circulating hot water (Hydro ThermAblator&reg;)",
"     </li>",
"     <li>",
"      microwave (Microwave Endometrial Ablation).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two other brands of hot liquid filled balloon devices are available outside of the United States: Cavaterm&trade; and Thermablate EAS&trade;.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL OPERATIVE TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positioning, sterile preparation, and cervical dilation are the same as for hysteroscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of hysteroscopy\", section on 'Procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    General perioperative practices (eg, endometrial preparation, prophylactic antibiotics) and complications of endometrial ablation, as well as comparison with resectoscopic ablation, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link&amp;anchor=H33#H33\">",
"     \"An overview of endometrial ablation\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link&amp;anchor=H40#H40\">",
"     \"An overview of endometrial ablation\", section on 'Non-resectoscopic versus resectoscopic ablation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Routine use of hysteroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most non-resectoscopic techniques do not require hysteroscopy, with the exception of the Hydro ThermAblator&reg;, during which hot water is instilled into the uterus through a hysteroscopic sheath. For other techniques, preoperative hysteroscopy is necessary only if the uterine cavity has not been assessed for leiomyomas or endometrial polyps in the preoperative period. Also of note, the manufacturer of the microwave ablation system advises hysteroscopic evaluation before and after ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The endometrial cavity should be assessed preoperatively in all patients undergoing endometrial ablation. Performing this assessment of the uterus during the preoperative evaluation is optimal, since it helps to guide surgical planning (eg, preparing for myomectomy if a submucosal fibroid is present). If the uterine cavity has not been assessed preoperatively, a diagnostic hysteroscopy should be performed just prior to the ablation procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link&amp;anchor=H23#H23\">",
"     \"An overview of endometrial ablation\", section on 'Assessment of the uterus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postoperative hysteroscopy is potentially useful to identify areas of remaining endometrium or detect uterine perforation. Some surgeons ablate endometrial remnants using resectoscopic instruments. However, the clinical benefit of hysteroscopy for these indications is uncertain. There are no data regarding whether small amounts of residual endometrium following non-resectoscopic ablation impact treatment success; data suggest that partial resectoscopic ablation is successful [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link&amp;anchor=H14#H14\">",
"     \"An overview of endometrial ablation\", section on 'Cavity size'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regarding uterine perforation, evaluation for this complication after blind transcervical procedures is usually performed only in selected women in whom there is reason to suspect perforation (eg, an instrument was inserted past the depth of the uterine fundus). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4408?source=see_link&amp;anchor=H16#H16\">",
"     \"Uterine perforation during gynecologic procedures\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ABLATION METHODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section will review the energy sources and technical specifications for current non-resectoscopic endometrial ablation devices. Uterine requirements and operative duration for each procedure are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef56492 \" href=\"UTD.htm?33/30/34284\">",
"     table 1",
"    </a>",
"    ). In general, endometrial destruction is achieved when the tissue is heated to 65&ordm;C or cooled to -60&ordm;C.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bipolar radiofrequency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bipolar radiofrequency device (Novasure&reg;) is a three-dimensional bipolar mesh probe that delivers radiofrequency current (a type of electrical energy) until a specific tissue impedance is reached (",
"    <a class=\"graphic graphic_figure graphicRef81118 graphicRef61150 \" href=\"UTD.htm?30/46/31461\">",
"     figure 1A-B",
"    </a>",
"    ). The NovaSure&reg; generator applies up to 180 watts of power.",
"   </p>",
"   <p>",
"    The device is inserted into the uterine cavity and the mesh is expanded until it is in contact with the endometrium. Suction is then applied to the endometrial cavity, thereby drawing the endometrium closer to the bipolar mesh probe. The suction also removes debris and vapor that can increase impedance and reduce the depth of energy penetration. The system will shut down when complete desiccation has occurred (calculated at a tissue impedance of 50 ohms of resistance) or after a total treatment time of two minutes. The average treatment time is just over one minute and the average depth of ablation is 4 to 5 millimeters.",
"   </p>",
"   <p>",
"    The system also evaluates cavity integrity by emitting carbon dioxide and assessing for leaks. If the integrity check fails, the user will not be able to activate the ablation phase of the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Uterine requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine cavity and cervical dilation parameters for Novasure&reg; ablation are [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diameter of device 7.5 mm",
"     </li>",
"     <li>",
"      Sounded cavity length &ge;6 to &le;10 cm; alternatively, &ge;4 cm from internal cervical os to fundus",
"     </li>",
"     <li>",
"      Cornua to cornua distance &ge;2.5 cm",
"     </li>",
"     <li>",
"      Women with submucosal leiomyomas or with endometrial polyps &gt;2 cm were excluded from the FDA approval studies",
"     </li>",
"     <li>",
"      No irregularly shaped cavities",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in which women who underwent Novasure&reg; ablation were followed for five or more years reported high rates of reduced uterine bleeding (97 to 98 percent) and amenorrhea (75 to 97 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. There were low rates of repeat ablation (1 to 4 percent) and hysterectomy (3 to 8 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Advantages/disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Novasure&reg; ablation does not require endometrial preparation, since it adjusts ablation depth by measuring tissue impedance. This may increase the ease of scheduling in comparison with other endometrial ablation techniques. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link&amp;anchor=H25#H25\">",
"     \"An overview of endometrial ablation\", section on 'Endometrial preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Novasure&reg; was not evaluated in the FDA approval studies for use in women with intracavitary fibroids. However, some data suggest that bipolar radiofrequency ablation is successful in this population. A prospective series of 65 women with endometrial polyps or fibroids up to 3 cm who underwent bipolar radiofrequency ablation reported, at one-year follow-up, that 95 percent had improvement in uterine bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Microwave",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microwave Endometrial Ablation (MEA) is a 9.2 GHz, 30 watt, microwave system (",
"    <a class=\"graphic graphic_figure graphicRef82626 \" href=\"UTD.htm?17/24/17793\">",
"     figure 2",
"    </a>",
"    ). When inserted into the uterine cavity, this energy will produce a tissue temperature of 75 to 85&ordm;C at a depth of 6 mm. In order to treat the entire uterine cavity, the surgeon moves the probe from cornu to cornu and across the lower uterine segment until the entire endometrium has reached the desired temperature. Total treatment time is three to five minutes. Unlike other non-resectoscopic ablation devices, the probe is reusable.",
"   </p>",
"   <p>",
"    The manufacturer of MEA advises hysteroscopic evaluation before and after ablation, in contrast with other non-resectoscopic ablation devices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Uterine requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine parameters for MEA ablation are [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diameter of device 8.5 mm",
"     </li>",
"     <li>",
"      Sounded cavity length &ge;6 to &le;12 cm is advised by the manufacturer, although the device was studied in women with a cavity length of up to 14 cm",
"     </li>",
"     <li>",
"      Women with submucosal leiomyomas that do not obstruct treatment access were included in the studies for FDA approval",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial compared MEA with endometrial resection in 263 women [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Perioperative complications included a uterine perforation in each treatment group. Excessive intraoperative bleeding occurred in five women in the resection group and none in the MEA group; however, three women treated with MEA were readmitted with secondary hemorrhage. In women followed for 10 or more years, those treated with MEA compared with resection had similar rates of amenorrhea (83 and 88 percent). The rate of repeat ablation was similar in women treated with MEA compared with resection (1 versus 2 percent); however, the hysterectomy rate differed significantly (17 versus 28 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Advantages/disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The labeling from the manufacturer of this device includes the treatment of women with small submucosal leiomyomas (&le;3 cm). The uterine cavity size maximum is larger than with the other non-resectoscopic ablation devices (12 to 14 cm versus 10 cm).",
"   </p>",
"   <p>",
"    The manufacturer of MEA advises extra precautions that are not advised for the other non-resectoscopic devices, including preoperative measurement of the thickness of the myometrium and pre- and postoperative hysteroscopy. These may serve as barriers for the use of this method for surgeons and patients.",
"   </p>",
"   <p>",
"    These requirements were likely added because prior to the introduction of MEA in the United States, there were case reports from Europe in which bowel burns occurred in women with no perforation of the uterus [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/11\">",
"     11",
"    </a>",
"    ]. The etiology was presumed to be passage of microwave energy through the uterine walls. As a result, the FDA trial required that ultrasound be performed prior to the procedure and that the myometrium be at least 1 cm in thickness in all areas. The potential risk of ablation-associated injury in women with thinning of the myometrium is not limited to microwave ablation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link&amp;anchor=H9#H9\">",
"     \"An overview of endometrial ablation\", section on 'Myometrial thinning following uterine surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hot liquid filled balloons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hot liquid filled balloon ablation is also referred to as thermal balloon ablation. There are three available brands of hot liquid filled balloons for endometrial ablation. ThermaChoice&reg; (",
"    <a class=\"graphic graphic_figure graphicRef52237 graphicRef75368 \" href=\"UTD.htm?11/44/11973\">",
"     figure 3A-B",
"    </a>",
"    ) is FDA-approved and Cavaterm&trade; and Thermablate EAS&trade; are available only outside the United States.",
"   </p>",
"   <p>",
"    All three devices utilize a silicon balloon which is inserted through the cervix into the uterine cavity via a probe [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. The balloon is expanded to a pressure of 160 to 220 mmHg with either 5 percent dextrose in water (ThermaChoice&reg;), glycine (Cavaterm&trade;), or glycerine (Thermablate EAS&trade;). For ThermaChoice&reg; and Cavaterm&trade;, the fluid is heated to approximately 68 to 87&ordm;C and ablation requires 8 to 10 minutes. Thermablate uses a higher temperature (173&ordm;C) and has shorter ablation time (two minutes).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Uterine requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine cavity and cervical dilation parameters for ThermaChoice&reg; ablation are [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diameter of device 5.5 mm",
"     </li>",
"     <li>",
"      Sounded cavity length &ge;6 to &le;10 cm",
"     </li>",
"     <li>",
"      Women with submucosal leiomyomas were excluded from the FDA approval studies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies with long-term follow-up report a wide range of treatment results. In women who underwent hot liquid filled balloon ablation with either ThermaChoice&reg;, Cavaterm&trade;, or an unspecified device and were followed for four or more years, there was reduced uterine bleeding in 22 to 81 percent and amenorrhea in 23 to 58 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Repeat ablation was performed in 5 to 11 percent, and hysterectomy in 2 to 13 percent.",
"   </p>",
"   <p>",
"    It is unclear whether these long-term data apply to current versions of the hot liquid filled balloon devices, since two of the devices have been revised (ThermaChoice&reg; III and Cavaterm&trade; plus) and Thermablate&reg; was introduced later than the other devices and follows a different protocol. For the current version of each of the devices, the reported rates of treatment success and failure are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ThermaChoice&reg; III &mdash; A prospective study of 148 women followed for 12 months reported reduced bleeding in 31 percent and amenorrhea in 66 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/18\">",
"       18",
"      </a>",
"      ]. No patient had undergone re-ablation or hysterectomy.",
"     </li>",
"     <li>",
"      Cavaterm&trade; plus &mdash; A prospective study of 220 women followed for 19 months reported reduced bleeding or amenorrhea in 74 to 83 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/19\">",
"       19",
"      </a>",
"      ]. No patient had undergone re-ablation, but 15 percent had undergone, or were planning, hysterectomy.",
"     </li>",
"     <li>",
"      Thermablate EAS&trade; &mdash; A prospective study of 47 women followed for 12 months reported reduced bleeding or amenorrhea in 77 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/20\">",
"       20",
"      </a>",
"      ]. There were no reports of re-ablation or hysterectomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Advantages/disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hot liquid filled balloon techniques may cause more perioperative pain than other non-resectoscopic ablation techniques (see",
"    <a class=\"local\" href=\"#H32\">",
"     'Perioperative pain'",
"    </a>",
"    below). The likely mechanism of this is the stimulation of pain fibers by both the heat and uterine distention pressure produced during the procedure. However, with adequate preoperative analgesia (eg, nonsteroidal antiinflammatory drugs, oral narcotics) and a paracervical block, the procedure can be performed in an office setting in appropriately selected patients.",
"   </p>",
"   <p>",
"    ThermaChoice&reg; was not evaluated in the FDA approval studies for use in women with intracavitary lesions. However, some data suggest that hot liquid filled balloon ablation is successful in this population. Hot liquid filled balloon ablation was used successfully in 45 women with submucosal fibroids &le;3 cm in a randomized trial comparing balloon versus rollerball ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An additional disadvantage is that hot liquid filled balloon techniques cannot be used in women with intracavitary lesions, since ablation occurs only where the balloon is in contact with the endometrium.",
"   </p>",
"   <p>",
"    While there is one report of successful use of a liquid balloon in a woman with bicornuate uterus, endometrial ablation in women with uterine anomalies is not standard practice [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link&amp;anchor=H8#H8\">",
"     \"An overview of endometrial ablation\", section on 'Uterine anomalies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cryoablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryoablation is a technique in which a cryoprobe is inserted into the uterine cavity (",
"    <a class=\"graphic graphic_figure graphicRef70561 graphicRef61286 \" href=\"UTD.htm?8/63/9204\">",
"     figure 4A-B",
"    </a>",
"    ). The probe is cooled either by liquid nitrogen or by differential gas exchange. An elliptical ice ball approximately 3.5 by 5 centimeters forms around the probe when it is cooled to less than -90&ordm;C. At the edge of the ice ball, the tissue temperature is 0&ordm;C, which is nondestructive. A temperature of &ndash;20&ordm;C is lethal to tissue; this temperature is reached approximately 3 to 5 mm from the edge of the ice ball. Therefore, the endometrial tissue exposed to this low temperature, including the basalis layer of the endometrium (",
"    <a class=\"graphic graphic_figure graphicRef54487 \" href=\"UTD.htm?43/27/44465\">",
"     figure 5",
"    </a>",
"    ), is permanently destroyed.",
"   </p>",
"   <p>",
"    The number of ice balls that must be created to destroy the entire uterine cavity is dependent upon the size of the cavity. Intraoperative ultrasonography is used to monitor probe placement and depth of tissue freezing. In general, two to three ice balls are sufficient (",
"    <a class=\"graphic graphic_figure graphicRef50633 \" href=\"UTD.htm?27/0/27662\">",
"     figure 6",
"    </a>",
"    ). Each freeze cycle takes two to six minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Uterine requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine parameters for Her Option&reg; ablation are [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diameter of device 5.5 mm",
"     </li>",
"     <li>",
"      Sounded cavity length &ge;4 to &le;10 cm",
"     </li>",
"     <li>",
"      Women with intramural leiomyomas &le;2 cm in diameter were included in the FDA approval studies; women with pedunculated fibroids or endometrial polyps were excluded",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial compared Her Option&reg; with rollerball ablation in 279 women [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. There were few adverse events; major complications included were: in the Her Option&reg; group, one woman underwent a hysterectomy 43 days after the procedure for severe uterine bleeding and one woman treated with rollerball was hospitalized for hematometra. At two-year follow-up, women in the Her Option&reg; group compared with the rollerball group had similar rates of either reduced uterine bleeding or amenorrhea (94 versus 92 percent). Rates of hysterectomy (7 and 8 percent) and repeat ablation (3 and 1 percent) were similar between groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Advantages/disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of cold destroys tissue and may also cause numbness. Therefore, cryoablation is potentially less painful than the other non-resectoscopic techniques, which all use high temperatures. Less perioperative pain is an advantage for use with no anesthesia or with local anesthesia.",
"   </p>",
"   <p>",
"    Another unique feature of cryoablation is the use of perioperative sonography. This serves as both an advantage and disadvantage. Cryoablation is not a totally blind procedure, which helps to ensure complete ablation and avoid complications. On the other hand, it can be difficult to visualize the ice ball if the patient is obese and the need for sonography adds to the expertise",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    personnel required to perform the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Circulating hot water (hydrothermal)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrothermal ablation (Hydro ThermAblator&reg; [HTA]) refers to a technique in which a hysteroscope sheath is inserted into the uterine cavity under direct hysteroscopic visualization (",
"    <a class=\"graphic graphic_figure graphicRef70543 \" href=\"UTD.htm?27/33/28176\">",
"     figure 7",
"    </a>",
"    ). Heated isotonic saline is administered into the uterus through the sheath. To maintain a low uterine distension pressure (&lt;70 mmHg), the fluid is instilled using gravity rather than a pump. The treatment phase lasts for 10 minutes, during which the fluid should be at a temperature of 90&ordm;C. An intrauterine cool down phase is then performed for one minute with the fluid at 45&ordm;C.",
"   </p>",
"   <p>",
"    Safety apparatus within the equipment detects whether any fluid has escaped from the closed system, which will shut down if more than 10 cc of fluid are lost, whether through the cervix, fallopian tubes, or a uterine perforation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Uterine requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine cavity and cervical dilation parameters for HTA ablation are [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diameter of device 7.8 mm",
"     </li>",
"     <li>",
"      Sounded cavity length &ge;6 to &le;10.5 cm",
"     </li>",
"     <li>",
"      Women with submucosal fibroids were excluded in the FDA approval studies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial compared HTA with rollerball in 276 women [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Women treated with HTA compared with rollerball were less likely to have postoperative hematometra (1 versus 6 percent), but they were significantly more likely to experience abdominal pain (53 versus 38 percent) and postoperative nausea and vomiting (22 versus 7 percent). Two patients in the HTA group had lower extremity burns due to contact with the device tubing.",
"   </p>",
"   <p>",
"    At three-year follow-up, women in the HTA group compared with those in the rollerball group had similar rates of reduced uterine bleeding (94 versus 91 percent) and amenorrhea (53 versus 46 percent). For HTA compared with rollerball, rates of hysterectomy were 9 and 6 percent and of repeat ablation were 2 and 4 percent. Tests of significance were not reported for the three-year follow-up data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Advantages/disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary advantage of this method is that it can be performed in women with intracavitary lesions. The circulating hot water will contact the entire endometrial surface regardless of cavity irregularity (",
"    <a class=\"graphic graphic_figure graphicRef62535 \" href=\"UTD.htm?43/19/44351\">",
"     figure 8",
"    </a>",
"    ). There is a report of use of HTA in two women with bicornuate uteri, but ablation in women with uterine anomalies is not standard practice [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link&amp;anchor=H8#H8\">",
"     \"An overview of endometrial ablation\", section on 'Uterine anomalies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another advantage of HTA is that it is done under direct visualization, so the operator can ensure that the entire uterine lining has been destroyed.",
"   </p>",
"   <p>",
"    Perioperative pain is a potential disadvantage of HTA. The hysteroscope used has a large diameter (7.8 mm) and hot water stimulates pain from nerve fibers within the myometrium.",
"   </p>",
"   <p>",
"    In addition, external burns appear to be more frequent following HTA than other non-resectoscopic ablation procedures. There have been reports of vaginal, perineal, and leg burns from contact with hot water when there was a poor seal on the cervix or when the sheath was removed before the intrauterine fluid has cooled [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. From 2003 to 2006, voluntary reports by device manufacturers to the FDA Manufacturer and User Facility Device database regarding circulating hot water ablation included 54 cases of burns (22 were major burns); it is not possible to calculate the incidence of these injuries, since the total number of procedures performed during this time period is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     CHOOSING AMONG TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The five non-resectoscopic ablation devices that are available in the United States all reduce uterine bleeding in 80 percent or more of women treated. Complication rates are low for all five devices.",
"   </p>",
"   <p>",
"    In the absence of differences in efficacy and complications, choosing among the non-resectoscopic ablation methods is based upon the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      uterine characteristics (cavity size and the presence of intracavitary lesions)",
"     </li>",
"     <li>",
"      factors that facilitate use in an office setting",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      under local anesthesia (eg, operative duration, perioperative pain)",
"     </li>",
"     <li>",
"      ease of preoperative preparation",
"     </li>",
"     <li>",
"      surgeon familiarity and preference",
"     </li>",
"     <li>",
"      device availability",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The feasibility of use in an office setting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    under local anesthesia is of particular importance when deciding among non-resectoscopic ablation techniques. Office use offers benefits of greater patient acceptability, ease of scheduling, and reduced expense. Many surgeons do not have the office set-up to perform ablation; however, use of local anesthesia has fewer risks and adverse effects than general anesthesia, regardless of the operative setting. All non-resectoscopic methods can be performed in an office setting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    under local anesthesia, but some are more amenable to this approach than others (eg, shorter operative duration, less perioperative pain). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link&amp;anchor=H29#H29\">",
"     \"An overview of endometrial ablation\", section on 'Office versus operating room procedures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link&amp;anchor=H28#H28\">",
"     \"An overview of endometrial ablation\", section on 'Anesthesia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Efficacy and complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the few studies that have compared between non-resectoscopic endometrial ablation techniques, radiofrequency and microwave methods were found to have comparable efficacy to hot liquid filled balloon devices, while radiofrequency was found to be superior to circulating hot water ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/34-39\">",
"     34-39",
"    </a>",
"    ]. Further data are needed to compare among non-resectoscopic ablation techniques.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bipolar radiofrequency versus hot liquid filled balloon &ndash; Novasure&reg; was compared with ThermaChoice&reg; balloon ablation in a randomized trial of 126 women [",
"      <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. There were no operative complications in either group. At five-year follow-up, the Novasure&reg; versus ThermaChoice&reg; groups had no significant differences in the frequency of amenorrhea (48 versus 32 percent), repeat ablation (one woman in each group), or hysterectomy (10 versus 13 percent).",
"      <br/>",
"      <br/>",
"      Similarly, a randomized trial in 57 women compared Novasure&reg; with the Cavaterm&trade; balloon [",
"      <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/36\">",
"       36",
"      </a>",
"      ]. There were no major complications in either group; perioperative pain was lower in the radiofrequency group. At 12 months, rates of amenorrhea were significantly higher in the Novasure&reg; compared with Cavaterm&trade; group (42 versus 12 percent); the rate of eumenorrhea between groups did not show a significant difference (16 versus 29 percent). Among women treated with Novasure&reg;, three women (8 percent) were planning repeat ablation and two (5 percent) underwent hysterectomy.",
"     </li>",
"     <li>",
"      Bipolar radiofrequency versus circulating hot water &ndash; In a randomized trial of 160 women with menorrhagia without pretreatment therapy, at 12-month follow-up, Novasure&reg; compared with HTA had significantly higher rates of patient satisfaction (87 versus 68 percent), amenorrhea (47 versus 24 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/39\">",
"       39",
"      </a>",
"      ]. In addition, Novasure&reg; was associated with one-third the risk of reintervention and one-half the risk of hysterectomy.",
"     </li>",
"     <li>",
"      Microwave versus hot liquid filled balloon &ndash; The MEA system appears to result in less postoperative pain and nausea than hot liquid filled balloon ablation. This was illustrated in a randomized trial of 320 women comparing MEA with ThermaChoice&reg; III [",
"      <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/37\">",
"       37",
"      </a>",
"      ]. There were no major complications in either group; patients in the microwave versus balloon group had a significantly lower rate of using postoperative opiates (80 versus 89 percent) or antiemetics were used by fewer patients in the microwave versus balloon group (26 versus 48 percent). At one-year follow-up, there were no significant differences between microwave and balloon ablation in pictorial blood chart assessment scores (3.0 versus 4.0; menorrhagia is defined as &ge;100 [",
"      <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/38\">",
"       38",
"      </a>",
"      ]) or amenorrhea (41 versus 38 percent). No patient underwent re-ablation or hysterectomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    General complications of resectoscopic and non-resectoscopic endometrial ablation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link&amp;anchor=H33#H33\">",
"     \"An overview of endometrial ablation\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Thermal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burns to the vagina, vulva, or thighs are a rare, but serious, complication that is associated mainly with circulating hot water ablation. Only a few cases of this complication have been reported by device manufacturers to the FDA Manufacturer and User Facility Device database [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/32\">",
"     32",
"    </a>",
"    ]. Further study of the risk of thermal injury with HTA ablation is needed (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Circulating hot water (hydrothermal)'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Use with leiomyomas or polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microwave ablation and cryoablation were evaluated in the FDA approval studies in women with small submucosal or intramural fibroids; labeling for circulating hot water ablation permits use in women with submucosal fibroids that are &le;4 cm, although these women were excluded from the approval studies.",
"   </p>",
"   <p>",
"    Endometrial polyps can generally be easily removed prior to endometrial ablation. Of note, women with small endometrial polyps (&le;2 cm) were included in the FDA approval studies for the microwave, bipolar radiofrequency, and Thermachoice&reg; hot liquid filled balloon devices.",
"   </p>",
"   <p>",
"    Use of endometrial ablation in women with intracavitary lesions is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link&amp;anchor=H13#H13\">",
"     \"An overview of endometrial ablation\", section on 'Leiomyomas or polyps'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Preoperative preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial preparation is advised by the manufacturer used for all non-resectoscopic ablation procedures with the exception of the bipolar radiofrequency device. The other device manufacturers advise 30 to 60 days of pretreatment with a gonadotropin-releasing hormone antagonist (eg, intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    3.75",
"    <span class=\"nowrap\">",
"     mg/month);",
"    </span>",
"    preparation for ThermaChoice&reg; can be either hormonal suppression or uterine curettage.",
"   </p>",
"   <p>",
"    Endometrial preparation for endometrial ablation is discussed in detail separately. Methods that do not require hormonal suppression avoid the drug-associated 30- to 60-day delay and adverse effects (eg, menopausal symptoms). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link&amp;anchor=H25#H25\">",
"     \"An overview of endometrial ablation\", section on 'Endometrial preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MEA ablation requires sonographic measurement of the myometrium in all patients, since endometrial ablation in women with severe myometrial thinning can potentially result in visceral injury. This requirement, however, does not add to the relative inconvenience of the procedure, since uterine imaging is required prior to all non-resectoscopic ablation procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link&amp;anchor=H9#H9\">",
"     \"An overview of endometrial ablation\", section on 'Myometrial thinning following uterine surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Operative duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;A shorter procedure is easier for a patient to tolerate under local anesthesia. Also, differences in operative duration impact upon a surgeon's operative or office schedule.",
"   </p>",
"   <p>",
"    The duration of energy delivery of the non-resectoscopic endometrial ablation procedures, from shortest to longest, are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Novasure&reg; bipolar radiofrequency (90 to 120 seconds)",
"     </li>",
"     <li>",
"      MEA (3 to 5 minutes)",
"     </li>",
"     <li>",
"      ThermaChoice&reg; hot liquid filled balloon (8 minutes)",
"     </li>",
"     <li>",
"      HTA circulating hot water (10 minutes)",
"     </li>",
"     <li>",
"      Her Option&reg; cryoablation (10 minutes).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thermablate EAS&trade; hot liquid filled balloon ablation has an operative time of just two minutes, but it is not currently available in the United States.",
"   </p>",
"   <p>",
"    These times do not include other parts of the procedure, which are similar across ablation methods, including patient set-up and anesthesia time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Perioperative pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few comparative data regarding perioperative pain across non-resectoscopic endometrial ablation methods [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/40\">",
"     40",
"    </a>",
"    ]. Bipolar radiofrequency ablation and MEA appear to be associated with less perioperative pain than hot liquid filled balloon procedures, based upon on randomized trials data [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/393/abstract/36,37,40\">",
"     36,37,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pain is stimulated by cervical dilation, uterine distention and burning of the endometrium. The Thermachoice&reg; hot liquid filled balloon and cryoablation devices use probes with the smallest diameter (approximately 5 mm), which require no or minimal cervical dilation. No uterine distention is required with the bipolar radiofrequency, cryoablation, and microwave devices. HerOption provides cryoanesthesia while all other devices use heat to burn the endometrium, which stimulates pain fibers within the endometrium and myometrium. Taking into consideration all sources of pain, the cryoablation device likely results in the least amount of perioperative pain, although comparative data are needed to fully evaluate this.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the endometrial ablation devices have similar efficacy and complication rates and each device has advantages and disadvantages. Cryoablation appears to result in the least patient discomfort. Bipolar radiofrequency ablation has the shortest energy delivery time. Circulating hot water is the only non-resectoscopic method performed using direct visualization. Each surgeon should determine which device is most appropriate in their practice.",
"   </p>",
"   <p>",
"    In women with submucosal fibroids or endometrial polyps, we suggest use of microwave ablation or cryoablation over other methods since the success of the other devices was not evaluated in the FDA studies. Although radiofrequency ablation and hot liquid filled balloon ablation were not initially evaluated in women with intracavitary lesions (submucosal fibroids, endometrial polyps), some data suggest that these methods can be used effectively in this population. Further study of this issue is needed. In contrast, microwave has been evaluated and used successfully in these women. Microwave ablation has the additional advantage of allowing for a larger cavity size than other methods (12 to 14 versus 10 cm). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Bipolar radiofrequency'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H22\">",
"     'Circulating hot water (hydrothermal)'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Microwave'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H678723\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative care and other follow-up issues for endometrial ablation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link&amp;anchor=H51#H51\">",
"     \"An overview of endometrial ablation\", section on 'Follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/8/143?source=see_link\">",
"       \"Patient information: Endometrial ablation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-resectoscopic endometrial ablation is a treatment for abnormal uterine bleeding that is performed with a device which is inserted into the uterine cavity and delivers energy to uniformly destroy the uterine lining. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Comparative studies have found comparable treatment efficacy for bipolar radiofrequency, microwave, and hot liquid filled balloon ablation devices. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Efficacy and complications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H32\">",
"       'Perioperative pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The non-resectoscopic endometrial ablation devices with the shortest energy delivery times are bipolar radiofrequency (90 to 120 seconds) and microwave (one to four minutes); hot liquid filled balloon device with an operative duration of two minutes is available outside the United States. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Operative duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with small (&le;4 cm) submucosal fibroids or endometrial polyps, we suggest use of microwave ablation or cryoablation rather than other non-resectoscopic ablation methods (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Women with larger intracavitary lesions require resectoscopic endometrial ablation or other treatment methods. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Microwave'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All of the non-resectoscopic devices appear to have similar efficacy and complication rates. Specific methods have advantages or disadvantages regarding operative duration, perioperative pain, and use in women with irregular uterine cavities. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Choosing among techniques'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/1\">",
"      Deb S, Flora K, Atiomo W. A survey of preferences and practices of endometrial ablation/resection for menorrhagia in the United Kingdom. Fertil Steril 2008; 90:1812.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma.cfm?num=p020031. (Accessed February 16, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/3\">",
"      McCausland AM, McCausland VM. Partial rollerball endometrial ablation: a modification of total ablation to treat menorrhagia without causing complications from intrauterine adhesions. Am J Obstet Gynecol 1999; 180:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/4\">",
"      Bae IH, Pagedas AC. Comparison of Partial and Complete Endomyometrial Resection with Rollerball Endometrial Ablation. J Am Assoc Gynecol Laparosc 1996; 3:S2.",
"     </a>",
"    </li>",
"    <li>",
"     www.novasure.com/novasure-procedure/novasure-instructions.cfm. (Accessed February 24, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/6\">",
"      Fulop T, R&aacute;k&oacute;czi I, Barna I. NovaSure impedance controlled endometrial ablation: long-term follow-up results. J Minim Invasive Gynecol 2007; 14:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/7\">",
"      Gallinat A. An impedance-controlled system for endometrial ablation: five-year follow-up of 107 patients. J Reprod Med 2007; 52:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/8\">",
"      Sabbah R, Desaulniers G. Use of the NovaSure Impedance Controlled Endometrial Ablation System in patients with intracavitary disease: 12-month follow-up results of a prospective, single-arm clinical study. J Minim Invasive Gynecol 2006; 13:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/9\">",
"      Cooper KG, Bain C, Parkin DE. Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet 1999; 354:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/10\">",
"      Sambrook AM, Bain C, Parkin DE, Cooper KG. A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. BJOG 2009; 116:1033.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/cdrh_docs/pdf2/P020031b.pdf. (Accessed May 26, 2010).",
"    </li>",
"    <li>",
"     41. www.ethicon360.com/products/gynecare-thermachoice-uterine-balloon-therapy-system. (Accessed February 24, 2010).",
"    </li>",
"    <li>",
"     file://www.pnnmedical.com/?tabid=75. (Accessed February 24, 2010).",
"    </li>",
"    <li>",
"     file://www.thermablate-eas.com/thermablate/AboutThermablate/ForMedical/ForMedicalPage1.aspx (Accessed February 24, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/15\">",
"      Amso NN, Fernandez H, Vilos G, et al. Uterine endometrial thermal balloon therapy for the treatment of menorrhagia: long-term multicentre follow-up study. Hum Reprod 2003; 18:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/16\">",
"      Ahonkallio S, Martikainen H, Santala M. Endometrial thermal balloon ablation has a beneficial long-term effect on menorrhagia. Acta Obstet Gynecol Scand 2008; 87:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/17\">",
"      Mettler L. Long-term results in the treatment of menorrhagia and hypermenorrhea with a thermal balloon endometrial ablation technique. JSLS 2002; 6:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/18\">",
"      Chapa HO, Venegas G, Antonetti AG, et al. In-office endometrial ablation using a third-generation uterine balloon therapy system: 12-month prospective follow-up on menstrual patterns and dysmenorrhea impact. J Reprod Med 2009; 54:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/19\">",
"      El-Toukhy T, Chandakas S, Grigoriadis T, et al. Outcome of the first 220 cases of endometrial balloon ablation using Cavaterm plus. J Obstet Gynaecol 2004; 24:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/20\">",
"      Karamanidis D, Nicolaou P, Byros A, Koutsougeras G. Two-year results of a new two-minute hot liquid balloon endometrial ablation system (Thermablate): a pilot study. Clin Exp Obstet Gynecol 2009; 36:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/21\">",
"      ACOG Committee on Practice Bulletins. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 81, May 2007. Obstet Gynecol 2007; 109:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/22\">",
"      Soysal ME, Soysal SK, Vicdan K. Thermal balloon ablation in myoma-induced menorrhagia under local anesthesia. Gynecol Obstet Invest 2001; 51:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/23\">",
"      Thamban S, Garg S, Al-Habib A, El-Farra KE. Thermal balloon endometrial ablation in bicornuate uteri. J Obstet Gynaecol 2007; 27:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/24\">",
"      Townsend DE, Duleba AJ, Wilkes MM. Durability of treatment effects after endometrial cryoablation versus rollerball electroablation for abnormal uterine bleeding: two-year results of a multicenter randomized trial. Am J Obstet Gynecol 2003; 188:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/25\">",
"      Duleba AJ, Heppard MC, Soderstrom RM, Townsend DE. A randomized study comparing endometrial cryoablation and rollerball electroablation for treatment of dysfunctional uterine bleeding. J Am Assoc Gynecol Laparosc 2003; 10:17.",
"     </a>",
"    </li>",
"    <li>",
"     file://74.125.47.132/search?q=cache:8V53ZDQy8K0J:www.accessdata.fda.gov/cdrh_docs/pdf/P000040c.pdf+fda+hydrothermablator&amp;cd=1&amp;hl=en&amp;ct=clnk&amp;gl=us&amp;client=firefox-a (Accessed February 25, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/27\">",
"      Lethaby A, Hickey M, Garry R. Endometrial destruction techniques for heavy menstrual bleeding. Cochrane Database Syst Rev 2005; :CD001501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/28\">",
"      Goldrath MH. Evaluation of HydroThermAblator and rollerball endometrial ablation for menorrhagia 3 Years after treatment. J Am Assoc Gynecol Laparosc 2003; 10:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/29\">",
"      Ammar K, Koukoura O. Management of menorrhagia with hydrothermal endometrial ablation in 2 women with bicornuate uteri. J Minim Invasive Gynecol 2009; 16:795.",
"     </a>",
"    </li>",
"    <li>",
"     wfile://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/search.CFM (Accessed April 21, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/31\">",
"      Gurtcheff SE, Sharp HT. Complications associated with global endometrial ablation: the utility of the MAUDE database. Obstet Gynecol 2003; 102:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/32\">",
"      Della Badia C, Nyirjesy P, Atogho A. Endometrial ablation devices: review of a manufacturer and user facility device experience database. J Minim Invasive Gynecol 2007; 14:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/33\">",
"      Milingos S, Protopapas A, Papadimitriou C, et al. Laparoscopy in the evaluation of women with unexplained ascites: an invaluable diagnostic tool. J Minim Invasive Gynecol 2007; 14:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/34\">",
"      Bongers MY, Bourdrez P, Mol BW, et al. Randomised controlled trial of bipolar radio-frequency endometrial ablation and balloon endometrial ablation. BJOG 2004; 111:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/35\">",
"      Kleijn JH, Engels R, Bourdrez P, et al. Five-year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. BJOG 2008; 115:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/36\">",
"      Abbott J, Hawe J, Hunter D, Garry R. A double-blind randomized trial comparing the Cavaterm and the NovaSure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertil Steril 2003; 80:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/37\">",
"      Sambrook AM, Cooper KG, Campbell MK, Cook JA. Clinical outcomes from a randomised comparison of Microwave Endometrial Ablation with Thermal Balloon endometrial ablation for the treatment of heavy menstrual bleeding. BJOG 2009; 116:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/38\">",
"      Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990; 97:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/39\">",
"      Penninx JP, Mol BW, Engels R, et al. Bipolar radiofrequency endometrial ablation compared with hydrothermablation for dysfunctional uterine bleeding: a randomized controlled trial. Obstet Gynecol 2010; 116:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/393/abstract/40\">",
"      Clark TJ, Samuel N, Malick S, et al. Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office: a randomized controlled trial. Obstet Gynecol 2011; 117:109.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3293 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-210.101.131.231-1C6C0C3C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_24_393=[""].join("\n");
var outline_f0_24_393=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CURRENT NON-RESECTOSCOPIC ABLATION DEVICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL OPERATIVE TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Routine use of hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ABLATION METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bipolar radiofrequency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Uterine requirements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Advantages/disadvantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Microwave",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Uterine requirements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Advantages/disadvantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hot liquid filled balloons",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Uterine requirements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Advantages/disadvantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cryoablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Uterine requirements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Advantages/disadvantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Circulating hot water (hydrothermal)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Uterine requirements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Advantages/disadvantages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      CHOOSING AMONG TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Efficacy and complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Thermal injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Use with leiomyomas or polyps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Preoperative preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Operative duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Perioperative pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H678723\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3293\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3293|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/24/1408\" title=\"figure 1A\">",
"      Bipolar radiofrequency ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/46/17121\" title=\"figure 1B\">",
"      Bipolar radiofrequency ablation 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/24/17793\" title=\"figure 2\">",
"      Microwave endometrial ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/0/40975\" title=\"figure 3A\">",
"      Hot liquid balloon ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/5/43088\" title=\"figure 3B\">",
"      Hot liquid balloon ablation 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/25/16785\" title=\"figure 4A\">",
"      Endometrial cryoablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/27/35262\" title=\"figure 4B\">",
"      Placement of cryoprobe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/27/44465\" title=\"figure 5\">",
"      Endometrium layers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/0/27662\" title=\"figure 6\">",
"      Ice ball formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/33/28176\" title=\"figure 7\">",
"      Circulating hot water ablation 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/19/44351\" title=\"figure 8\">",
"      Circulating hot water ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3293|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/30/34284\" title=\"table 1\">",
"      Nonresectoscopic ablation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=related_link\">",
"      An overview of endometrial ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=related_link\">",
"      Chronic menorrhagia or anovulatory uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44708?source=related_link\">",
"      Endometrial ablation or resection: Resectoscopic techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=related_link\">",
"      Overview of hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/8/143?source=related_link\">",
"      Patient information: Endometrial ablation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4408?source=related_link\">",
"      Uterine perforation during gynecologic procedures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_24_394="Childhood lead poisoning: Clinical manifestations and diagnosis";
var content_f0_24_394=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Childhood lead poisoning: Clinical manifestations and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/24/394/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/24/394/contributors\">",
"     Richard L Hurwitz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/24/394/contributors\">",
"     Dean A Lee, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/24/394/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/24/394/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/24/394/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/24/394/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/24/394/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/24/394/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/24/394/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lead (Pb), a stable metallic element with an atomic number of 82 and atomic weight of 207, was first smelted around 4000 BC as a by-product of silver processing. The consequences of lead toxicity have been recognized for millennia and are thought to have contributed to the fall of the Roman Empire [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/1\">",
"     1",
"    </a>",
"    ]. Complications of lead poisoning were first acknowledged in the United States in the early 20th century. Despite this knowledge, lead was included as an ingredient of gasoline in the 1920s and continued to be used in paint until the 1970s [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As lead was removed from gasoline and paint, the average blood lead level (BLL) in children decreased from 16",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.77",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    to less than 3",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.14",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Residual lead from these and other products remains in the environment because elemental lead cannot be degraded. In many parts of the developing world, lead continues to be used in gasoline, pigment (eg, in paint, cosmetics, and crayons), pottery glaze, solder, cooking vessels, and even medications. These products occasionally are imported into the United States and are potential sources of lead exposure.",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of lead toxicity will be reviewed here. Prevention and treatment of lead poisoning are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11001?source=see_link\">",
"     \"Childhood lead poisoning: Exposure and prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link\">",
"     \"Childhood lead poisoning: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The toxic lead level in the United States is determined by the Centers for Disease Control (CDC) based upon the current understanding of the complications caused by a given concentration of lead in the blood. Between 1970 and 2012, the toxic level or &ldquo;reference value&rdquo; was gradually decreased from 60",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2.9",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    to the 97.5",
"    <sup>",
"     th",
"    </sup>",
"    percentile of blood lead levels in US children (5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [0.24",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    as of 2012) (",
"    <a class=\"graphic graphic_table graphicRef64183 \" href=\"UTD.htm?9/33/9755\">",
"     table 1",
"    </a>",
"    ). The decrease in 1991 was prompted by evidence of cognitive and behavioral effects of low-level lead toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/6,7\">",
"     6,7",
"    </a>",
"    ] Changes in the definition of the toxic level have been accompanied by changes in policies for screening, treatment, and prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/8\">",
"     8",
"    </a>",
"    ]. Subsequently, a reference level corresponding to the 97.5",
"    <sup>",
"     th",
"    </sup>",
"    percentile of blood lead levels in US children (5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [0.24",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    as of 2012) has been adopted [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of lead toxicity has decreased in the United States since the 1970s because of preschool screening programs, increased public awareness, and the removal of lead from gasoline and paint products. The prevalence of BLLs &gt;10",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.48",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in American children between one and five years of age decreased from 88 to 4.4 percent between 1976 and 1994 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/10\">",
"     10",
"    </a>",
"    ], and to 0.8 percent for the period 2007 to 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/5,11\">",
"     5,11",
"    </a>",
"    ]. Although the incidence and severity of lead poisoning in the United States are decreasing, an estimated 450,000 children in the United States were above the reference value of 5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.24",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in 2012 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children younger than six years of age (and particularly those between 12 and 36 months) are more susceptible to the toxic effects of lead than are adults because they have an incomplete blood-brain barrier that permits the entry of lead into the developing nervous system and because they have a greater prevalence of iron deficiency, which is associated with lead poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/12\">",
"     12",
"    </a>",
"    ] and may permit increased absorption of lead from the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, they are at greater risk of exposure to lead dust because of crawling and hand-to-mouth behavior.",
"   </p>",
"   <p>",
"    The prevalence of elevated lead levels is highest among inner-city children who live in deteriorating housing that was built before the 1970s [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/13\">",
"     13",
"    </a>",
"    ]. Lead poisoning is more common among urban than rural children, low-income than middle-income children, and children who live in older housing [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/5,14-16\">",
"     5,14-16",
"    </a>",
"    ]. In addition, the prevalence of lead poisoning is increased in refugee children who have arrived recently in the United States and in children entering foster care [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sources",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children typically are exposed to environmental lead through ingestion or inhalation. Common sources include chips of paint or lead dust from lead-painted surfaces, food or beverages purchased, stored, or served in lead-soldered cans or lead-glazed pottery, water from lead-soldered plumbing, automobile emissions, or lead-using industry (",
"    <a class=\"graphic graphic_table graphicRef53953 \" href=\"UTD.htm?9/3/9277\">",
"     table 2",
"    </a>",
"    ). Although the United States phased out lead-soldered food cans during the 1980s, imported canned goods may still contain lead [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/13\">",
"     13",
"    </a>",
"    ]. Less common sources of lead exposure include herbal and folk medications, imported crayons and other toys, mini blinds, cosmetics, and imported cookware [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/13,19\">",
"     13,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11001?source=see_link\">",
"     \"Childhood lead poisoning: Exposure and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TOXICOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inorganic lead is not metabolized but is directly absorbed, distributed, and excreted. The absorption of lead depends upon the route of exposure and the age and nutritional status of the exposed individual [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/13\">",
"     13",
"    </a>",
"    ]. Lead that is inhaled into the lower respiratory tract is absorbed completely. Children absorb a greater proportion of lead from the gastrointestinal tract than do adults (up to 70 percent versus 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Fasting, iron deficiency, and calcium deficiency also may increase the gastrointestinal absorption of lead [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/13,22,23\">",
"     13,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lead that is absorbed from the gastrointestinal or respiratory tracts is distributed in the blood, soft tissues, and mineralized tissues (eg, bones and teeth). The half-life of lead varies depending upon the body compartment [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/13,24-27\">",
"     13,24-27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Blood &ndash; 28 to 36 days",
"     </li>",
"     <li>",
"      Soft tissue &ndash; 40 days",
"     </li>",
"     <li>",
"      Mineralizing tissues &ndash; Greater than 25 years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lead that is not retained in the tissues is excreted by the kidneys or through biliary clearance into the gastrointestinal tract. Children younger than two years of age retain approximately one-third of absorbed lead, whereas adults ultimately retain only 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/13\">",
"     13",
"    </a>",
"    ]. More than 70 percent of the total body burden of lead in children is contained in the mineralized tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/13,28\">",
"     13,28",
"    </a>",
"    ]. Thus, the BLL is not a good reflection of the total body lead burden.",
"   </p>",
"   <p>",
"    The lead in mineralizing tissues accumulates in two subcompartments: a labile compartment that readily exchanges lead with the blood, and an inert pool [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/27\">",
"     27",
"    </a>",
"    ]. The inert pool of lead can be mobilized during periods of physiologic stress (eg, pregnancy, lactation, fractures, chronic disease) and represents an endogenous source of lead that can maintain an elevated BLL long after the exogenous exposure source has been removed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/13\">",
"     13",
"    </a>",
"    ]. Because the body accumulates lead over a lifetime and releases it slowly, lead toxicity may occur without a major acute exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Molecular toxicology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lead is a potent toxic substance with no apparent threshold [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/29\">",
"     29",
"    </a>",
"    ]. Lead interferes with the interactions of divalent cations and sulfhydryl groups. It has widespread physiologic effects because most biochemical reactions are regulated by these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In vitro, many of the reactions in which lead serves as a competitive inhibitor are reversible. However, in vivo, downstream events lead to cell death and irreversible damage, particularly in the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lead can disrupt signal transduction cascades by activating protein kinase C, competing with magnesium and inhibiting cyclic nucleotide hydrolysis by phosphodiesterases, or inhibiting function at the N-methyl-D-aspartate-type glutamate receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. Lead also can uncouple mitochondrial oxidative phosphorylation in the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/34,39\">",
"     34,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Magnetic resonance spectroscopy (MRS) in individuals with elevated BLLs demonstrates reduction in the",
"    <span class=\"nowrap\">",
"     N-acetylaspartate/creatine",
"    </span>",
"    and phosphocreatine ratios in the frontal gray matter, suggesting that lead poisoning affects metabolism in the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lead competes with calcium for entry into synaptosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/42\">",
"     42",
"    </a>",
"    ] and interacts with numerous receptor-activated and voltage-gated cation channels [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. In addition, lead increases the infidelity of DNA and RNA polymerase, leading to somatic and germline mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Lead-exposed rodents have an increased incidence of cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/47-52\">",
"     47-52",
"    </a>",
"    ]. However, this association has not been found in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/53-55\">",
"     53-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hematologic complications of lead toxicity result from the ability of lead to directly inhibit &delta;-aminolevulinic acid synthetase (ALAS) and &delta;-aminolevulinic acid dehydratase (ALAD), enzymes necessary for heme biosynthesis, and ferrochelatase, a mitochondrial sulfhydryl enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. Inhibition of ferrochelatase results in an increased level of zinc protoporphyrin in the blood. In addition, lead can inhibit pyrimidine 5' nucleotidase activity, which results in the basophilic stippling sometimes observed in erythrocytes in individuals with lead poisoning (",
"    <a class=\"graphic graphic_picture graphicRef71989 \" href=\"UTD.htm?39/22/40294\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of lead poisoning vary depending upon the lead exposure and the age of the exposed individual (",
"    <a class=\"graphic graphic_table graphicRef76585 \" href=\"UTD.htm?10/25/10652\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link\">",
"     \"Adult lead poisoning\"",
"    </a>",
"    .) However, some children with severely elevated BLL (greater than 250",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [12.1",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    may be asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/60\">",
"     60",
"    </a>",
"    ]. The early symptoms of acute lead poisoning in children are episodic and nonspecific (eg, anorexia, decreased activity, irritability, and insomnia). The symptoms slowly intensify over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Neurologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurologic effects of lead poisoning range from developmental delay or loss of milestones, particularly in language, to encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/6,13,61\">",
"     6,13,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most children who have toxic BLLs are asymptomatic at the time of screening. However, population-based studies consistently have shown that lead levels greater than 10",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.48",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    affect the cognitive and behavioral development of children [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/6,7,62-69\">",
"     6,7,62-69",
"    </a>",
"    ]. Neurocognitive effects also have been demonstrated at even lower BLLs and no known threshold is known to exist [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/70-73\">",
"     70-73",
"    </a>",
"    ]. In utero exposure to lead adversely affects infant neurodevelopment (measured at 24 months) independent of post-natal BLL [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/9,74\">",
"     9,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The neurobehavioral effects of lead poisoning appear to persist, at least in part, into adolescence, despite a decline in BLL [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/7,64,75-81\">",
"     7,64,75-81",
"    </a>",
"    ]. Although these studies cannot predict performance in an individual child with elevated BLL [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/82\">",
"     82",
"    </a>",
"    ], they do suggest that young children are better off in a lead-free environment.",
"   </p>",
"   <p>",
"    In addition to cognitive and behavior problems, lead poisoning can cause hearing loss, peripheral neuropathy, and decreased nerve conduction velocity. The hearing loss occurs primarily in the higher frequencies and may contribute to learning and behavior problems [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/13,83\">",
"     13,83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peripheral neuropathy, rare in children with isolated lead poisoning, is more common in children with concomitant sickle cell anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/84-87\">",
"     84-87",
"    </a>",
"    ]. Decreased nerve conduction velocity occurs at BLLs as low as 20",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (1.0",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute encephalopathy occurs at BLLs greater than 100 to 150",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (4.8 to 7.2",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and is indicated by persistent vomiting, altered or fluctuating state of consciousness, ataxia, seizures, or coma. Cerebral edema is a variable finding, more often present in younger than older children. Children with lead encephalopathy may develop inappropriate antidiuretic hormone secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/90\">",
"     90",
"    </a>",
"    ], partial heart block [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/91\">",
"     91",
"    </a>",
"    ], and marked decrease in renal function. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Renal'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hematologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lead poisoning in children rarely results in anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/13\">",
"     13",
"    </a>",
"    ]. The two major mechanisms are decreased hemoglobin synthesis and hemolysis. Decreased hemoglobin synthesis has been well documented at BLLs of 40",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (1.9",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/92\">",
"     92",
"    </a>",
"    ] and is caused by the interference of lead with several enzymatic steps in the heme pathway. With prolonged exposure to high levels of lead, red blood cell survival is diminished. Acute, high-level lead poisoning (BLL &gt;70",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [3.4",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    has been associated with hemolytic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=see_link&amp;anchor=H19#H19\">",
"     \"Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins\", section on 'Lead'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5\">",
"     'Molecular toxicology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Anemia in children with lead poisoning may in fact be caused by iron deficiency because lead poisoning and iron deficiency have similar risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. Anemia secondary to lead toxicity usually is mild, hemolytic, and normocytic. In contrast, anemia secondary to iron deficiency is hypochromic, microcytic, and reticulocytopenic [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=see_link\">",
"     \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Renal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lead nephropathy, which is characterized histologically by chronic interstitial nephritis, is a potential complication of prolonged high-level lead exposure. In addition, current levels of lead exposure have the potential for lead-related nephrotoxicity, primarily in adults with diabetes, hypertension, or underlying chronic kidney disease. These issues, including the long-term renal outcomes of childhood lead poisoning, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5705?source=see_link&amp;anchor=H13#H13\">",
"     \"Lead nephropathy and lead-related nephrotoxicity\", section on 'Risk in children'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lead colic, which includes sporadic vomiting, intermittent abdominal pain, and constipation, may occur with a lead level as low as 60",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2.9",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Endocrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood lead levels and vitamin D levels are inversely related [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/13,97\">",
"     13,97",
"    </a>",
"    ]. Vitamin D metabolism is decreased at BLLs of 30",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (1.45",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/97\">",
"     97",
"    </a>",
"    ]. The effects of lead toxicity on cell growth and maturation and tooth and bone development probably are mediated through the effects on vitamin D [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, mildly elevated BLL may affect pubertal development. In one cross-sectional study, after adjustment for potential confounding factors, mild elevations of BLL (3",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    versus 1",
"    <span class=\"nowrap\">",
"     mcg/dL)",
"    </span>",
"    were associated with decreased height in all girls and delays in breast and pubic hair development (statistically significant only in African-American and Mexican-American girls) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lead poisoning is diagnosed in the United States when the venous blood lead level is greater than 97.5",
"    <sup>",
"     th",
"    </sup>",
"    percentile for the pediatric population (5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [0.24",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    in 2012) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/9\">",
"     9",
"    </a>",
"    ]. Early diagnosis is desirable because most of the effects of lead toxicity are irreversible [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/99-101\">",
"     99-101",
"    </a>",
"    ]. Once diagnosed, treatment depends on the degree of the blood lead elevation and the presence of symptoms. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Lead levels'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link\">",
"     \"Childhood lead poisoning: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of lead toxicity usually is made through a lead screening program because most children with mild lead toxicity are asymptomatic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43225?source=see_link&amp;anchor=H17#H17\">",
"     \"Screening tests in children and adolescents\", section on 'Lead poisoning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Symptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of lead toxicity are diverse and nonspecific. They include vomiting, cognitive impairment, language delay, hearing loss, and behavior problems at low concentrations and colicky abdominal pain, anemia, intellectual disability (mental retardation), seizures, renal insufficiency, and encephalopathy at higher concentrations (",
"    <a class=\"graphic graphic_table graphicRef76585 \" href=\"UTD.htm?10/25/10652\">",
"     table 3",
"    </a>",
"    ). Lead poisoning should be included in the differential diagnosis for children with any of these complaints or conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient presents with acute encephalopathy of unknown etiology and a BLL cannot be obtained immediately, several clinical findings constitute strong supportive evidence for a diagnosis of lead poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. They include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Strongly positive qualitative urine coproporphyrin",
"     </li>",
"     <li>",
"      Basophilic stippling of peripheral RBCs or erythroblasts in the bone marrow (",
"      <a class=\"graphic graphic_picture graphicRef71989 \" href=\"UTD.htm?39/22/40294\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypophosphatemia",
"     </li>",
"     <li>",
"      Glycosuria",
"     </li>",
"     <li>",
"      Lead flecks on abdominal radiograph (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81950 \" href=\"UTD.htm?10/14/10464\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lead lines on long-bone radiographs (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81488 \" href=\"UTD.htm?13/51/14143\">",
"       image 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children with lead encephalopathy almost always have elevated blood erythrocyte protoporphyrin (EP) or zinc protoporphyrin (ZPP) concentrations (greater than 35",
"    <span class=\"nowrap\">",
"     mcg/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/105\">",
"     105",
"    </a>",
"    ]. Thus, elevated EP or ZPP concentrations can be used as a rapid confirmatory test in most hospitals. Similarly, detection of &delta;-aminolevulinic acid levels in the urine can be used to support a diagnosis of lead intoxication if BLL results cannot be obtained immediately [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/106-109\">",
"     106-109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment should begin emergently if encephalopathy secondary to severe lead toxicity is suspected. A BLL should be obtained to confirm the diagnosis, but treatment should not be delayed while awaiting the result. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link&amp;anchor=H6#H6\">",
"     \"Childhood lead poisoning: Management\", section on 'Severe intoxication (&ge;70 mcg/dL)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful history should be obtained from the families of all children suspected of toxic lead exposure (",
"    <a class=\"graphic graphic_table graphicRef58514 \" href=\"UTD.htm?2/34/2605\">",
"     table 4",
"    </a>",
"    ). The history should include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Onset and severity of symptoms of toxicity (",
"      <a class=\"graphic graphic_table graphicRef76585 \" href=\"UTD.htm?10/25/10652\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nutritional history with particular attention to intake of iron and calcium",
"     </li>",
"     <li>",
"      History of pica",
"     </li>",
"     <li>",
"      Family history of lead poisoning",
"     </li>",
"     <li>",
"      Foreign birthplace and recent foreign residence [",
"      <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/110\">",
"       110",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Assessment of potential sources of lead exposure: work history of the parents and other significant caregivers, hobbies, age of the home and history of home renovations, source of water supply, location and condition of play areas, use of imported or glazed ceramics, and proximity to industrial facilities or hazardous waste sites (",
"      <a class=\"graphic graphic_table graphicRef53953 \" href=\"UTD.htm?9/3/9277\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should assess the possible neurologic consequences of lead toxicity: language development and neurobehavioral function must be included. Lethargy is particularly concerning because it indicates encephalopathy. Lead lines, at the junction of the teeth and gums, are rarely seen. If present, they usually indicate severe and prolonged lead exposure (",
"    <a class=\"graphic graphic_picture graphicRef77682 \" href=\"UTD.htm?16/27/16819\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Lead levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory evaluation of the child with lead poisoning should include a repeat BLL to confirm the diagnosis. BLLs also should be obtained in the patient's siblings, housemates,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    playmates. Confirmatory samples should be obtained through venous sampling and processed in lead-free collection tubes.",
"   </p>",
"   <p>",
"    Capillary blood sampling is simpler than venous blood sampling for lead screening and is a valid collection method if it is performed properly [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. However, capillary samples are subject to contamination with exogenous lead and can yield false-positive results. Common causes of falsely elevated BLLs from capillary lead sampling include inadequate use of gloves by phlebotomists, use of alcohol wipes contaminated with lead-based ink, inadequate cleansing of the child's finger, and failure to wipe off the first drop of blood [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/113\">",
"     113",
"    </a>",
"    ]. All patients who have elevated lead levels on capillary samples must have confirmatory venous blood testing.",
"   </p>",
"   <p>",
"    Federal regulations in the United States permit laboratories that perform BLL testing to operate with an allowable error of &plusmn;4",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.19",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    or 10 percent, whichever is greater [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/114\">",
"     114",
"    </a>",
"    ]. As an example, a laboratory that meets proficiency standards may report an actual BLL of 8",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.38",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    as any value ranging from 4",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    to 12",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.19 to 0.58",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"   </p>",
"   <p>",
"    Bone and dentine lead levels, measured by K x-ray fluorescence spectroscopy or atomic absorption spectroscopy, respectively, are better indicators of the child's total lead burden than BLLs [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/27,62,75\">",
"     27,62,75",
"    </a>",
"    ]. However, these tests are not routinely available, and are not recommended by the American Academy of Pediatrics (AAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/112\">",
"     112",
"    </a>",
"    ] or the Centers for Disease Control and Prevention (CDC) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/115\">",
"     115",
"    </a>",
"    ]. BLLs remain the gold standard for the diagnosis of lead poisoning in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Erythrocyte protoporphyrin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythrocyte protoporphyrin (EP), typically assayed as zinc protoporphyrin (ZPP), is elevated (greater than 35",
"    <span class=\"nowrap\">",
"     mcg/dL)",
"    </span>",
"    in both iron deficiency and lead poisoning. The EP is elevated to a greater extent in patients with lead toxicity than in patients with iron deficiency and is most elevated in patients with inherited porphyrias.",
"   </p>",
"   <p>",
"    EP levels usually are not elevated until lead levels are greater than 30",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (1.45",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/13,109,116\">",
"     13,109,116",
"    </a>",
"    ]. Thus, EP is not a good screening test for mild lead toxicity. However, it is a useful confirmatory test for lead poisoning if BLLs are not available immediately, and it can be helpful in monitoring response to therapeutic interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Additional tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory evaluation also should include a complete blood count, reticulocyte count, serum iron, iron binding capacity, and ferritin to determine if the child has iron deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/115\">",
"     115",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=see_link&amp;anchor=H16#H16\">",
"     \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional tests are necessary for children who require chelation therapy. These tests include serum electrolytes, blood urea nitrogen, creatinine, calcium, magnesium, transaminases, and urinalysis. Screening for G6PD deficiency should be performed in patients with risk factors of findings consistent with the disease who will be treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"     dimercaprol",
"    </a>",
"    or succimer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link\">",
"     \"Childhood lead poisoning: Management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=see_link\">",
"     \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link\">",
"     \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Diagnostic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In symptomatic patients or children with a history of pica or acute ingestion of lead containing objects (eg, fishing weights), an abdominal radiograph should be obtained to evaluate the presence of foreign material as the lead source.",
"   </p>",
"   <p>",
"    Radio-opaque lead flecks in the intestinal tract suggesting recent ingestion are found inconsistently (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81950 \" href=\"UTD.htm?10/14/10464\">",
"     image 1",
"    </a>",
"    ). However, their presence may have implications for treatment at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/103\">",
"     103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link\">",
"     \"Childhood lead poisoning: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lead lines at the end of growing long bones (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81488 \" href=\"UTD.htm?13/51/14143\">",
"     image 2",
"    </a>",
"    ) are found only in children with moderate lead toxicity (eg, blood levels greater than 45",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [2.2",
"    <span class=\"nowrap\">",
"     micromol/L]).",
"    </span>",
"    Thus, long bone radiographs are not useful as part of the diagnostic evaluation of children with lead levels less than 45",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2.2",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"   </p>",
"   <p>",
"    The AAP and CDC do not recommend obtaining long bone radiographs in the evaluation of children with lead exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/112,115\">",
"     112,115",
"    </a>",
"    ]. However, in areas of the world where BLLs cannot be obtained easily and in patients with encephalopathy in whom BLLs cannot be obtained immediately, the findings of lead in the gastrointestinal tract or lead lines on skeletal survey are important diagnostic tools for defining severe lead toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/24/394/abstract/117,118\">",
"     117,118",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with lead toxicity typically are asymptomatic. The diagnosis usually is made through routine blood lead screening. False-positive elevation caused by contamination of the fingertip can occur if capillary samples are obtained. Management decisions should be based upon confirmation of results through venous blood samples that are collected in lead-free tubes. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Lead levels'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link\">",
"       \"Childhood lead poisoning: Management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with elevated blood lead levels (BLLs), the laboratory evaluation also should include a complete blood count, reticulocyte count, serum iron, iron binding capacity, and ferritin to determine if the child has iron deficiency. Children whose BLLs warrant chelation therapy should also undergo measurement of serum electrolytes, blood urea nitrogen, creatinine, calcium, magnesium, transaminases, and urinalysis. Screening for G6PD deficiency should be performed in patients with risk factors of findings consistent with the disease who will be treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"       dimercaprol",
"      </a>",
"      or succimer. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Additional tests'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link&amp;anchor=H6#H6\">",
"       \"Childhood lead poisoning: Management\", section on 'Severe intoxication (&ge;70 mcg/dL)'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link&amp;anchor=H15#H15\">",
"       \"Childhood lead poisoning: Management\", section on 'Moderate intoxication (45 to 69 mcg/dL)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In symptomatic patients or children with a history of pica or acute ingestion of lead containing objects (eg, fishing weights), an abdominal radiograph should be obtained to evaluate the presence of foreign material as the lead source. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Diagnostic imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Detectable BLL are associated with irreversible neurocognitive deficits and a lower limit for this toxicity has",
"      <strong>",
"       not",
"      </strong>",
"      been established. Lead levels &gt;5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (0.24",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      are considered toxic in the United States, requiring additional testing or intervention. Children with detectable BLL &lt;5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      are at risk and warrant close followup and retesting. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Neurologic'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link\">",
"       \"Childhood lead poisoning: Management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When lead toxicity causes symptoms, they are diverse and include vomiting, cognitive impairment, language delay, hearing loss, and behavior problems at low concentrations and colicky abdominal pain, anemia, intellectual disability (intellectual disability), seizures, renal insufficiency, and encephalopathy at higher concentrations (",
"      <a class=\"graphic graphic_table graphicRef76585 \" href=\"UTD.htm?10/25/10652\">",
"       table 3",
"      </a>",
"      ). Lead poisoning should be included in the differential diagnosis for children with any of these complaints or conditions. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Symptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When a patient presents with acute encephalopathy of unknown etiology and a BLL cannot be obtained immediately, several clinical findings constitute strong supportive evidence for a diagnosis of lead poisoning including elevated blood erythrocyte protoporphyrin, elevated zinc protoporphyrin, strongly positive qualitative urine coproporphyrin, basophilic stippling of peripheral RBCs or erythroblasts in the bone marrow (",
"      <a class=\"graphic graphic_picture graphicRef71989 \" href=\"UTD.htm?39/22/40294\">",
"       picture 1",
"      </a>",
"      ), glycosuria, hypophosphatemia, lead flecks on abdominal radiograph (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81950 \" href=\"UTD.htm?10/14/10464\">",
"       image 1",
"      </a>",
"      ), or lead lines on long-bone radiographs (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81488 \" href=\"UTD.htm?13/51/14143\">",
"       image 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Encephalopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment should begin emergently if encephalopathy secondary to severe lead toxicity is suspected. A BLL should be obtained to confirm the diagnosis, but treatment should not be delayed while awaiting the result. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Encephalopathy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link&amp;anchor=H6#H6\">",
"       \"Childhood lead poisoning: Management\", section on 'Severe intoxication (&ge;70 mcg/dL)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/1\">",
"      Nriagu JO. Saturnine gout among Roman aristocrats. Did lead poisoning contribute to the fall of the Empire? N Engl J Med 1983; 308:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/2\">",
"      Needleman HL. The removal of lead from gasoline: historical and personal reflections. Environ Res 2000; 84:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/3\">",
"      Hernberg S. Lead poisoning in a historical perspective. Am J Ind Med 2000; 38:244.",
"     </a>",
"    </li>",
"    <li>",
"     Annest JL. Trends in the blood lead levels of the US population. In: Lead Versus Health, Rutter M, Jones RR.  (Eds), John Wiley and Sons, New York 1983. p.33.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/5\">",
"      Centers for Disease Control and Prevention (CDC). Blood lead levels--United States, 1999-2002. MMWR Morb Mortal Wkly Rep 2005; 54:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/6\">",
"      Bellinger D, Sloman J, Leviton A, et al. Low-level lead exposure and children's cognitive function in the preschool years. Pediatrics 1991; 87:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/7\">",
"      Needleman HL, Schell A, Bellinger D, et al. The long-term effects of exposure to low doses of lead in childhood. An 11-year follow-up report. N Engl J Med 1990; 322:83.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Preventing lead poisoning in young children: a statement by the Centers for Disease Control, 1991.",
"    </li>",
"    <li>",
"     CDC response to Advisory Committee on Childhood Lead Poisoning Prevention Recommendations in \"Low Level Lead Exposure Harms Children:  A Renewed Call of Primary Prevention\" file://www.cdc.gov/nceh/lead/ACCLPP/activities.htm (Accessed on May 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/10\">",
"      Pirkle JL, Brody DJ, Gunter EW, et al. The decline in blood lead levels in the United States. The National Health and Nutrition Examination Surveys (NHANES). JAMA 1994; 272:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Blood lead levels in children aged 1-5 years - United States, 1999-2010. MMWR Morb Mortal Wkly Rep 2013; 62:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/12\">",
"      Wright RO, Tsaih SW, Schwartz J, et al. Association between iron deficiency and blood lead level in a longitudinal analysis of children followed in an urban primary care clinic. J Pediatr 2003; 142:9.",
"     </a>",
"    </li>",
"    <li>",
"     Agency for Toxic Substances and Disease Registry. Case Studies in Environmental Medicine (CSEM): Lead Toxicity Cover Page. www.atsdr.cdc.gov/csem/lead/pbcover_page2.html (Accessed on January 2, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/14\">",
"      Melman ST, Nimeh JW, Anbar RD. Prevalence of elevated blood lead levels in an inner-city pediatric clinic population. Environ Health Perspect 1998; 106:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Blood lead levels in young children--United States and selected states, 1996-1999. MMWR Morb Mortal Wkly Rep 2000; 49:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/16\">",
"      Centers for Disease Control and Prevention (CDC). Update: blood lead levels--United States, 1991-1994. MMWR Morb Mortal Wkly Rep 1997; 46:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/17\">",
"      Geltman PL, Brown MJ, Cochran J. Lead poisoning among refugee children resettled in Massachusetts, 1995 to 1999. Pediatrics 2001; 108:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/18\">",
"      Chung EK, Webb D, Clampet-Lundquist S, Campbell C. A comparison of elevated blood lead levels among children living in foster care, their siblings, and the general population. Pediatrics 2001; 107:E81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/19\">",
"      Centers for Disease Control and Prevention (CDC). Infant lead poisoning associated with use of tiro, an eye cosmetic from Nigeria--Boston, Massachusetts, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/20\">",
"      Alexander FW, Clayton BE, Delves HT. Mineral and trace-metal balances in children receiving normal and synthetic diets. Q J Med 1974; 43:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/21\">",
"      Ziegler EE, Edwards BB, Jensen RL, et al. Absorption and retention of lead by infants. Pediatr Res 1978; 12:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/22\">",
"      James HM, Hilburn ME, Blair JA. Effects of meals and meal times on uptake of lead from the gastrointestinal tract in humans. Hum Toxicol 1985; 4:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/23\">",
"      Mahaffey KR. Environmental lead toxicity: nutrition as a component of intervention. Environ Health Perspect 1990; 89:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/24\">",
"      Griffin TB, Coulston F, Wills H, Russell JC. Biologic effects of airborne particulate lead on continuously exposed rats and rhesus monkeys. Environ Qual Saf Suppl 1975; 2:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/25\">",
"      Rabinowitz MB, Wetherill GW, Kopple JD. Kinetic analysis of lead metabolism in healthy humans. J Clin Invest 1976; 58:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/26\">",
"      Griffin TB, Coulston F, Wills H, Russell JC. Clinical studies on men continuously exposed to airborne particulate lead. Environ Qual Saf Suppl 1975; 2:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/27\">",
"      Hu H, Rabinowitz M, Smith D. Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms. Environ Health Perspect 1998; 106:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/28\">",
"      Barry PS. A comparison of concentrations of lead in human tissues. Br J Ind Med 1975; 32:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/29\">",
"      Lidsky TI, Schneider JS. Lead neurotoxicity in children: basic mechanisms and clinical correlates. Brain 2003; 126:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/30\">",
"      Al-Modhefer AJ, Bradbury MW, Simons TJ. Observations on the chemical nature of lead in human blood serum. Clin Sci (Lond) 1991; 81:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/31\">",
"      Johnson FM. The genetic effects of environmental lead. Mutat Res 1998; 410:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/32\">",
"      Fox DA, Campbell ML, Blocker YS. Functional alterations and apoptotic cell death in the retina following developmental or adult lead exposure. Neurotoxicology 1997; 18:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/33\">",
"      Fox DA, He L, Poblenz AT, et al. Lead-induced alterations in retinal cGMP phosphodiesterase trigger calcium overload, mitochondrial dysfunction and rod photoreceptor apoptosis. Toxicol Lett 1998; 102-103:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/34\">",
"      He L, Poblenz AT, Medrano CJ, Fox DA. Lead and calcium produce rod photoreceptor cell apoptosis by opening the mitochondrial permeability transition pore. J Biol Chem 2000; 275:12175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/35\">",
"      Markovac J, Goldstein GW. Picomolar concentrations of lead stimulate brain protein kinase C. Nature 1988; 334:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/36\">",
"      Johnston MV, Goldstein GW. Selective vulnerability of the developing brain to lead. Curr Opin Neurol 1998; 11:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/37\">",
"      Srivastava D, Hurwitz RL, Fox DA. Lead- and calcium-mediated inhibition of bovine rod cGMP phosphodiesterase: interactions with magnesium. Toxicol Appl Pharmacol 1995; 134:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/38\">",
"      Srivastava D, Fox DA, Hurwitz RL. Effects of magnesium on cyclic GMP hydrolysis by the bovine retinal rod cyclic GMP phosphodiesterase. Biochem J 1995; 308 ( Pt 2):653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/39\">",
"      Holtzman D, Hsu JS. Early effects of inorganic lead on immature rat brain mitochondrial respiration. Pediatr Res 1976; 10:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/40\">",
"      Trope I, Lopez-Villegas D, Cecil KM, Lenkinski RE. Exposure to lead appears to selectively alter metabolism of cortical gray matter. Pediatrics 2001; 107:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/41\">",
"      Trope I, Lopez-Villegas D, Lenkinski RE. Magnetic resonance imaging and spectroscopy of regional brain structure in a 10-year-old boy with elevated blood lead levels. Pediatrics 1998; 101:E7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/42\">",
"      Cooper GP, Suszkiw JB, Manalis RS. Heavy metals: effects on synaptic transmission. Neurotoxicology 1984; 5:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/43\">",
"      Zwart R, van Kleef RG, Van Hooft JA, et al. Cellular aspects of persistent neurotoxicants: effects of Pb2+ on neuronal nicotinic acetylcholine receptors. Neurotoxicology 1997; 18:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/44\">",
"      Oortgiesen M, Leinders T, van Kleef RG, Vijverberg HP. Differential neurotoxicological effects of lead on voltage-dependent and receptor-operated ion channels. Neurotoxicology 1993; 14:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/45\">",
"      Sirover MA, Loeb LA. Infidelity of DNA synthesis in vitro: screening for potential metal mutagens or carcinogens. Science 1976; 194:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/46\">",
"      Hoffman DJ, Niyogi SK. Metal mutagens and carcinogens affect RNA synthesis rates in a distinct manner. Science 1977; 198:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/47\">",
"      Kobayashi N, Okamoto T. Effects of lead oxide on the induction of lung tumors in Syrian hamsters. J Natl Cancer Inst 1974; 52:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/48\">",
"      Kasprzak KS, Hoover KL, Poirier LA. Effects of dietary calcium acetate on lead subacetate carcinogenicity in kidneys of male Sprague-Dawley rats. Carcinogenesis 1985; 6:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/49\">",
"      Buzard GS, Kasprzak KS. Possible roles of nitric oxide and redox cell signaling in metal-induced toxicity and carcinogenesis: a review. J Environ Pathol Toxicol Oncol 2000; 19:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/50\">",
"      Koller LD, Kerkvliet NI, Exon JH. Neoplasia induced in male rats fed lead acetate, ethyl urea, and sodium nitrite. Toxicol Pathol 1985; 13:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/51\">",
"      ZOLLINGER HU. [Renal adenoma and carcinoma produced by lead poisoning in rats, and relations to corresponding neoplastic formations in man]. Virchows Arch 1953; 323:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/52\">",
"      Van Esch GJ, Kroes R. The induction of renal tumours by feeding basic lead acetate to mice and hamsters. Br J Cancer 1969; 23:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/53\">",
"      DINGWALL-FORDYCE I, LANE RE. A FOLLOW-UP STUDY OF LEAD WORKERS. Br J Ind Med 1963; 20:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/54\">",
"      Moore MR, Meredith PA. The carcinogenicity of lead. Arch Toxicol 1979; 42:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/55\">",
"      Nelson DJ, Kiremidjian-Schumacher L, Stotzky G. Effects of cadmium, lead, and zinc on macrophage-mediated cytotoxicity toward tumor cells. Environ Res 1982; 28:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/56\">",
"      Johnson DR, Foulkes EC, Hammond PB. The renal handling of delta-aminolevulinic acid in normal and lead-poisoning rabbits. Toxicol Appl Pharmacol 1976; 38:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/57\">",
"      Hammond PB. Exposure of humans to lead. Annu Rev Pharmacol Toxicol 1977; 17:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/58\">",
"      Campbell BC, Brodie MJ, Thompson GG, et al. Alterations in the activity of enzymes of haem biosynthesis in lead poisoning and acute hepatic prophyria. Clin Sci Mol Med 1977; 53:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/59\">",
"      Rees DC, Duley JA, Marinaki AM. Pyrimidine 5' nucleotidase deficiency. Br J Haematol 2003; 120:375.",
"     </a>",
"    </li>",
"    <li>",
"     Needleman HL. Lead poisoning. In: Oski's Pediatrics: Principles and Practice, 4th, McMillan JA, Feigin RD, DeAngelis C, Jones MD.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.767.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/61\">",
"      Campbell TF, Needleman HL, Riess JA, Tobin MJ. Bone lead levels and language processing performance. Dev Neuropsychol 2000; 18:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/62\">",
"      Needleman HL, Riess JA, Tobin MJ, et al. Bone lead levels and delinquent behavior. JAMA 1996; 275:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/63\">",
"      Mendelsohn AL, Dreyer BP, Fierman AH, et al. Low-level lead exposure and behavior in early childhood. Pediatrics 1998; 101:E10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/64\">",
"      Dietrich KN, Krafft KM, Bornschein RL, et al. Low-level fetal lead exposure effect on neurobehavioral development in early infancy. Pediatrics 1987; 80:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/65\">",
"      Dietrich KN, Berger OG, Succop PA, et al. The developmental consequences of low to moderate prenatal and postnatal lead exposure: intellectual attainment in the Cincinnati Lead Study Cohort following school entry. Neurotoxicol Teratol 1993; 15:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/66\">",
"      Baghurst PA, McMichael AJ, Wigg NR, et al. Environmental exposure to lead and children's intelligence at the age of seven years. The Port Pirie Cohort Study. N Engl J Med 1992; 327:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/67\">",
"      Mendelsohn AL, Dreyer BP, Fierman AH, et al. Low-level lead exposure and cognitive development in early childhood. J Dev Behav Pediatr 1999; 20:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/68\">",
"      Pocock SJ, Smith M, Baghurst P. Environmental lead and children's intelligence: a systematic review of the epidemiological evidence. BMJ 1994; 309:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/69\">",
"      Chen A, Cai B, Dietrich KN, et al. Lead exposure, IQ, and behavior in urban 5- to 7-year-olds: does lead affect behavior only by lowering IQ? Pediatrics 2007; 119:e650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/70\">",
"      Lanphear BP, Dietrich K, Auinger P, Cox C. Cognitive deficits associated with blood lead concentrations &lt;10 microg/dL in US children and adolescents. Public Health Rep 2000; 115:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/71\">",
"      Canfield RL, Henderson CR Jr, Cory-Slechta DA, et al. Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. N Engl J Med 2003; 348:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/72\">",
"      Lanphear BP, Hornung R, Khoury J, et al. Low-level environmental lead exposure and children's intellectual function: an international pooled analysis. Environ Health Perspect 2005; 113:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/73\">",
"      T&eacute;llez-Rojo MM, Bellinger DC, Arroyo-Quiroz C, et al. Longitudinal associations between blood lead concentrations lower than 10 microg/dL and neurobehavioral development in environmentally exposed children in Mexico City. Pediatrics 2006; 118:e323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/74\">",
"      Gomaa A, Hu H, Bellinger D, et al. Maternal bone lead as an independent risk factor for fetal neurotoxicity: a prospective study. Pediatrics 2002; 110:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/75\">",
"      Fergusson DM, Horwood LJ, Lynskey MT. Early dentine lead levels and educational outcomes at 18 years. J Child Psychol Psychiatry 1997; 38:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/76\">",
"      Finkelstein Y, Markowitz ME, Rosen JF. Low-level lead-induced neurotoxicity in children: an update on central nervous system effects. Brain Res Brain Res Rev 1998; 27:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/77\">",
"      Bellinger D, Leviton A, Waternaux C, et al. Longitudinal analyses of prenatal and postnatal lead exposure and early cognitive development. N Engl J Med 1987; 316:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/78\">",
"      Schroeder SR, Hawk B, Otto DA, et al. Separating the effects of lead and social factors on IQ. Environ Res 1985; 38:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/79\">",
"      Ruff HA, Bijur PE, Markowitz M, et al. Declining blood lead levels and cognitive changes in moderately lead-poisoned children. JAMA 1993; 269:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/80\">",
"      Soong WT, Chao KY, Jang CS, Wang JD. Long-term effect of increased lead absorption on intelligence of children. Arch Environ Health 1999; 54:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/81\">",
"      Bellinger DC, Stiles KM, Needleman HL. Low-level lead exposure, intelligence and academic achievement: a long-term follow-up study. Pediatrics 1992; 90:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/82\">",
"      Ruff HA. Population-based data and the development of individual children: the case of low to moderate lead levels and intelligence. J Dev Behav Pediatr 1999; 20:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/83\">",
"      Osman K, Pawlas K, Sch&uuml;tz A, et al. Lead exposure and hearing effects in children in Katowice, Poland. Environ Res 1999; 80:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/84\">",
"      CHISOLM JJ Jr, HARRISON HE. The exposure of children to lead. Pediatrics 1956; 18:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/85\">",
"      Erenberg G, Rinsler SS, Fish BG. Lead neuropathy and sickle cell disease. Pediatrics 1974; 54:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/86\">",
"      Anku VD, Harris JW. Peripheral neuropathy and lead poisoning in a child with sickle-cell anemia. Case report and review of the literature. J Pediatr 1974; 85:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/87\">",
"      Imbus CE, Warner J, Smith E, et al. Peripheral neuropathy in lead-intoxicated sickle cell patients. Muscle Nerve 1978; 1:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/88\">",
"      Feldman RG, Hayes MK, Younes R, Aldrich FD. Lead neuropathy in adults and children. Arch Neurol 1977; 34:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/89\">",
"      Schwartz J, Landrigan PJ, Feldman RG, et al. Threshold effect in lead-induced peripheral neuropathy. J Pediatr 1988; 112:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/90\">",
"      Suarez CR, Black LE 3rd, Hurley RM. Elevated lead levels in a patient with sickle cell disease and inappropriate secretion of antidiuretic hormone. Pediatr Emerg Care 1992; 8:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/91\">",
"      MYERSON RM, EISENHAUER JH. Atrioventricular conduction defects in lead poisoning. Am J Cardiol 1963; 11:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/92\">",
"      Lubran MM. Lead toxicity and heme biosynthesis. Ann Clin Lab Sci 1980; 10:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/93\">",
"      Meredith PA, Moore MR, Goldberg A. Erythrocyte delta-aminolaevulinic acid dehydratase activity and blood protoporphyrin concentrations as indices of lead exposure and altered haem biosynthesis. Clin Sci (Lond) 1979; 56:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/94\">",
"      Hammad TA, Sexton M, Langenberg P. Relationship between blood lead and dietary iron intake in preschool children. A cross-sectional study. Ann Epidemiol 1996; 6:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/95\">",
"      Clark M, Royal J, Seeler R. Interaction of iron deficiency and lead and the hematologic findings in children with severe lead poisoning. Pediatrics 1988; 81:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/96\">",
"      Bhambhani K, Aronow R. Lead poisoning and thalassemia trait or iron deficiency. The value of the red blood cell distribution width. Am J Dis Child 1990; 144:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/97\">",
"      Rosen JF, Chesney RW, Hamstra A, et al. Reduction in 1,25-dihydroxyvitamin D in children with increased lead absorption. N Engl J Med 1980; 302:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/98\">",
"      Selevan SG, Rice DC, Hogan KA, et al. Blood lead concentration and delayed puberty in girls. N Engl J Med 2003; 348:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/99\">",
"      Tong S, Baghurst PA, Sawyer MG, et al. Declining blood lead levels and changes in cognitive function during childhood: the Port Pirie Cohort Study. JAMA 1998; 280:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/100\">",
"      Rosen JF, Mushak P. Primary prevention of childhood lead poisoning--the only solution. N Engl J Med 2001; 344:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/101\">",
"      Rogan WJ, Dietrich KN, Ware JH, et al. The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. N Engl J Med 2001; 344:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/102\">",
"      Lewendon G, Kinra S, Nelder R, Cronin T. Should children with developmental and behavioural problems be routinely screened for lead? Arch Dis Child 2001; 85:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/103\">",
"      Gordon RA, Roberts G, Amin Z, et al. Aggressive approach in the treatment of acute lead encephalopathy with an extraordinarily high concentration of lead. Arch Pediatr Adolesc Med 1998; 152:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/104\">",
"      Chisolm JJ Jr. The use of chelating agents in the treatment of acute and chronic lead intoxication in childhood. J Pediatr 1968; 73:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/105\">",
"      Chisolm JJ Jr. The continuing hazard of lead exposure and its effects in children. Neurotoxicology 1984; 5:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/106\">",
"      Rajkumar S, Geibel V, Devanagondi B, et al. The diagnostic significance of free erythrocyte protoporphyrin and the FEP/hemoglobin ratio in plumbism. N Y State J Med 1987; 87:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/107\">",
"      Carraccio CL, Bergman GE, Daley BP. Combined iron deficiency and lead poisoning in children. Effect on FEP levels. Clin Pediatr (Phila) 1987; 26:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/108\">",
"      Piomelli S. The diagnostic utility of measurements of erythrocyte porphyrins. Hematol Oncol Clin North Am 1987; 1:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/109\">",
"      McElvaine MD, Orbach HG, Binder S, et al. Evaluation of the erythrocyte protoporphyrin test as a screen for elevated blood lead levels. J Pediatr 1991; 119:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/110\">",
"      Tehranifar P, Leighton J, Auchincloss AH, et al. Immigration and risk of childhood lead poisoning: findings from a case control study of New York City children. Am J Public Health 2008; 98:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/111\">",
"      Parsons PJ, Reilly AA, Esernio-Jenssen D. Screening children exposed to lead: an assessment of the capillary blood lead fingerstick test. Clin Chem 1997; 43:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/112\">",
"      American Academy of Pediatrics Committee on Environmental Health. Lead exposure in children: prevention, detection, and management. Pediatrics 2005; 116:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/113\">",
"      Screening for elevated blood lead levels. American Academy of Pediatrics Committee on Environmental Health. Pediatrics 1998; 101:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/114\">",
"      Binns HJ, Campbell C, Brown MJ, Centers for Disease Control and Prevention Advisory Committee on Childhood Lead Poisoning Prevention. Interpreting and managing blood lead levels of less than 10 microg/dL in children and reducing childhood exposure to lead: recommendations of the Centers for Disease Control and Prevention Advisory Committee on Childhood Lead Poisoning Prevention. Pediatrics 2007; 120:e1285.",
"     </a>",
"    </li>",
"    <li>",
"     Roberts, JR, Reigart, JR. Medical Assessment and Interventions. In: Managing Elevated Blood Lead Levels Among Young children: Recommendations from the Advisory Committee on Childhood Lead Poisoning Prevention. Centers for Disease Control and Prevention, Atlanta, GA, 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/116\">",
"      Porru S, Alessio L. The use of chelating agents in occupational lead poisoning. Occup Med (Lond) 1996; 46:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/117\">",
"      Kulshrestha MK. Lead poisoning diagnosed by abdominal X-rays. J Toxicol Clin Toxicol 1996; 34:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/24/394/abstract/118\">",
"      Woolf DA, Riach IC, Derweesh A, Vyas H. Lead lines in young infants with acute lead encephalopathy: a reliable diagnostic test. J Trop Pediatr 1990; 36:90.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6491 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-FED1FB5BDE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_24_394=[""].join("\n");
var outline_f0_24_394=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sources",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TOXICOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Molecular toxicology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Neurologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hematologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Renal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Endocrine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Lead levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Erythrocyte protoporphyrin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Additional tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Diagnostic imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6491\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6491|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/14/10464\" title=\"diagnostic image 1\">",
"      Lead flecks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/51/14143\" title=\"diagnostic image 2\">",
"      Skeletal lead lines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6491|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/22/40294\" title=\"picture 1\">",
"      Basophilic stippling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/27/16819\" title=\"picture 2\">",
"      Lead line gums",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6491|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/33/9755\" title=\"table 1\">",
"      Toxic blood lead levels children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/3/9277\" title=\"table 2\">",
"      Sources of lead exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/25/10652\" title=\"table 3\">",
"      Signs symptoms lead toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/34/2605\" title=\"table 4\">",
"      Lead poisoning evaluation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=related_link\">",
"      Adult lead poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11001?source=related_link\">",
"      Childhood lead poisoning: Exposure and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=related_link\">",
"      Childhood lead poisoning: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=related_link\">",
"      Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=related_link\">",
"      Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=related_link\">",
"      Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=related_link\">",
"      Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5705?source=related_link\">",
"      Lead nephropathy and lead-related nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43225?source=related_link\">",
"      Screening tests in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_24_395="Early pregnancy U-S landmarks";
var content_f0_24_395=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Development of intrauterine pregnancy by transvaginal ultrasound examination",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        A gestational sac size of 2 to 3 mm may be visualized at four weeks and one to three days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The yolk sac can be noted initially at the beginning of the fifth week of gestation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        An embryonic pole with cardiac activity can be first detected at 5.5 to 6 weeks",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_24_395=[""].join("\n");
var outline_f0_24_395=null;
var title_f0_24_396="CT patterns bronchiolitis";
var content_f0_24_396=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    CT patterns of bronchiolitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Pattern of bronchiolitis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Characteristic radiologic features",
"      </td>",
"      <td class=\"subtitle1\">",
"       Prototype disease/association",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cellular",
"      </td>",
"      <td>",
"       <p>",
"        Centrilobular nodularity",
"       </p>",
"       <p>",
"        Tree-in-bud pattern",
"       </p>",
"      </td>",
"      <td>",
"       Acute infection (viral, mycoplasma)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Constrictive",
"      </td>",
"      <td>",
"       Diffuse or geographic air trapping/mosaic pattern",
"      </td>",
"      <td>",
"       Cryptogenic bronchiolitis obliterans",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Follicular",
"      </td>",
"      <td>",
"       <p>",
"        Centrilobular nodules",
"       </p>",
"       <p>",
"        Peribronchial nodules",
"       </p>",
"       <p>",
"        Ground glass opacity",
"       </p>",
"      </td>",
"      <td>",
"       Rheumatoid lung disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Airway centered interstitial fibrosis",
"      </td>",
"      <td>",
"       <p>",
"        Peribronchovascular ground glass opacities",
"       </p>",
"       <p>",
"        Traction bronchiectasis",
"       </p>",
"       <p>",
"        Thickening of bronchial walls",
"       </p>",
"      </td>",
"      <td>",
"       Airway centered interstitial fibrosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Panbronchiolitis",
"      </td>",
"      <td>",
"       <p>",
"        Tree-in-bud pattern",
"       </p>",
"       <p>",
"        Bronchiolectasis",
"       </p>",
"       <p>",
"        Bronchiectasis",
"       </p>",
"      </td>",
"      <td>",
"       Diffuse panbronchiolitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Respiratory bronchiolitis",
"      </td>",
"      <td>",
"       <p>",
"        Poorly defined centrilobular nodules",
"       </p>",
"       <p>",
"        Patchy ground glass attenuation",
"       </p>",
"      </td>",
"      <td>",
"       Smoker's lung",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Pipavath, SJ, Lynch, DA, Cool, C, et al. Radiologic and pathologic features of bronchiolitis. AJR Am J Roentgenol 2005; 185:354.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_24_396=[""].join("\n");
var outline_f0_24_396=null;
var title_f0_24_397="Timeline for diagnosis of pertussis";
var content_f0_24_397=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Timeline for diagnosis of pertussis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 175px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Pertussis (Whooping Cough). Available at:",
"     <a href=\"file://www.cdc.gov/pertussis/clinical/diagnostic-testing/diagnosis-confirmation.html\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      file://www.cdc.gov/pertussis/clinical/diagnostic-testing/diagnosis-confirmation.html",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_24_397=[""].join("\n");
var outline_f0_24_397=null;
var title_f0_24_398="Segmental changes in urine pH";
var content_f0_24_398=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urine pH along the nephron",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 229px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fall in pH of the tubular fluid along the nephron of the rat. The major reduction in pH occurs in the collecting tubules (the difference between the distal tubule and ureteral urine specimens).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gottschalk, CW, Lassiter, W, William, E, Mylle, M, Am J Physiol 1960; 198:581.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_24_398=[""].join("\n");
var outline_f0_24_398=null;
var title_f0_24_399="Rising incidence brain cancer";
var content_f0_24_399=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Age-specific incidence of malignant neoplams of the brain, cerebral meninges and cranial nerves, Connecticut 1960-1964 and 1990-94, stratified by gender",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 343px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data partially derived from both NCI Monograph #70, and Heston, JF, Kelly, JA, Meigs, JW, Flannery, JT. Forty-five years of cancer incidence in Connecticut: 1935-79. Cusano, MM, Young, JL Jr (Eds), CT Cancer Epidemiology Unit, Department of Epidemiology and Public Health, Yale University, New Haven, CT 1986.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_24_399=[""].join("\n");
var outline_f0_24_399=null;
